

LEADERSHIP
INNOVATION
TRANSFORMATION

Anthem Biosciences 2024





Anthem BioSciences



Corporate Information

Anthem Biosciences Private Limited

CIN: U24233K A2006PTC039703

Registered Office

Unit I: No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area Phase 1, Bommasandra, Bangalore, 560 099, India

Unit II: Plot No. 276-P & 277-P, Survey No. 20, Harohalli Industrial Area, Phase II, Near Bannikuppe Village, Kanakapura Taluk, Ramnagar District, Harohalli, Karnataka 562112, India

NeoAnthem Lifesciences Private Limited

CIN: U24239KA2020PTC136337

Registered Office

No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Bengaluru, Bangalore, Karnataka, India, 560099

Unit III: 313-P, 314-P & 318-P, Bannikuppe Road, Harohalli Industrial Area, Phase II, Harohalli, Kanakapura Taluk, Ramanagara District, Harohalli, Karnataka, 562112, India

Auditors

KP Rao & Co.

Chartered Accountants

Poornima, 2nd Floor, 25, State Bank Road, Bangalore, Karnataka, 560001, India

Index

Message from Chief Executive Officer, Founder and Managing Director	05
Message from Chief Scientific Officer, Co-Founder and Director	06
Message from Chief Operating Officer, Co-Founder and Director	07
Anthem - Overview	
Anthem Biosciences: Empowering Global Healthcare Since 2006	10
Mission, Vision and Values	12
Growth Journey	13
Anthem's Products and Service Offerings	14
a. CRDMO Services: Integrated NCE and NBE Life Cycle Offerings	14
b. Specialty Ingredients	15
Global Reach and Strategic Partnerships	18
Manufacturing Infrastructure	19
Advancing Sustainability through Green Chemistry	20
Digital Transformation	22
Board of Directors and Board's Report	
Founding Team and Board of Directors	25
Board's Report FY 2023-2024	26
Financial Statements	
Consolidated Financials	59
a. Auditors Report (Consolidated Financials)	60
b. Consolidated Financial Statements	66
c. Accounting Policies (Consolidated Financial Statements)	94
Standalone Financials	102
a. Auditors Report (Standalone Financials)	103
b. Standalone Financial Statements	112
c. Accounting Policies (Standalone Financial Statements)	140
NeoAnthem Financials	148
a. Auditors Report (NeoAnthem Financials)	149
b. NeoAnthem Financial Statements	152
c. Accounting Policies (NeoAnthem Financial Statements)	163
Sustainability and CSR	
ESG Report FY 2023-2024	167
CSR Impact Report FY 2023-2024	175

Message from Chief Executive Officer, Founder and Managing Director



As we close another year, I want to take a moment to reflect on our collective journey, and look ahead to the exciting opportunities that lie before us.

Fiscal 2024 has been a year of remarkable progress for Anthem. Together, we have navigated both challenges and triumphs, always staying focused on our mission and values. This year, we saw significant growth in our revenues across both CRDMO and Specialty Ingredients business, registering a 34%+ growth over Fiscal 2023, which also reflected across our revenue from both exports as well as domestic sales. This was attributable to receiving USFDA approval for Unit II in June 2023. I am also delighted to share that we have successfully completed the second USFDA inspection for Unit II in March 2024, along with successfully clearing the TGA (Australia) Audit for Unit II and the ANVISA (Brazil) Audit for both Unit I and Unit II in Fiscal 2024, thus opening up new business opportunities for us.

On the technology and manufacturing front, we have been investing significantly in adding to our infrastructure. Last year, we inaugurated our oligonucleotide lab in Unit I. We are currently in the midst of expansion in Unit II, viz: custom synthesis expansion of 130 kL in CP 6 and CP 7, and scaled up fermentation capacity in Unit II to 140 kL. The new custom synthesis expansion at Unit II will be operational by the first half of 2025. The construction of our new site, Unit III, in Harohalli, is in full swing. We inaugurated the chemistry lab at Unit III in the beginning of 2024, and in a phased manner, the other blocks at Unit III, viz: peptides, hi-potent, hydrogenation and probiotics is expected to be completed in a phased manner from end 2024 until the first half of 2025.

With the three pillars of innovation and technology, high quality standards, and a customer-first approach, we are committed to our firmness to solve problems in biology and chemistry using technology. These accomplishments are a direct result of the collective efforts of our team members; our team's resilience has been nothing short of inspiring. We have successfully launched new projects, expanded our reach, and strengthened the relationships with our partners and clients.

As we turn the page to Fiscal 2025, I am excited about the future. The coming year promises new opportunities for innovation, collaboration, and growth. We have an ambitious roadmap ahead. We have invested ahead of time in advanced platform technologies, viz: biotransformation, flow chemistry, ADCs, HPAPI, RNAi, oligos, peptides and we will continue to expand our technological capabilities to include laboratory-scale photochemistry and electro-synthesis capabilities, which are alternative procedures for the synthesis of new complexes. We will also continue to focus on growing complex specialty ingredients business, which has a large market opportunity, especially in the complex biologics manufacturing space. Most importantly, we will also continue to invest in our culture, ensuring that we remain a company where every individual feels empowered, valued, and equipped to succeed.

Our commitment to excellence will be our guiding principle in everything we do, and we will continue to set new standards of success and impact.

Ajay Bhardwaj

CEO

Message from Chief Scientific Officer, Co-Founder and Director



Innovation forms the cornerstone of our organization, and as we navigate the fast-paced and ever-evolving landscape of science and technology let us reflect on the incredible strides we have made in innovation and R&D here at Anthem.

Our commitment to scientific excellence and groundbreaking innovation has always been at the heart of our mission. We have undertaken several initiatives to differentiate ourselves across modalities and manufacturing capabilities aimed at meeting our customers' evolving requirements. We significantly expanded our R&D facilities and invested in cutting-edge technologies that enable us to accelerate the development of next-generation products. Whether it is ADCs, RNAi, Peptides, Lipids, Oligonucleotides, these investments are positioning us to stay at the forefront of innovation in our field. Last year, we inaugurated our oligonucleotide lab in Unit I and have commercial scale capacity across the other modalities, viz: ADCs, RNAi, Peptides and Lipids, which are among the fastest growing in the pharmaceutical industry.

Our success in innovation relies on collaboration across disciplines. By breaking down silos and fostering cross-functional partnerships between chemists and biologists, scientists and engineers, we are able to generate new ideas and bring them to life faster. Our bio-catalysis and biosynthesis capabilities, where we bring chemists and biologists together, enable us to provide differentiated solutions for custom synthesis and chemical manufacturing using enzymes. Likewise, we had designed our flow chemistry capabilities by bring in scientists and engineers together. This spirit of teamwork and shared purpose is a key driver of our ability to stay ahead of the curve. Today, we offer the broadest range of technology capabilities for drug development, including biotransformation, flow chemistry, customer synthesis and fermentation-based manufacturing.

We are increasingly focused on aligning our R&D efforts with the evolving needs of our customers. This means prioritizing solutions that not only address current challenges but also anticipate future demands. Implementing green chemistry practices wherever possible, including performing multi-stage reactions telescopically and using greener solvents, and adopting flow chemistry for hazardous processes to lower safety risks and significantly reduce effluent generation compared to batch reactor operations. These sustainable manufacturing processes substantially improve the safety of the manufacturing process, as well as enhance reaction efficiency, generate higher yields with fewer by-products and reduces hazardous wastes and effluents. By engaging with our customers and incorporating their insights into the R&D process, we are creating products that deliver real, long-term value.

As we look ahead, we are poised to make even greater strides in R&D. The challenges we face are significant, but with our collective passion for discovery and our unwavering commitment to excellence, we will continue pushing the boundaries of what is possible in the world of biopharmaceuticals.

Ganesh Sambasivam

Chief Scientific Officer

Message from Chief Operating Officer, Co-Founder and Director



As part of our ongoing commitment to excellence and continuous improvement, let me take this moment to talk about the significant progress we have made in strengthening our manufacturing quality standards.

At Anthem, quality is at the core of everything we do. Our customers depend on us to deliver products that meet the highest standards, and it is our responsibility to ensure that every step of our manufacturing process reflects that commitment.

In the last few years, we have proactively made various investments to enhance our manufacturing capabilities by increasing our capacity and bringing in machine automation to improve efficiency and quality.

- **Distributed Control System:** We have implemented an integrated DCS system combining our API, fermentation, biologics, continuous flow, purified, WFI water plants, building management, and continuous monitoring systems. The DCS system has enabled us to integrate and automate various production and monitoring processes, BMS, and utilities, and allows us to monitor our operations on a scalable platform. The system also collects and stores process data, which is analysed to optimize production efficiency, improve product quality, and ensure adherence to regulatory requirements such as those from the USFDA and EMA.
- **Enterprise resource planning:** We adopt a globally recognised enterprise resource-planning tool for data processing and analytics support to manage our different business units and our supply chain, streamline our operations, enhance efficiency and ensure compliance.
- **Building management system:** We adopt BMS for monitoring, managing and reporting on utility data in our manufacturing units. The BMS monitors and manages the condition of our utility-related equipment to predict and prevent failures; schedules maintenance activities based on equipment condition and performance data, analyses energy usage patterns for efficiency improvements, and identifies peak load periods and implements load-shifting strategies. The BMS also monitors and regulates temperature, humidity, and air quality in critical areas such as clean rooms and storage facilities, which ensures that conditions remain within specified limits and optimizes energy consumption, reduces costs in maintaining the necessary environmental conditions for production and storage of the materials, and provides real-time monitoring and alerts for deviations in critical parameters to enable rapid response to prevent product spoilage or contamination.

- **Quality Management Tools:** We use an integrated cloud-based platform designed to manage quality processes in regulated industries. Their services range across quality management, document control, training, and lab processes, ensuring compliance and operational efficiency by managing the authoring, review and approval of quality documents. We also utilize a quality management system that enables us to monitor our manufacturing practices to ensure our operations comply with the relevant cGMPs, regulations and standards.

We have focused on adopting sustainable manufacturing practices to minimize our impact on the environment and reduce operational costs. We have been utilising green chemistry techniques such as biotransformation, micellar technology, pincer catalysis and flow chemistry, which has enabled us to minimize wastage, realize cleaner reactions and achieve cost efficiencies.

We have also been able to reduce our GHG emission intensity from ₹1.25 tCO₂e/million in Fiscal 2023 to ₹1.24 tCO₂e/million in Fiscal 2024, which is one of the lowest in the industry. We have increased our use of renewable energy from ~75% in Fiscal 2022 to ~90% in Fiscal 2024, and we aim to sustain the 90% dependency on renewables.

While these efforts have already yielded impressive results, we recognize that quality is a never-ending journey. We will continue to challenge ourselves to find new ways to enhance every aspect of our manufacturing operations.

Anthem remains dedicated to continuous improvement, innovation, responsible business practices and in our goal of delivering excellence.

Ravindra KC

Chief Operating Officer

The background is a deep blue gradient. A wide, light blue diagonal band runs from the top left towards the middle right. In the lower half, there is a complex network diagram consisting of two large, glowing blue spheres connected by a web of thin, branching lines. The spheres and lines are composed of a mesh of small dots and triangles, giving them a digital or molecular appearance. Scattered throughout the background are various small, faint geometric shapes like triangles and polygons.

Anthem Biosciences – An Overview

Anthem Biosciences: Empowering Global Healthcare Since 2006



Founded in 2006 in Bangalore, Anthem Biosciences Private Limited ("**Anthem**") is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization ("**CRDMO**") with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem is one of the few companies in India with integrated New Chemical Entity ("**NCE**") and New Biological Entity ("**NBE**") capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, Anthem serves across a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. With a strong presence across various modalities such as RNAi, ADC, peptides, and oligonucleotides and manufacturing techniques such as custom synthesis, flow chemistry, fermentation and biotransformation, Anthem offers the widest range of complex solutions for drug development.


Anthem's business comprises of CRDMO services and the manufacture and sale of specialty ingredients. CRDMO business caters to customers in regulated markets, while Specialty Ingredients business complements CRDMO business by targeting both regulated markets (such as United States and Europe) as well as semi-regulated markets (such as India, South and Southeast Asia, Latin America and Middle East). Specialty Ingredients business enables leveraging on technological capabilities across chemistry and biology and fermentation capacity to manufacture and commercialize specialty ingredients as an additional revenue stream.

Anthem's products and services offered under these two businesses are as outlined below:

- **CRDMO Services:** Anthem offers a comprehensive, integrated and highly customizable range of CRDMO services across the NCE and NBE lifecycles, from target identification and lead selection to preclinical development, supporting customers by manufacturing development batches of molecules used for clinical (Phase I, II and III) trials, and by offering commercial manufacturing capabilities.
- **Specialty Ingredients:** Anthem manufactures and sell complex specialized fermentation-based Active Pharmaceutical Ingredients ("**APIs**"), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.

Anthem served more than 550 customers across both CRDMO and Specialty Ingredients businesses, spread over more than 44 countries including the United States, European countries and Japan. The following diagram sets forth a summary of the business:

Anthem: An Integrated Drug Discovery, Development & Manufacturing Company



1,500+

World-class team of scientists and engineers

8,000+

Global projects handled

500+

Trusted global clients across US, Europe, Japan and ROW

75+

Acre campus to expand our market research and product portfolio

96%

Success rate for all projects

Mission, Vision and Values



MISSION

Transforming Lives by Accelerating Discovery

VISION

1. Innovation and Technology
2. High Quality Standards
3. Customer-First Approach

VALUES



Innovation driven
technology mindset



Customer-centric
approach




Agile and
flexible organization



Integrity and
transparency




Entrepreneurial
spirit with ESG focus



Cooperative
environment

Growth Journey

A Preferred CDMO Partner for Big Pharma & Emerging Biotech Innovators Globally



Anthem's Products and Service Offerings


Anthem's business segments comprises of:

- **CRDMO Services:** Anthem serves as a one-stop shop, providing comprehensive, integrated and highly customizable range of end-to-end services across the NCE and NBE lifecycles, from target identification and the concept stage, preclinical development, supporting customers by manufacturing development batches of molecules used for clinical (Phase I, II and III) trials up to commercial manufacturing, for both small molecules and biologics.
- **Specialty Ingredients:** Anthem manufactures and sell complex specialized fermentation-based APIs, including probiotics, enzymes, nutritional actives, vitamin analogues and biosimilars.




a) CRDMO Services: Integrated NCE and NBE Life Cycle Offerings

Anthem provides comprehensive, integrated services across the NCE and NBE life cycle, covering discovery, development, and manufacturing. For small molecules, Anthem's expertise includes medicinal chemistry, biology, integrated drug discovery, as well as drug substance development, process chemistry, and custom synthesis. For large molecules, Anthem offers specialized fermentation services, including high-density fermentation and biologics manufacturing, alongside cell culture services for microbial and mammalian systems to support clinical-scale production.



Integrated service offering enables Anthem to deliver flexible operating model and reduces time-to-market for customers

As an end-to-end CRDMO, Anthem has the capability to provide integrated services and onboard, transfer and deliver drug technology across various stages of the drug development lifecycle, which leads to reduced lead time and cost efficiencies for customers. In the CRDMO segment, Anthem provides versatile and adaptable solutions catering to a wide spectrum of therapeutic areas and scientific disciplines and across molecule sizes. The following diagram displays the modalities and technological capabilities:



b) Specialty Ingredients:

In Specialty Ingredients business, Anthem has leveraged on its technological capabilities across biology and chemistry and developed and commercialized specialty products, serving as a complementary revenue stream. The specialty ingredients market is broadly divided to biosimilars which includes microbial and mammalian, vitamin K2, probiotics, peptides, industrial enzyme, protease, serratiopeptidase, nutritional actives and vitamin analogues. Some notable examples of Specialty Ingredients portfolio are as follows:

Details	Biosimilar	Fermentation Products ⁽¹⁾	Probiotics & Enzymes	Peptides	Nutritional Actives and Vitamin Analogues
Market Size (2023)⁽²⁾	US\$25.0bn	US\$0.2bn	US\$7.2bn	US\$39.8bn	US\$29.7bn
Growth (2023 to 2028F)⁽²⁾	14.9%	8.9%	5.5%	23.0%	6.7%
Growth Drivers⁽²⁾	<ul style="list-style-type: none"> Patent expiry of biologics Approximately 200 biosimilars under development in India as of 2023 – faster & cheaper than western countries 	<ul style="list-style-type: none"> Vitamin K2: requirement of blended vitamin K products Serratiopeptidase: Non-opioid alternative to pain relief and inflation management 	<ul style="list-style-type: none"> Probiotics: Rising awareness, regulatory support on new strains & product approvals Enzymes: Growing focus on sustainable production technologies 	<ul style="list-style-type: none"> Prevalence of chronic diseases Significant opportunity with GLP-1 across diabetes and weight loss treatment (approximately 92.5% of peptides market in 2023) 	<ul style="list-style-type: none"> Higher incidence of lifestyle diseases Preference of preventive healthcare options Increasing demand for supplements
Use Case⁽²⁾	<ul style="list-style-type: none"> Oncology, immunology, musculoskeletal, endocrine (anti-diabetes), ophthalmology and hematology 	<ul style="list-style-type: none"> Vitamin K2: Dietary supplements, nutrition F&B, childcare products, cosmetics, pharma Serratiopeptidase: Pain management, inflammation drugs 	<ul style="list-style-type: none"> Probiotics: Functional F&B, dietary supplement, infant formula Enzymes: Pharma, home care, paper & pulp processing, textiles 	<ul style="list-style-type: none"> Wide range of therapeutic areas, such as Gastro-intestinal and metabolic disorders 	<ul style="list-style-type: none"> Dietary supplements, F&B, personal care, pharma grade vitamins, specialized nutrition
Our Capabilities	<ul style="list-style-type: none"> E. coli expression systems for commercial production of human insulin & insulin analogues Diabetes related disorders + recombinant GCSF & PEG-GCSF for patients with neutropenia 	<ul style="list-style-type: none"> Commercialized products like Serratiopeptidase Protease Combined chemical synthesis & fermentation in Unit II 	<ul style="list-style-type: none"> cGMP compliant manufacturing facility Multi-ton supply capacity Potent for exclusive supply arrangements with large domestic pharma 	<ul style="list-style-type: none"> GLP-1 manufacturing capabilities Providing GLP-1 samples to global and domestic customers looking to enter markets by 2026 	<ul style="list-style-type: none"> Human nutrition and dietary supplements, animal nutrition and industrial product segments Exclusive product line and technical support to global markets

(1) Fermentation products include Vitamin K2 and Serratiopeptidase only.

The manufacturing process of these products often involve green chemistry techniques, such as biotransformation, enabling a delivery of stable, quality and cost-effective products while maintaining high margins. The following summarizes some of the specialty ingredients products:

- (i) Fermentation Products: The two flagship commercialized fermentation products are (a) serratiopeptidase protease and (b) vitamin K2 (Menaquinone-7).
 - o **Serratiopeptidase protease** is a proteolytic enzyme to reduce inflammation and has antiedemic, analgesic, fibrinolytic and caesinolytic properties. Serratiopeptidase protease is produced through large-scale fermentation manufacturing facilities in Unit II.
 - o **Vitamin K2 (Menaquinone-7)** is a natural fermentation product which is essential for regulating calcium in human body. Vitamin K2 (Menaquinone-7) is produced at Anthem;s large-scale fermentation manufacturing facilities in Unit II through a biotransformation process by combining chemical synthesis and fermentation.
- (ii) Biosimilars: Anthem is able to produce biosimilars ranging from microbial biosimilars, mammalian biosimilars. Some examples are as follows:
 - o **Microbial Biosimilars:** Anthem uses E. coli as a host system to produce microbial biosimilars such as insulin, glargine, lispro, granulocyte-colony stimulating factor ("GCSF") and pegylated GCSF ("PEG-GCSF"). Through R&D programs on insulin and analogs, Anthem has developed E. coli expression systems for commercially viable production of a range of products. This includes recombinant human insulin and insulin analogues through the establishment of three different E. coli clones for production of r-human insulin, r-insulin glargine and r-insulin lispro to address diabetes-related disorders. Anthem also developed a recombinant GCSF and PEG-GCSF for patients with neutropenia, where E. coli is used for expression of GCSF. To address the short half-life of GCSF, we E. coli is also used for expression of PEG-GCSF to avoid repeated administration.
 - o **Mammalian Biosimilars:** The Company develops high expression Chinese hamster ovary ("CHO") cell line – ICH Q5B, which is a mammalian biosimilar typically used in the manufacturing of recombinant proteins to produce imaging proof of mAb and to establish clone stability.

(iii) Probiotics, Enzymes and Peptides

Anthem develops clones to produce probiotics such as Bacillus species, Lactobacillus species, Bifidobacterium species, Streptococcus Species and Saccharomyces boulardii by media optimization, animal-free media, filter optimization, drying parameter optimization and analytical method development. The Company possesses technical capabilities for bulk production of both sporulating and non-sporulating probiotic strains with 10 - 1,000 billion strength. The probiotics are available in liquid and powder forms, namely drug substance (DS) and pre-formulation ingredients (PFI), and the biocatalyst enzymes are supplied in various forms, including whole cell, cell-free extract solution, lyophilized powder and spray dried powder.

Anthem also has the technical know-how and capabilities in peptide synthesis, employing three distinct approaches – (a) solution phase, (b) solid phase, and (c) innovative hybrid mode, thus providing flexibility in designing an efficient synthesis route for the molecule. The peptide profile consists of therapeutic peptides like Semaglutide, Plecanatide, Linaclotide, Liraglutide, and Cilengitide, which target conditions such as Type 2 Diabetes mellitus, Chronic Idiopathic Constipation, Irritable Bowel Syndrome, and Obesity.

The table below sets forth examples of the probiotics, enzymes and peptides that are produced and commercialized:

Probiotics	Enzymes	Peptides and their respective target therapeutic areas
<ul style="list-style-type: none"> • Lactobacillus species (Lactobacillus acidophilus, Lactobacillus rhamnosus GG, Lactobacillus reuteri) • Bifidobacterium species (Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis) • Bacillus species (Bacillus clausii, Bacillus subtilis, Bacillus coagulans) • Streptococcus species • Saccharomyces boulardi • Customised Probiotic blends 	<ul style="list-style-type: none"> • GDH • DHFR • Lipase • Keto reductase • Transaminase • Tyrosin • Carboxypeptidase • Enterokinase 	<p>Semaglutide</p> <ul style="list-style-type: none"> • Type 2 Diabetes mellitus • Obesity <p>Plecanatide</p> <ul style="list-style-type: none"> • Chronic Idiopathic Constipation (CIC) • Irritable Bowel syndrome with constipation <p>Linaclotide</p> <ul style="list-style-type: none"> • Irritable Bowel syndrome with constipation • Chronic constipation with no known cause • Liraglutide • Type 2 Diabetes mellitus • Obesity <p>Cilengitide</p>


(iv) Nutritional Actives, Vitamin Analogues and APIs

The nutritional actives, vitamin analogues and APIs cater to human nutrition and dietary supplements, animal nutrition and industrial product segments. The table below sets forth examples of the nutritional actives, vitamin analogues and APIs that are produced and commercialized:

Nutritional Actives	Vitamin Analogues	APIs
<ul style="list-style-type: none"> • Bioavailable ResArgin • Pyrroloquinoline quinone • Disodium (PQQ) • S-Equol • Ubiquinol Acetate (EnQ10) 	<ul style="list-style-type: none"> • L-Methylfolate Calcium USP • Pyridoxal 5 phosphate • Vitamin K2 MK7 (microencapsulated powder and in oil form) • Vitamin MK4 – Menatetranone 	<ul style="list-style-type: none"> • Cabergoline IP/USP • Calcium folinate IP/USP/PhEU • L-Methyl Tetrahydrofolate USP • Calcium USP • Ormeloxifene IP • Valganciclovir IP/USP • Voglibose IP/JP/CP









Global Reach and Strategic Partnerships

Anthem's proven record of accomplishment includes working on over 600 molecules of varying complexities. The company collaborates with top global pharmaceutical companies and biotech clients globally. To target biotech and pharmaceutical companies in the United States, Anthem formed a strategic partnership with DavosPharma, sales partner in the United States, which is an affiliate of one of the Shareholders. Established in 1972, DavosPharma, as a strategic partner, has granted access to their local industry knowledge, and helped maintain front-end presence, servicing functions as well as customer connections in the United States.



Manufacturing Infrastructure

Anthem has three manufacturing facilities, namely Unit I in Bommasandra, Unit II in Harohalli and Unit III in Harohalli, which is under construction and is expected to be fully operational in the first half of 2025. Units I and II has an aggregate annual custom synthesis capacity and fermentation capacity of 270 kL and 142 kL, respectively. The Company is also in the process of expanding custom synthesis capacity at Unit II by 130 kL, and adding Unit III both of which is expected to be completed by the first half of 2025. Following the completion of such expansion activities, the aggregate annual custom synthesis capacity and fermentation capacity is expected to increase to 425 kL and 182 kL, respectively. The following table sets forth certain key features and functions of each of the manufacturing facilities:

	Unit I: Bommasandra	Unit II: Harohalli	Unit III: NeoAnthem
			
Established	2007	2016	2022
Total area (in acres)	5 acres	15 acres	8 acres
Discovery	✓		✓
Development	✓	✓	✓
Custom Synthesis capacity*	24 KL (27 reactors)	246 KL (60 reactors) Additional 130 KL by 2025 ⁽¹⁾	25 KL
Flow chemistry capacity	✓ (Lab Scale)	✓ (GMP Scale)	✓ (GMP Scale)
Fermentation capacity*	2 KL	140 KL	40 KL
Key Modalities	Chemistry Lab	250 Fume hoods with supporting infrastructure	100 Fume hoods with supporting infrastructure
	Peptide synthesis	50 L (Pilot Scale)	16 KL capacity (500 L SPPS, 1.2 m DAC purification)
	High potent compounds	55 L (Lab/Pilot Scale)	2.5 KL capacity (24 isolators, Designed for OEB 5-7 (1 – 0,001 µg))
	Oligonucleotide	Lab Scale	
	RNAi	✓	
	Biotransformation	200 L (Pilot Scale)	10 KL (GMP Scale)
Certifications	       	      	Phase wise under commissioning, to be fully commissioned in the first half of 2025 ⁽¹⁾

*includes peptide synthesis and high potent synthesis capacity, # includes Biotransformation capacity

In addition, land parcels have been acquired in Harohalli (30 acres) for proposed Unit IV facility, as well as in Hosur, Tamilnadu, which is located near Karnataka, for proposed Unit V facility.




Advancing Sustainability through Green Chemistry


Anthem Biosciences is deeply committed to green chemistry, prioritizing processes that minimize environmental impact while enhancing efficiency, safety, and sustainability. By integrating innovative approaches such as flow chemistry, micellar chemistry, pincer catalysis, and biocatalysis, the company continues to set benchmarks in environmentally responsible practices.

- (i) Biocatalysis: Anthem has adopted biocatalysis, harnessing enzymes derived from living sources to accelerate chemical reactions. This method delivers chirally pure compounds with a minimal environmental footprint, reinforcing Anthem's dedication to eco-friendly production.
- (ii) Flow Chemistry: Anthem has pioneered the development and scale-up of chemical processes using flow technology, addressing challenges like safety hazards, batch variability, and effluent load in traditional batch processes. With over two decades of expertise, the team has successfully transitioned several batch processes to flow chemistry, delivering notable benefits such as enhanced safety, scalability, and consistency, along with reduced solvent usage and shorter synthesis cycles.
- (iii) Pincer Catalysis: Anthem incorporates pincer catalysis, utilizing proprietary and commercially available pincer complexes as a safer and more efficient alternative to hazardous pyrophoric metal hydrides. This approach not only ensures ease of isolation but also significantly reduces solid waste generation.
- (iv) Micellar Chemistry: Anthem employs micellar chemistry technology to produce biodegradable and recyclable surfactants using minimal solvents. This enables chemical synthesis in water, providing superior reaction kinetics and cleaner reaction profiles. The process underscores Anthem's commitment to reducing reliance on harmful solvents while advancing sustainable innovation.

With commercialized products developed through biocatalysis, biotransformation, and flow-catalysis, Anthem exemplifies the potential of green chemistry to revolutionize industrial processes. The company's unwavering focus on sustainability continues to drive innovation, paving the way for a cleaner, safer, and more efficient future in biosciences.




Anthem is committed to implementing environmental management policies across its business, with commitment to the near-term science-based targets initiative (“SBTi”) to reduce Scope-1 and Scope-2 greenhouse gas emissions. To support these efforts, dependency on renewable energy has been sustained at approximately 90% levels of the total energy consumption, as well as waste and water stewardship is prioritised. These includes striving to achieve a “Zero Liquid Discharge” status at its manufacturing sites and designing an effective waste (hazardous and non-hazardous) management system. The use of renewable energy (consisting of wind energy and solar energy) as a percentage of the total energy consumption has increased from 74.46% in Fiscal 2022 to 88.86% in Fiscal 2024. The following diagram illustrates the breakdown of energy sources for the years indicated:



To reduce greenhouse gas emissions, other initiatives have also been undertaken, including the installation of gas scrubbing systems, vent condensers, cold traps at the vent of vacuum pumps and the use of High Efficiency Particulate Air (HEPA) filters to control indoor air quality in powder handling areas. As a result of these efforts, the GHG emission intensity has reduced from ₹1.25 tCO₂e/million in Fiscal 2023 to ₹1.24 tCO₂e/million in Fiscal 2024.

The following sets forth a breakdown of the GHG emissions intensity reductions from Fiscal 2023 to Fiscal 2024.

	Scope 1 Emissions (tCO ₂ e)	Scope 2 Emissions (tCO ₂ e)	Biogenic Emissions (tCO ₂ e)	Total Emissions (tCO ₂ e)	Revenues (₹ million)	GHG Emission Intensity (tCO ₂ e per ₹ million)
Fiscal 2023	10,798	2,355	33	12,650	10,569.24	1.25
Fiscal 2024	13,561	3,923	147	17,631	14,193.70	1.24



One of the lowest GHG Intensity in the industry (like-to-like comparison based on Scope 1 + Scope 2 emissions)


Digital Transformation

As part of the commitment to implement a robust quality system and as part of digital transformation from a paper-based system to a compliance digital system, Anthem has implemented the following quality control systems:

- **Veeva Vault Quality:** Anthem uses Veeva Vault Quality, an integrated cloud-based platform to collect, track, analyze and report data in testing and production processes, which grants them the access to real-time data and facilitates comprehensive quality decision making. Anthem also employs the use of Veeva Vault QualityDocs, which enhances compliance by managing the creation, review, approval, and storage of quality documents. This platform enables to produce; secure and compliant audit trails in accordance with applicable regulations stipulated by the US FDA. The Veeva quality management system also monitors the manufacturing practices to ensure operations comply with the relevant cGMPs, regulations and standards.
- **SAP S4/ HANA:** SAP S4/HANA system enable to monitor all areas of business processes from R&D and raw material procurement to manufacturing to packaging and delivery. The facilities at Unit I and Unit II are compliant with ISO 9001:2015 quality management systems.
- **Building management system (“BMS”):** Anthem adopts BMS for monitoring, managing and reporting on utility data in the manufacturing units. The BMS monitors and manages the condition of the utility-related equipment to predict and prevent failures, schedules maintenance activities based on equipment condition and performance data, analyzes energy usage patterns for efficiency improvements, and identifies peak load periods and implements load-shifting strategies. The BMS also monitors and regulates temperature, humidity, and air quality in critical areas such as clean rooms and storage facilities, which ensures that conditions remain within specified limits and optimizes energy consumption, reduces costs in maintaining the necessary environmental conditions for production and storage of the materials, and provides real-time monitoring and alerts for deviations in critical parameters to enable rapid response to prevent product spoilage or contamination.
- **Distributed Control System (“DCS”):** Anthem has implemented an integrated DCS system combining API, fermentation, biologics, continuous flow, purified, water for injection (“WFI”) water plants, building management, and continuous monitoring systems. The DCS system has enabled to integrate and automate various production and monitoring processes, BMS, and utilities, and allows to monitor operations on a scalable platform. The system also collects and stores process data, which is analyzed to optimize production efficiency, improve product quality, and ensure adherence to regulatory requirements such as those from the USFDA and European Medicines Agency (“EMA”).
- **Control process automation system:** Control process automation systems are implemented in the manufacturing units, which monitors critical process parameters such as temperature, pressure, pH value, flow rate on a real-time basis. The control process automation system enables precise and automated controls on the manufacturing processes to ensure efficiency, consistency, and compliance in production flow.



Anthem's Digital Transformation: World Class Automated Systems and Framework, provides Flexibility, Efficiency and Access to Detailed Analytics



Anthem's IT systems are extremely robust, with every unit and division securely connected to one another

In-house data centers, infrastructure, applications and endpoints are virtualized and delivered from Data Centres

Anthem Adopted Next Generation cyber security systems and Security Operations Centre(SOC)

Anthem implementing platform based approach on Quality systems - DMS, LMS and OMS

Anthem's Digital Transforming Architecture



The background is a dark blue field filled with glowing orange and yellow particles, some of which are connected by thin, faint lines, creating a network-like or molecular structure. A large, textured blue sphere is positioned in the center-left. Two thick, solid orange diagonal stripes cross the image: one from the top-left towards the bottom-right, and another from the top-right towards the bottom-left, intersecting near the center. The text is centered in the lower half of the image, overlaid on the dark blue background.

Board of Directors and Board's Report

Founding Team and Board of Directors



Mr. Ajay Bharadwaj

CEO & Founder

Industry Experience: 38 Years

Ajay Bharadwaj, CEO, Founder, Chairman, and Managing Director, holds a B.Tech. in Chemical Engineering from IIT Delhi (1982) and earned his Master's from Louisiana State University in 1984. Commencing his career at Max India, he later played a pivotal role in the early stages of Biocon's growth, contributing significantly to the company's success alongside Kiran Mazumdar Shaw. Serving as the President of Marketing at Biocon, he was a driving force behind the company's rapid expansion, leading initiatives in brand development and pioneering ventures into new domains such as life sciences, contract research, and clinical research.



Mr. K.C. Ravindra

COO & Co-Founder

Industry Experience: 33 Years

K.C. Ravindra, COO, Co-Founder, and Director, holds a B.Tech. in Chemical Engineering from Bangalore University (1990). Commencing his career in industrial production in 1990, he held key positions at Cipla, Recon Limited (now Hikal), and Biocon. Notably, as General Manager, Operations at Biocon, he played a pivotal role in establishing scalable processes and building world-class manufacturing facilities that met global standards, successfully navigating USFDA and European regulatory approvals. With extensive exposure to international inspections from regulatory bodies like USFDA and customer audits, Mr. K.C. Ravindra brings a wealth of experience to his role.



Dr. Ganesh Sambasivam

CSO & Co-Founder

Industry Experience: 30 Years

Dr. Ganesh Sambasivam, CSO, Co-Founder, and Director, earned his Ph.D. from the National Chemical Laboratory, Pune, India, in 1993. His academic journey includes undergraduate studies in Chemistry at Madras University, postgraduate studies with a Fellowship at the National Chemical Laboratory, and a Master's program in Organic Chemistry from the University of Pune. With over a decade of experience at Syngene International Private Limited, where he served as Chief Scientific Officer before cofounding Anthem, Dr. Sambasivam specializes in process R&D related to combinatorial chemistry building blocks, reagents, generic drugs, and novel flavor chemicals for food industry applications.



Private Equity

Nominee Director

Satish Chander

Nominee Director

Satish Chander, Nominee Director representing the PE investor, holds a Mechanical Engineering degree from IIT Chennai and a Post Graduate Diploma in Management from IIM, Kolkata. He was part of JP Morgan's equity research team covering Indian companies in the oil & gas sector. Before that, he was a management consultant at Accenture, India and worked across pharma, FMCG, auto ancillary sectors, handling projects in strategy, post-merger integration, supply chain restructuring and procurement optimisation. He was part of the business management team and has worked with companies across healthcare, media, retail, and industrial sectors. He now leads investments in the healthcare and life sciences sector.

Board's Report FY 2023-2024

Dear Shareholders,

The Board of Directors hereby submits the report of the business and operations of your Company ("the Company" or "Anthem"), along with the audited financial statements, for the financial year ended March 31st, 2024. The consolidated performance of the Company and its subsidiaries has been referred to wherever required.

Particulars	Standalone Financial Highlights		Consolidated Financial Highlights	
Financial Year	As on 31st March, 2024	As on 31st March, 2023	As on 31st March, 2024	As on 31st March, 2023
Revenue	141,753.90	105,692.43	141,936.96	105,692.43
Other income	7,051.98	7,737.17	6,369.92	7,706.84
Total Income	148,805.88	113,429.60	148,306.87	113,399.27
Expenses:				
Operating Expenditure	92,179.60	63,461.97	92,392.67	63,480.15
Depreciation & Amortization Expenses	8,149.02	6,369.60	8,182.42	6,369.60
Total Expenses:	100,328.61	69,831.57	100,575.09	69,849.75
Profit before Tax (PBT)	48,477.27	43,598.03	47,731.79	43,549.52
Add: Exceptional & Extra Ordinary items	-	6,180.25	-	6,180.25
Less: Tax Expenses	10,999.20	11,211.16	11,000.79	11,211.26
Profit after Tax (PAT)	37,478.07	38,567.12	36,731.00	38,518.51
Opening balance of Retained Earnings	122,097.04	97,465.38	122,011.58	97,423.67
Profits for the year	37,478.07	38,567.11	36,731.00	38,518.51
Adjustment during the year	4.6	-10,078.75	4.6	-10,078.75
Less: Dividend (inclusive of dividend tax)	3416.86	-	3,416.86	-
Less: Trf to General Reserve	3,747.81	3,856.71	3,673.10	3,851.85
Closing balance of Retained Earnings	152,415.04	122,097.04	151,657.22	122,011.58

2) Performance Overview

The Standalone and Consolidated Financial Statements of the Company have been prepared in accordance with the Indian Accounting Standards ('Ind AS') as notified under the Companies (Indian Accounting Standards) Rules, 2015, as amended.

On a standalone level, the Company witnessed:

- Increase in revenues by 34.12% as compared to the previous year;
- PBT increased to Rs. 48,477.27 lacs in FY2024, as compared to Rs. 43,598.03 lacs in FY2023;
- PAT for FY2024 & FY2023 was Rs. 37,478.07 lacs & Rs. 38,567.12 lacs respectively.

On a consolidated level, the Company witnessed:

- Increase in revenues by 34.29% as compared to the previous year;
- PBT increased to Rs. 47,731.79 lacs, as compared to Rs. 43,549.52 lacs in FY2023;
- PAT for FY2024 & FY2023 was Rs. 36,731.00 lacs & Rs. 38,518.51 lacs respectively.

3) Operational Overview

Anthem Biosciences Private Limited, incorporated in Bengaluru, India in 2006 is an innovation-driven and technology-focused CRDMO ("Contract Research, Development and Manufacturing Organization") with fully integrated operations spanning across drug discovery, development and manufacturing across both chemical synthesis and biologics. As a one-stop service provider, Anthem is a trusted partner of choice for both innovator focused new-age emerging biotechs and large pharmaceutical companies globally.

With 2,000+ scientists and research professionals, Anthem is a market leader in the Indian CRDMO space and the youngest and the fastest CRDMO in India to achieve a milestone of ₹ 1,000 Crore of revenues in FY 2021.

Anthem commenced operations as an export-oriented unit (EOU) and over the years has added new technologies, expanding them from laboratory-scale level to commercial scale cGMP manufacturing units. As of 31st March 2024, there are three manufacturing units, all located in Bangalore, and two land parcels earmarked in Harohalli and Hosur for future expansion. The three manufacturing locations are as below:

- Unit I (Bommasandra industrial area);
- Unit II (Harohalli industrial area);
- Unit III (NeoAnthem @ Harohalli), a wholly owned subsidiary, expected to commence operations in Fiscal 2025.

4) Dividend

No dividend shall be declared for the Financial Year ended 31st March 2024.

5) Transfer to Reserves

The Board of Directors propose to transfer Rs. 17,135.37 lacs to the General Reserves and the balance of Rs. 151,657.22 lacs will be retained in the Profit and Loss account.

6) Subsidiaries

The Company has one Wholly Owned Subsidiary as on 31st March 2024.

NEOANTHEM LIFESCIENCES PRIVATE LIMITED is a wholly owned subsidiary of Anthem Biosciences Private Limited and was incorporated on the 22nd July 2020 with its registered office at 49, F1&F2, Canara Bank Road, Bommasandra Industrial Area-Phase I-560099, was established with the objective to discover, develop, manufacture and commercialize biopharmaceutical products that address significant unmet needs and provide biological solutions to improve industrial performance in all areas.

As per Sec. 129(3) of the Companies Act, 2013, where a company has one or more subsidiaries, it shall, in addition to its financial statement, prepare a consolidated financial statement of the Company and all subsidiaries in the same form and manner as that of its own and also attach along with its financial statement, a separate statement containing the salient features of the financial statement of its subsidiaries.

There is no Company, which have become or ceased to be the subsidiary, joint venture or associate company of Anthem during the year 2023-2024. In accordance with the above, the consolidated financial statement of the Company and its subsidiary is prepared in accordance with Accounting Standards 21 and 27 as specified in the Companies (Accounts) Rules, 2014, form part of the annual report. Further, a statement containing the salient features of the financial statement of our subsidiary in the prescribed format AOC-1 is attached as "Annexure 1" to the Board Report.

7) Directors:

Mr. Ravindra K.C. (DIN:01580534), shall retire by rotation at the ensuing Annual General Meeting and is eligible for reappointment.

8) Number of Board Meetings

The Board of Directors met four (4) times during the financial year ending 31st March 2024. The intervening gap between any two meetings was within the period prescribed by the Companies Act, 2013. The Board passed resolution by Circulation one time during the year.

Board Meeting Date	Ajay Bhardwaj	Ganesh Sambasivam	Ravindra KC	Satish Chander S
31st May 2023	√	√	√	√
6th September 2023	√	√	√	√
11th December 2023	√	√	√	√
14th March 2024	√	√	√	√

Committees of the Board Currently, the Company has two (2) Board level Committees:

- Corporate Social Responsibility Committee and
- Environment, Social and Governance & Climate Change Committee.

9) Director's Responsibility Statement

In compliance with the section 134 (5) of the Companies Act, 2013, the board of directors hereby confirms the following:

- In the preparation of annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departure, if any;
- We have selected such accounting policies and applied them consistently. We have made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs and of the profit of the company at the end of the financial year;
- We have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- We have prepared the annual accounts on a going concern basis; and
- We have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

10) Material Changes and Commitments occurred between the date of Balance Sheet and the date of Audit Report

On March 14, 2024, the Company's Board of Directors approved the allotment of 1,14,09,700 (one crore fourteen lakhs nine thousand and seven hundred) employee stock options ("Options"), in one or more tranches to the Employees of the Company. This action was endorsed by the shareholders at the Extraordinary General Meeting held on April 15, 2024, allowing the grant of equity shares of the Company in tranches.

11) Change in Nature of Business

The Company continues to be a pioneer biopharmaceutical company engaged in manufacturing active pharmaceutical ingredients and formulations, with sales in markets across the globe.

There has been no change in the nature of the business of the Company.

12) Deposits

The Company has not accepted any deposit, including from the public, and as such no amount of principal and interest were outstanding as on 31st March 2024.

13) Particulars of Loans, Guarantees or Investment

Details of loans, guarantees and investments covered under the provisions of Section 186 of the Companies Act, 2013 forms part of the notes to the Financial Statements provided in this Annual Report.

14) Policy on Directors' Appointment and Remuneration

The Company has no policy on Directors' Appointment and Remuneration as per the provision of the Companies Act, 2013.

15) Employee Stock Option Plan

The Shareholders have vide special resolutions passed on 15th April, 2024 approved the 'Anthem Employee Stock Option Plan 2024' ("ESOP 2024"/ "Plan") for grant of options to eligible employees of the Company, subsidiary(ies), which based on the vesting schedule will be exercisable to shares of the Company.

The Company has not granted any options / share units during FY2024 under the scheme.

16) Risk Management Policy / Framework

The Company has no risk management policy and no formal committee is constituted for this purpose. The Company, however, lays emphasis on risk management and has an enterprise-wide approach to risk management, which emphasizes on identifying and managing key operational and strategic risks with a dynamic business continuity plan. The Company strives to identify opportunities that enhance organizational values while managing or mitigating risks.

17) Related Party Transactions

In accordance with Section 134 (3) (h) of the Companies Act, 2013, read with Rule 8(2) of the Companies (Accounts) Rules, 2014, the particulars of contract or arrangement entered into by the Company with related parties referred to in Section 188(1) in form AOC-2 is attached as "Annexure-2" to this report.

18) Vigil Mechanism

The Vigil Mechanism is envisaged pursuant to Section 177(9) of the Companies Act, 2013, through the Company's Whistle Blower Policy. The Whistle Blower Policy intends that the employees of the Company observe high standards of business, professional and personal ethics to conduct the affairs of the Company in a fair and transparent manner by practicing the highest standards of honesty and integrity while complying with all applicable laws and regulations.

The Whistle Blower policy of the Company is available on the website of the Company at <https://www.anthembio.com/Whistle%20Blower%20Policy.html>

19) Auditors:

Statutory Auditors: M/s. K. P. Rao & Co., Chartered Accountants, (Firm Registration no. 003135S) were appointed as the Statutory Auditors of the Company to hold office from the conclusion of the 13th Annual General Meeting held on September 30, 2019 until the conclusion of the 18th Annual General Meeting of the Company to be held in the calendar year 2024. The Auditors are to be re-appointed in the Annual General Meeting to be held on 27th September 2024 for the second term for two consecutive years, upto the conclusion of the Annual General Meeting to be held in 2026.

- **Board's response on Auditors Qualification, Reservation or Adverse Remark or Disclaimer made** There are no qualifications, reservations or adverse remarks made by the Statutory Auditors in their report.
- **There are no frauds reported by auditors under Section 143(12).**

Cost Auditors: The Cost Records of the Company are maintained in accordance with the provisions of Section 148(1) of the Companies Act, 2013. In the current year, the foreign exchange revenue of the Company for the preceding Financial Year i.e.2023-24 exceeds seventy five per cent (75%) of its total revenues and thereby the Company is exempted from conducting cost audit for the FY2025 pursuant to Rule 4 clause 3(i) of the Companies (Cost Records and Audit) Rules, 2014.

Secretarial Auditors: Pursuant to the provisions of Section 204 of the Companies Act, 2013 and rules thereunder, M/s V. Sreedharan & Associates, Practicing Company Secretaries were appointed to conduct the secretarial audit of the Company for the Financial Year 2023-24. The Secretarial Audit Report for the Financial Year 2023-24 does not contain any qualification, reservation or adverse remark or disclaimer and is appended herewith as "Annexure 3" to the Boards' report.

20) Annual Return

The Annual Return of the Company as per the provisions of Section 134(3)(a) and 92(3) of the Companies Act, 2013, will be available on the website of the Company at <https://www.anthembio.com/Corporate%20Compliance.html>

21) Significant and Material Order

There are no significant and material orders passed during the year by the regulators, courts or tribunals impacting the going concern status and Company's operations in the future.

22) Corporate Social Responsibility

In compliance with Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules 2014, the Company has established the Corporate Social Responsibility Committee (CSR Committee). The Board, on the recommendation of the CSR Committee, adopted a CSR Policy. The same is available on the Company's website at <https://anthembio.com/Corporate%20Social%20Responsibility.html>

The annual report on our CSR activities is appended as "Annexure-4" to the Board's Report.

23) Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal), Act, 2013

The Company has a policy and framework for employees to report sexual harassment cases at the workplace and the said process ensures complete anonymity and confidentiality of information. Anthem has constituted an Internal Complaints Committee in compliance with the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules there under. The policy provides for creating a healthy and safe work environment that enables employees to work free from any unwelcome, offensive and discriminatory behavior. During the year, the Company has not received any complaints. The Company has been conducting regular awareness programmes aimed at prevention of sexual harassment. During the financial year, no complaints were received under the POSH Act.


24) Conservation of Energy, Technology Absorption, Foreign Exchange Earnings & Out Flow

The information required under Section 134 (3) (m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 with respect to these matters is given below:

a) Conservation of Energy


The steps taken or impact on conservation of energy:

- **Increase in dependency on renewable source of energy (wind and solar energy):** Anthem has increased the dependency on renewable energy by utilizing wind energy and solar energy through group captive arrangements. The amount of renewable energy wheeled is 38.3 million kWh in FY2024 as compared to 35.0 million kWh in FY2023. The overall dependency on renewable energy as a percentage of total energy consumption stands at 89% in FY2024 as compared to 93% in FY2023, 75% in FY2022 and 44% in FY2021.



As of 31st March 2024, Anthem has group captive arrangements for 21.0 MW of renewable energy (wind and solar).


- **Air Emission Reduction Initiatives:** Current air emissions are within the KSPCB permissible limits as shown for both our units: Bommasandra (Unit I) and Harohalli (Unit II) below:



Following initiatives are being used to reduce air emissions across both the units:


- Use of HEPA filters to control indoor air quality in powder handling areas
- Efficient gas scrubbing systems
- Use of vent condensers
- Cold Traps introduced at the vent of the vacuum pumps

- **Reduction in Green House Gas Emissions:** Anthem has implemented various sustainable manufacturing practices, such as (a) increased use of renewable (b) new sustainable power sources, including the use of PNG in boilers and thermic fluid heaters and harvested biogas as a sustainable fuel source in boilers, resulting in significant reduction in CO₂ emissions. Anthem's GHG emission has reduced over Fiscal 2023 to Fiscal 2024 and currently has one of the lowest GHG intensity of ₹1.25 tCO₂e/million INR as compared to Indian peers.



One of the lowest GHG Intensity in the industry (like-to-like comparison based on Scope 1 + Scope 2 emissions)

- **Effluent Treatment Initiatives:** The effluent produced during operations undergoes treatment in an in-house Zero Liquid Discharge (ZLD) plant, with the treated water being reused into utilities. Additionally, the sewage generated by the Units are processed in an on-site Sewage Treatment Plant (STP). The treated sewage is reused for gardening. Anthem's use of recycled water has increased from 48.5% in Fiscal 2023 to 97.8% in Fiscal 2024 at Unit I and 77.1% in Fiscal 2023 to 87.2% in Fiscal 2024 at Unit II. 85% of Process Effluent generated at Bommasandra (Unit I) is recycled and 94% of Process Effluent generated at Harohalli (Unit II) is recycled.



Anthem is committed to adopting strategies for effective waste and water management through the implementation of innovative technologies and solutions aimed at minimizing waste, enforcing stringent waste segregation, and ensuring proper disposal. This approach significantly alleviates the burden on landfills and the associated costs. For instance, Anthem has installed a sludge dryer at Unit-II to reduce both the volume of sludge and the environmental impacts linked to its disposal, such as leachate generation and greenhouse gas emissions. Likewise, at Unit I, the sludge produced from ETP operations has been reduced by approximately 50% through the elimination of conventional coagulant aids, such as lime.

Other Initiatives

- o Automation Exercise: in chilled water secondary pump, process cooling tower pump and cooling tower fans
- o Replacing existing thermodynamic steam traps with inverted bucket steam traps
- o Installation of solar panels at Harohalli (Unit II)
- o Procurement of additional Biogas Boiler for utilization of Biogas over conventional fuel such as Furnace Oil and High Speed Diesel

b) Technology absorption: The Company continues to adopt and use the latest technologies to incorporate green chemistry and sustainable manufacturing practices to reduce costs and improve the business margins. Anthem intends to make customer move towards flow chemistry and bio-transformation, both greener and cost efficient.

- o **Biotransformation:** Anthem utilizes living source enzymes to speed up reactions and produce chirally pure compounds, which has lower environmental impact due to their specific targeted biological activity, reduced side effects, differential degradation and lower dosage requirements

- o **Pincer Catalysts:** Anthem uses pincer complex, which is a coordination compound with a pincer ligand, in its production for ease of isolation. The inflexible pincer-metal interaction confers high thermal stability to the resulting complexes and avoids generating excessive solid waste
- o **Flow Chemistry:** Flow chemistry involves conducting chemical reactions in a continuously flowing stream rather than in traditional batch reactors. It is an automatic continuous process that substantially generates less byproducts and waste materials, maintains a steady production flow with reduced solvent requirements and synthesis cycle time and substantially improves the safety, yield, waste disposal, cost efficiency and stability of the end products and the manufacturing processes
- o **Micellar Chemistry:** Anthem uses the interior of micelles to harbor chemical reactions, resulting in biodegradable and recyclable surfactants with minimal solvent and cleaner reaction profile.

New-age technologies: In new-age technologies, Anthem aims to add lab scale capabilities on Photochemistry and electro synthesis, both are alternative procedures for the synthesis of new complexes. Photochemistry will be experimentally simpler and less expensive than the thermal alternative and will also be environment friendly. Electro-synthesis will lead to successfully replacing harmful terminal oxidizers and reducing agents, thus making the chemistry greener. Both technologies will thus aid in the push towards greener chemistry cost efficient processes.

c) Foreign Exchange Earnings and Outgo

- o Foreign Exchange earnings: Rs. 110,866.49 lacs
- o Foreign Exchange outgo : Rs. 33,072.75 lacs

25) Expenditure on Research & Developments: Company has its own in house R&D centre, with best in class infrastructure facility equipped with modern plant and machinery and scientific labs to carry out the scientific research and development related activities in the field of custom synthesis and biological / biosimilar activities. Innovation and research are critical to ensuring better health and creating financial value.

Expenditure incurred for R&D during FY2024 & FY2023 is as given below:

Sl. No.	Particulars (Rs. in lacs)	FY 2024	FY 2023
a.	Capital expenditure	104.82	570.05
b.	Other recurring expenditure	2316.05	2,586.13
(a+b)		2420.87	3,156.18

26) Details of application made or any proceeding pending under the Insolvency and Bankruptcy Code, 2016 during the year along with their status as at the end of the financial year

There was no application made or proceeding pending against the Company under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year under review.

27) Details of difference between amount of valuation done at the time of one-time settlement and valuation done while taking loan from the banks or financial institutions along with reasons thereof

There is no difference between the amount of valuation done at the time of one-time settlement and valuation done while taking loan from the banks or financial institutions.

28) Environment, Social and Governance & Climate Change, (ESG)

The Company's commitment towards environment & climate change, social and governance (ESG) is a result of an increasingly volatile world where economic realities transform overnight. There is a growing conviction that a robust ESG fabric enhances stability, increases counter cyclicity and establishes the basis for long-term stakeholder value. The Company believes that this commitment is critical considering that the products manufactured consumes land, water, natural resources, fossil fuels and electricity, any moderation in which can have upsides for the local terrain, habitat and ecology.

Anthem defines sustainability as its efforts to reduce energy consumption, water usage, waste disposal and promotion of strategies that progress towards combating climate change and transitioning to a low carbon economy. The Company believes that, adopting financially responsible steps towards improving environmental sustainable operational practices represents good and responsible corporate citizenship and serves in the best interests of its clients.

The Board has adopted an Environmental, Social and Governance Policy. The same along with the annual ESG report for the year is available on Company's website at <https://www.anthembio.com/ESG%20Policy%20Anthem.html>

The ESG & CC Committee of the Company was constituted on 30th May, 2022 and comprises of the following directors as on 31st March 2024:

Sl. No.	Name of the Individuals	Designation	Category	ESG & CC Committee Meetings held during the year	ESG & CC Committee Meetings attended during the year
1	Ajay Bhardwaj	Chairperson	Managing Director	2	2
2	Sambasivam Ganesh	Member	Director	2	2
3	K.C. Ravindra	Member	Director	2	2
4	Md. Gawir Baig	Member	CFO	2	2
5	Sajith Sahadevan	Member	Head – EHS	2	2

29) Management's Discussion and Analysis

The Company has, on a voluntary basis furnished the requirements on the Management Discussion and Analysis Report for the year 2024 and this forms a part of Annual Report.

30) Significant Events During Financial Year 2023-24

(a) Buyback of Equity Shares of the Company

The Board of Directors in its meeting held on 11th December, 2023 approved buyback of 11,409,700 number of equity shares by the Company of its fully paid up equity shares of the face value of ₹ 2 /- (Rupees Two) each from the members of the Company at a price not exceeding Rs. 130.55/- (Rupees One Hundred Thirty and Fifty Five Paise Only) per equity share ("Maximum Buyback Price") and such aggregate amount, up to ₹ 148,95,36,335.00 (Rupees One Hundred Forty Eight Crores Ninety Five Lakhs Thirty Six Thousand Three Hundred Thirty Five Only) ("Maximum Buyback Size"), representing 7.84% of the aggregate of the total paid-up share capital and free reserves of the Company based on the latest financial statements of the Company as at September 30, 2023 (on a standalone basis) ("Buyback").

Acknowledgement

The Board of Directors take this opportunity to thank the customers, shareholders, suppliers, bankers, business associates, financial institutions for their consistent support and encouragement to the Company.

We are sure you will join our Directors in conveying our sincere appreciation to employees at all levels of the Company for their hard work, dedication and commitment, in particular during this unprecedented year, thereby ensuring uninterrupted supply of quality services across the globe.

For and on Behalf of the Board

Place: Bangalore

Ajay Bhardwaj

Date: September 05, 2024

Chairman & Managing Director

ANNEXURE 1

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

Part "A": Subsidiaries

Sl. No.	Particulars	Details
1.	Name of the subsidiary	Neoanthem Lifesciences Private Limited
2.	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	Same as Holding Company
3.	Reporting currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries	NA
4.	Share capital	15,00,000
5.	Reserves & surplus	-
6.	Total assets	2,486,646,494.06
7.	Total Liabilities	2,486,646,494.06
8.	Investments	0
9.	Turnover	19,502,558.61
10.	Profit before taxation	(74,548,003.10)
11.	Provision for taxation	0
12.	Profit after taxation	(74,707,111.55)
13.	Proposed Dividend	0
14.	% of shareholding	100%

Notes: The following information shall be furnished at the end of the statement:

1. Names of subsidiaries which are yet to commence operations

None

2. Names of subsidiaries which have been liquidated or sold during the year.

There are no such subsidiaries which have been liquidated or sold during the year.

Part "B": Associates and Joint Ventures

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures

There are no Associates and/or Joint Ventures with the company as on March 31, 2024.

ANNEXURE 2

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies

(Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto:

1. Details of contracts or arrangements or transactions not at arm's length basis:

- Name(s) of the related party and nature of relationship: NIL
- Nature of contracts/arrangements/transactions: NIL
- Duration of the contracts / arrangements/transactions: NIL

d. Salient terms of the contracts or arrangements or transactions including the value, if any: NIL

e. Justification for entering into such contracts or arrangements or transactions NIL

f. Date(s) of approval by the Board: NIL

g. Amount paid as advances, if any: NIL

h. Date on which the special resolution was passed in general meeting as required under first proviso to section 188: NIL

2. Details of material contracts or arrangement or transactions at arm's length basis:

a. Name(s) of the related party and nature of relationship:

Sl. No.	Particulars	Details
1	Anthem Bio Pharma Pvt. Ltd.	Common directors
2	Ishaan Bhardwaj	Relative of Director
3	Krithika Ganesh	Relative of Director
4.	Keerthana Ravindra	Relative of Director

(b) Nature of contracts/arrangements/transactions:

Sl. No.	Particulars	Details
1	Anthem Bio Pharma Pvt. Ltd.	Rent received from Anthem Bio Pharma Pvt. Ltd.
2	Ishaan Bhardwaj	Salary paid to relative of Managing Director
3	Krithika Ganesh	Salary paid to relative of Director
4.	Keerthana Ravindra	Salary paid to relative of Director

(c) Duration of the contracts / arrangements/transactions:

Sl. No.	Particulars	Details
1	Rent received from Anthem Bio Pharma Pvt. Ltd.	12 years
2	Salary paid to relative of Managing Director	4 years
3	Salary paid to relative of Director	2 year
4.	Salary paid to relative of Director	2 year

(d) Salient terms of the contracts or arrangements or transactions including the value, if any:

Sl. No.	Particulars	Details
1	Rent received from Anthem Bio Pharma Pvt. Ltd.	As per the agreement entered by the Company with Anthem Bio Pharma Pvt. Ltd. on 24th May 2012.
2	Salary paid to relative of Managing Director	As per the letter of appointment issued by the Company dated 18th February 2019.
3	Salary paid to relative of Director	As per the letter of appointment issued by the Company dated 26th August 2021.
4.	Salary paid to relative of Director	As per the letter of appointment issued by the Company dated 04th April 2022.

(e) Date(s) of approval by the Board, if any:

Sl. No.	Particulars	Details
1	Rent received from Anthem Bio Pharma Pvt. Ltd.	24/05/2012
2	Salary paid to relative of Managing Director	-
3	Salary paid to relative of Director	-
4.	Salary paid to relative of Director	-

(f) Amount paid as advances, if any: NIL

ANNEXURE 3

Form No. MR-3

SECRETARIAL AUDIT REPORT

[Pursuant to Sub Section (1) of Section 204 of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

For the Financial Year Ended March 31, 2024

To

The Members

ANTHEM BIOSCIENCES PRIVATE LIMITED

No. 49, F1 & F2, Canara Bank Road,
Bommasandra Industrial Area, Phase I,
Bommasandra, Bengaluru- 560099.

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Anthem Biosciences Private Limited ("the Company"). The Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the financial year ended on March 31, 2024 (the audit period) complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed, and other records maintained by the Company for the financial year ended on March 31, 2024, according to the provisions of:

- i. The Companies Act, 2013 (the Act) and the rules made thereunder;
- ii. The Depositories Act, 1996 and the Regulations and Byelaws framed thereunder;
- iii. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment. No Overseas Direct Investment and External Commercial Borrowings were made by the Company during the period under review;
- iv. Other laws specifically applicable to the Company:
 1. Drugs and Cosmetics Act, 1940
 2. Bio Medical Waste (Management & Handling) Rules, 1998
 3. ICH Guidelines
 4. National Biodiversity Act, 2002
 5. Narcotic Drugs and Psychotropic Substance Act, 1985
 6. Drugs (Control) Act, 1950
 7. Local laws laid down by Karnataka State Pollution Control Board (KSPCB), Central Pollution Control Board, Ministry of Environment and Forest, National Green Tribunal, Dept. of Factories, Boilers Industrial Safety and Health.
 8. FSSAI Regulation 2011.

The Company being a Private limited company, the following Regulations prescribed under Securities and Exchange Board of India Act, 1992 ('SEBI Act') were not applicable to the Company during the audit period:

- (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (b) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder.
- (c) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (d) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
- (e) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;

- (f) Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021;
- (g) The Securities and Exchange Board of India (Registrar to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- (h) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021;
- (i) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; and
- (j) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

As the Company is a private Company, entering agreement with stock exchanges does not arise.

We have also examined compliance with the applicable clauses of Secretarial Standards issued by the Institute of Company Secretaries of India on Meetings of the Board of Directors and General Meeting.

We have not examined compliance with applicable Financial Laws, like Direct and Indirect Tax Laws, since the same have been subject to review by statutory financial audit and other designated professionals.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines and Standards etc., mentioned above.

We further report that the Board of Directors of the Company is duly constituted. During the period under review there was no change in the composition of the Board of Directors.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent to all the directors for all the Board Meetings held during the period under review. A system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

As per the minutes of the meetings duly recorded and signed by the Chairperson, the decisions of the Board were unanimous, and no dissenting views have been recorded.

We have been informed by the Company that, there are adequate system of internal controls commensurate with the nature, size and complexity of its operations including controls over financial reporting to ensure compliance with applicable laws, rules, regulations, and guidelines. Appropriate review and control mechanisms are in place for ensuring the internal control systems are operating effectively. The internal control system is supported by qualified personnel and a continuous programme of internal audit. The Company constantly reviews its policies and procedures to adhere conformity of the various global and domestic regulations for its manufacturing facilities or statutory compliances.

Based on above information we report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations, and guidelines.

The following events/actions were having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines etc., during the audit period:

- a. Mr. Mohammed Gawir Baig was appointed as Chief Financial Officer (CFO) of the Company with effect from April 01, 2023.
- b. The Company has completed buyback of 1,14,09,700 fully paid-up Equity Shares of face value of Rs. 2 each for an aggregate amount not exceeding Rs. 1,48,95,36,335 on a proportionate basis, at a price of Rs. 130.55 each per Equity Share.

For V SREEDHARAN & ASSOCIATES

(Pradeep B. Kulkarni)

Partner

FCS: 7260; C.P. No: 7835

Place: Bengaluru

Date: September 05, 2024

UDIN: F007260F001145760

Peer Review Certificate: No. 5543/2024

This report (i.e., Form No. MR-3) is to be read with our letter of even date which is annexed as 'Annexure' and forms an integral part of this report.

'Annexure'

To

The Members

ANTHEM BIOSCIENCES PRIVATE LIMITED

No. 49, F1 & F2, Canara Bank Road,

Bommasandra Industrial Area, Phase I,

Bommasandra, Bengaluru- 560099

Our report of even date is to be read along with this letter:

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the company.
4. Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.
7. We have conducted online verification and examination of records, as facilitated by the Company for the purpose of issuing Secretarial Audit Report (Form No. MR-3).

For V SREEDHARAN & ASSOCIATES**Sd/-****(Pradeep B. Kulkarni)****Partner****FCS: 7260; C.P. No: 7835****Place: Bengaluru****Date: September 05, 2024****UDIN: F007260F001145760****Peer Review Certificate: No. 5543/2024**

ANNEXURE 4

ANNUAL REPORT ON CORPORATE SOCIAL RESPONSIBILITY ACTIVITIES

[Pursuant to section 135 of the Companies Act, 2013 and rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014]

- Brief Outline of the Company's CSR policy, including overview of the projects proposed to be undertaken:** The Company's contributions and initiatives towards social welfare have been integral to its business, and it shall continue to pursue Corporate Social Responsibility activities (hereinafter referred to as "CSR") as one of its fundamental priorities for a long-term sustainability of business, social wellbeing, and economic growth at large. The Company has drafted a CSR policy and the same is available at its website at www.anthembio.com

The policy inter-alia covers the following:

- Functioning of the CSR Committee
- Focus Areas:
 - To enhance Education, Differently abled, livelihood
 - Encouraging Sports
 - Environment, Animal Welfare, Conservation Of Resources
 - Gender Equality, Women Empowerment, Old Age Homes, Reducing Inequalities
 - Health, Eradicating Hunger, Poverty And Malnutrition, Safe Drinking Water, Sanitation
 - Other Sectors (Technology Incubator And Benefits To Armed Forces And Admin
 - Overheads)
 - Contributions to Prime Minister's National Relief Fund
 - Contributions to Swachh Bharat Kosh
- Planning, Implementation & Monitoring of CSR
- Annual Action Plan, Reporting & Documentation
- Treatment of Unspent CSR Obligation
- Contingency
- Policy Review & Future Amendment

2. The composition of the CSR Committee:

The CSR Committee of the Company was constituted on 2nd August, 2014 and comprises of the following directors as on 31st March 2024:

Sl. No.	Name of Director	Designation	Category	CSR Committee meetings held during the year	CSR Committee meetings attended during the year
1	Ajay Bhardwaj	Chairperson	Managing Director	2	2
2	Sambasivam Ganesh	Member	Director	2	2
3	K.C. Ravindra	Member	Director	2	2

- Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the Board are disclosed on the website of the Company: The web-link for CSR Policy and Committee is <https://anthembio.com/Corporate%20Social%20Responsibility.html>**
- Provide the details of impact assessment of CSR projects carried out in pursuance of sub rule (3) of rule 8 of Companies (CSR Policy) Rule, 2014, if applicable:** Not Applicable

5. Details of the amount available for set off in pursuance of sub rule (3) of rule 7 of the Companies (CSR Policy) Rules, 2014 and amount required to set off for the financial year, if any: NIL

6. Average Net Profit of the Company as per Section 135(5): ₹ 46,998 Lacs

7.

(a) 2% of the average net profit of the Company as per Section 135(5)	₹939.96 Lacs.
(b) Surplus arising out of the CSR projects or activities of the Previous financial year	NIL
(c) Amount required to be set off for the financial year, if any	NIL
(d) Total CSR obligation for the financial year (7a+7b+7c)	₹939.96 Lacs.

8. (a) CSR amount spent or unspent for the financial year:6. Average Net Profit of the Company as per Section 135(5): ₹ 46,998 Lacs

Amount unspent (In Rs.)				
Total amount spent for the financial year (In Rs.)	Total amount transferred to Unspent CSR account as per section 135(6)	Amount transferred to any fund specified under Schedule VII as per second proviso to Section 135 (5)		
94,52,693	8,45,44,249	-	-	-

(b)Details of CSR amount spent against ongoing projects for the financial year:												
1	2	3	4	5		6	7	8	9	10	11	
Sl. No.	Name of the Project	Item from the list of activities in Schedule VII to the Act	Local Area (Yes/No)	Location of the project		Project Duration	Amount allocated for the Project (in Rs.)	Amount sent in the current financial year (in rs.)	Amount transferred to unspent CSR account for the project as per section 135(6) (in Rs.)	Mode of Implementation – Direct (Yes/No)	Mode of implementation – Through implementing Agency	
				State	District						Name	CSR registration number
1	Meghshala Trust	Clause (ii)	Yes	Karnataka	Ramanagara	36 months	1,500,000	500,000	1,000,000	Yes	-	-
2	Government Model School	Clause (ii)	Yes	Karnataka	Ramanagara	36 months	47,500,000	-	47,500,000	Yes	-	-
3	Public Funded Universities (Plaksha)	Clause (i)	No	Punjab	Mohali	120 months	35,000,000	-	35,000,000	No	-	-
4	Administrative Overhead		Yes	Karnataka	Bangalore	-	2,996,942	2,138,700	858,242			
5	Total						86,996,942	2,638,700	84,358,242			

(c) Details of CSR amount spent against other than ongoing projects for the financial year:

1	2	3	4	5	6	7	8	9	10	11	
Sl.No.	Name of the Project	Item from the list of activities in Schedule VII to the Act	Local Area (Yes/No)	Location of the project		Project Duration	Amount allocated for the Project (in Rs.)	Amount sent in the current financial year (in rs.)	Amount transferred to unspent CSR account for the project as per section 135(6) (in Rs.)	Mode of Implementation – Direct – Yes/No	Mode of implementation –Through implementing Agency
				State	District						Name CSR registration number
1	Contribution to corporate care funds	Clause (i)	Yes	Karnataka	Bangalore	1 year	800,000	800,000	-	No	AIM for Seva CSR000003273
2	Promotion of sports	Clause (vii)	Yes	Karnataka	Bangalore	1 year	100,000	100,000	-	No	Bangalore Super Strikers FC CSR000029599.
3	"Contribution towards skilling and livelihood development for persons with disability "	Clause (ii)	Yes	Karnataka	Bangalore	1 year	1,200,000	852,426	347,574	No	Mitti Social Initiatives
4	Promoting education, including special education and employment enhancing vocation skills and livelihood enhancement projects.	Clause (i)	Yes	Karnataka	Bangalore	1 year	300,000	300,000	-	No	Centre for Cellular and molecular platforms CSR000004220.
5	Contribution towards healthcare	Clause (i)	Yes	Karnataka	Bangalore	1 year	500,000	500,000	-	Yes	-
6	Promoting education, employment enhancing vocation skills for children and women	Clause (i)	Yes	Karnataka	Bangalore	1 year	1,000,000	1,000,000	-	Yes	Bal Umang Drishya Sanstha CSR000003766.
7	Promoting Sustainable Development Goals	Clause (ix) (b)	No	Delhi	Delhi	1 year	200,000	200,000	-	No	Foundation for Excellence India Trust (IIT Delhi) NA
8	Contributions to public funded Universities	Clause (ix) (b)	No	Karnataka	Bangalore	1 year	300,000	300,000	-	Yes	National Organic Symposium Trust CSR000042950.
9	Contribution towards healthcare	Clause (i)	Yes	Karnataka	Bangalore	1 year	500,000	500,000	-	No	Sri Sringeri Sharada Peetham Charitable Trust CSR000005313.
10	Contribution towards uplifting the needy and deserving	Clause (ii)	Yes	Karnataka	Bangalore	1 year	500,000	500,000	-	No	Joy of Giving Trust CSR000064994
11	Environment sustainability	Clause (iv)	Yes	Karnataka	Ramanagara	1 year	1,600,000	1,761,567	-161,567	Yes	-
	Total						7,000,000	6,813,993	186,007		

(d) Amount spent in administrative overheads - Rs. 21,38,700

(e) Amount spent of Impact Assessment - Not Applicable

(f) Total amount spent for the Financial Year - Rs. 94,52,693 (Rupees Ninety Four Lakhs Fifty Two Thousand Six Hundred and Ninety Three Only)

(g) Excess amount for set off, if any - NIL

9. (a) Details of unspent CSR amount for the preceding three financial years:

Sl.No.	Preceding Financial Year	Amount transferred to Unspent CSR Account under Section 135 (6) (in Rs.)	Amount spent in the reporting Financial Year (in Rs.)	Amount transferred to any fund specified under Schedule VII as per Section 135(6) if any			Amount remaining to be spent in succeeding financial years (in Rs.)
				Name of the Fund	Amount (in Rs.)	Date Of transfer	
1	2020-2021	13,260,826	8,568,001	PM CARES Fund	11831	4/17/2024	-
2	2021-2022	36,778,281	18,751,383	-	-	-	22,941,720.62
3	2022-2023	22,762,791	14,846,430	-	-	-	7,916,361.19

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial years(s):

1	2	3	4	5	6	7	8	9
Sl. No.	Project ID	Name of the Project	Financial Year in which the project was commenced	Project duration	Total amount allocated for the project (in Rs.)	Amount spent on the project in the reporting financial year (in Rs.)	Cumulative amount spent at the end of reporting financial year (in Rs.)	Status of the project – Completed/On-going
1	FY31.03.2023_1	Government School @Jakkasandra	2022-2023	36 months	6,200,000	3,715,101	5,768,301	Ongoing
2	FY31.03.2023_2	Government School @Bannikuppe	2022-2023	36 months	6,000,000	1,239,000	3,555,045	Ongoing
3	FY31.03.2023_3	Government Schools and Public Sanitation	2022-2023	36 months	4,953,670	0	967,600	Ongoing
4	FY31.03.2023_4	Construction of Canteen Facility for homeless (AIR Humanitarian Homes)	2022-2023	36 months	5,000,000	4,913,963	4,913,963	Ongoing
5	FY31.03.2023_5	Infrastructural development	2022-2023	36 months	358,366	358,366	358,366	Completed
6	FY31.03.2023_6	Eradicating Hunger	2022-2023	36 months	4,250,194	1,620,000	4,250,000	Completed
7	FY31.03.2024_1	Government School @Doddakurubarahalli	2023-2024	12 months	4,070,001	4,070,001	4,070,001	Completed
8	FY31.03.2024_2	Kitchen in Government School (Bannikuppe)	2023-2024	12 months	2,368,000	2,368,000	2,368,000	Completed
9	FY31.03.2024_3	Diyaghar	2023-2024	12 months	850,000	850,000	850,000	Completed
10	FY31.03.2024_4	SCEAD Foundation	2023-2024	12 months	980,000	980,000	980,000	Completed
11	FY31.03.2021	Manipal Foundation	2020-2021	12 months	500,000	300,000	500,000	Completed
12	FY31.03.2024_5	Government School @Kadadibbur	2023-2024	36 months	3,000,000	2,593,893	2,593,893	Ongoing
13	FY31.03.2024_6	Government School @Gerahalli, Byregowdanavalase, Devarakagganahalli	2023-2024	36 months	2,000,000	1,425,946	1,425,946	Ongoing
14	FY31.03.2024_7	Government School @Devasthana Hosahalli	2023-2024	36 months	1,250,000	864,631	864,631	Ongoing
15	FY31.03.2024_8	Government School @Gerahalli	2023-2024	36 months	1,250,000	798,684	798,684	Ongoing
16	FY31.03.2024_9	Government School @P Rampura	2023-2024	36 months	6,000,000	829,371	829,371	Ongoing
17	FY31.03.2024_10	Government School @Anamanahallinahalli	2023-2024	36 months	3,000,000	1,244,057	1,244,057	Ongoing
18	FY31.03.2023_7	Government School @Adanakuppe Urdu school	2022-2023	36 months	1,500,000	2,902,800	6,634,971	Ongoing
19	FY31.03.2023_8	Government School @Hebbideramatu	2022-2023	36 months	3,000,000	2,924,000	4,751,000	Ongoing
20	FY31.03.2024_11	Government School @Kalegowdanadoddi	2023-2024	36 months	1,500,000	1,100,000	1,100,000	Ongoing
21	FY31.03.2024_12	Government School @Byregowdana Valase	2023-2024	36 months	3,000,000	4,068,000	4,068,000	Completed
22	FY31.03.2024_13	Public Sanitation	2023-2024	36 months	6,000,000	0	0	Ongoing

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year. (asset-wise details)

- a) Date of creation or acquisition of the Capital assets. NIL
- b) Amount of CSR spent for creation or acquisition of capital asset. NIL
- c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc. NIL
- d) Provide details of the Capital asset(s), created or acquired (including complete address and location of the capital asset). NIL

11. Specify the reason(s), if the Company has failed to spend 2% of the average net profit as per Section 135(5)

The Company has committed for the construction of an upcoming Government Model School Project in Harohalli. The Project cost is estimated to be Rs. 4.75 Cr. and the construction is under process. The Company is also contributing to Plaksha University under an MOU dated 12th February 2024, signed with them for driving inclusion through scholarships for students from the diverse socio-economic, gender and geographical background and building infrastructure facilities and delivery of programs at the campus. This is a long-term project and the Company has committed to pay an amount of Rs. 10.00 Cr. in installment as per the MOU.

Ajay Bhardwaj
(Managing Director & Chairman, CSR Committee)
DIN: 00333704

Ravindra K. C.
(Director)
DIN: 01580534

Management Discussion and Analysis

ANTHEM BIOSCIENCES PRIVATE LIMITED (hereinafter referred to as "**Anthem**"), incorporated in Bangalore on 13th June 2006 is an innovation-driven and technology-focused **CRDMO** with fully integrated operations spanning across drug discovery, development and manufacturing, and we are one of the few companies globally with integrated New Chemical Entity ("NCE") and New Biological Entity ("NBE") capabilities. As a one-stop service provider, we serve a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. We were the fastest and youngest CRDMO in India to achieve a milestone of ₹10,000 million of revenue after 14 years of operations in Fiscal 2021.

Innovation forms the cornerstone of our organization, and we have undertaken several initiatives to differentiate ourselves across modalities and manufacturing capabilities aimed at meeting our customers' evolving requirements and sustainability and efficiency targets, viz:

Innovation: We were one of the first in India to foray into the ADC space with the first Linker being worked in 2016, the first Payload being worked in 2019 and introduced glycolipids as RNAi delivery platform in 2016


Advanced manufacturing capabilities: We have incorporated latest technologies in our processes and we are one of the first CRDMOs in India to offer our customers manufacturing solutions across custom synthesis in 2011, flow chemistry in 2019, biotransformation in 2014, and large scale fermentation in 2017

Strategic investments to enhance our service offerings: Over the years, we have made strategic investments to enhance our offerings across modalities and technologies, including establishing our solid-state peptide synthesis laboratory in 2016, introducing fermentation capabilities in 2017, scaling our custom synthesis capacity by 10 times from 25 KI in 2011 to 250 KI in 2022, setting up a cGMP-scale continuous flow manufacturing facility in 2022 and developing oligonucleotide synthesis capabilities in 2023.


Globally CRDMOs, specializes in the development, scale-up and manufacturing of drug products both for clinical trials and for commercial distribution, offering a range of services that include drug development, process development, analytical testing, formulation development, scale-up, manufacturing, packaging, and distribution. These services can be provided on a stand-alone basis or as part of a complete end-to-end service offering.

A) Global Pharma Market

According to a Frost & Sullivan Report, the global pharmaceutical market is projected to grow at a CAGR of 6.2% from CY2023 to CY2028 to reach USD 1,956 billion by CY2028, driven mainly by the factors such as growth of the elderly population, rising incidence of chronic diseases, sedentary lifestyles, and increasing health awareness.




Source: Evaluate Pharma, Frost & Sullivan




Source: Evaluate Pharma, Frost & Sullivan

The innovator drug market (comprising NCEs and NBEs) continues to play a critical role in pharmaceutical growth and the share of revenue from innovator drugs is expected to increase from 50.8% in CY2023 to 53.5% of the global pharmaceutical market in CY2028


Global Pharma Market by Innovation Type, 2018-2028F (USD Billion)

Source: Evaluate Pharma, Frost & Sullivan

Growth Rate of Global Pharma Market by Innovation Type, 2018-2028F (%)


Source: IQVIA, Evaluate Pharma, Frost & Sullivan

Technological advancements, such as CRISPR gene editing, CAR-T cell therapy, and innovative bio-manufacturing techniques, are expected to continue propelling the biologics market forward, enhancing both the precision and scalability of these therapies. Between 2018 and 2023, the FDA approved 112 new biologics entity (NBE) drugs, highlighting the increasing importance of biologics alongside traditional small molecules. This includes monoclonal antibodies and advanced therapies such as gene and cell therapies, indicating a shift towards more complex, targeted therapies for high specificity and potentially curative outcomes for conditions that have been challenging to treat with conventional small molecule drugs.


US NBE and NCE Approval Trends, 2018 -2024

Source: US FDA, Frost & Sullivan Note: Data as of September, 2024

Pursuant to this, the market share of biologics has increased at a 9.4% CAGR, from 2018 to 2023 and is expected to grow at a 10.5% CAGR in 2023-2028F. Unlike traditional small molecules, biologics offer superior efficacy and specificity, often targeting complex diseases more precisely, which has elevated them to blockbuster status with significant commercial potential.


Global Pharma Market by Modality, 2018-2028F (USD Billion)

Source: Evaluate Pharma, Frost & Sullivan

Growth Rate of Global Pharma Market by Modality, 2018-2028F

Source: IQVIA, Evaluate Pharma, Frost & Sullivan

While the global pharmaceutical market is currently dominated by large multinational pharmaceutical companies, the aggregate market share of large pharmaceutical companies is expected to decline from 67% in CY2023 to 62% in CY2028, and the share of small pharmaceutical and biotech companies is expected to increase from 24% in CY2023 to 26% in CY2028 due to a shift towards high-value, innovation-driven growth.




B) Global Pharma R&D Spending

The pharmaceutical R&D value chain has four stages: discovery, followed by development (pre-clinical and clinical – Phase 1,2 and 3), and finally, approval of the new drug.

Phase	Stages	Description
Drug Discovery		Constitutes the processes from target identification to target validation to lead generation and lead optimization. During this stage thousands of compounds are narrowed down to a few hundred with promising potential.
Development	• Preclinical Development	Exhaustive laboratory and animal experimentation of the preclinical drug candidates for safety and therapeutic effect to determine whether a compound is suitable for human testing. The process may take several years, and the data generated during this stage is a critical part of the dossier to regulatory bodies to receive approvals for conducting clinical trials.
	• Clinical Trials	Promising drug candidates are presented to regulatory authorities for permission to conduct human clinical trials via "Investigational New Drug Applications". Once approved, these drug candidates are referred to as an Investigational New Drugs ("IND"). INDs proceed to clinical trials which are studies in humans to determine the safety, efficacy, and suitable drug dosage of potential drug candidates
	• Drug Substance Development	Covers early stage and late-stage process development and optimization. Small quantities of drug substance are manufactured under non-GMP conditions for toxicology evaluation and under GMP conditions for initial clinical studies. Depending on the outcome of these studies, larger quantities of drug substance are manufactured for late-stage clinical programs.
	• Clinical Supplies/ Drug Product Development	Covers early stage and late-stage formulation development and manufacture. As the molecule moves further along the development cycle, the formulation becomes increasingly nuanced in line with the data being generated through the trials
Commercial Manufacturing		Large scale commercial production of approved Drug Product with highest level of quality. Companies must adhere to FDA or all other relevant regulations for manufacturing.

Source: Frost & Sulliv


Global Pharma R&D Process (Illustrative)



Source: Frost & Sullivan; Note: IND = Investigational New Drug, NDA = New Drug Approval

Pharmaceutical R&D spending has increased significantly from USD 213.8 billion in 2018 to USD 276.8 billion in 2023. This surge is linked to the increasing intricacy of drug discovery and development processes, necessitating substantial investments in research infrastructure and sophisticated technologies. The average investment required to develop and bring a new drug to market now surpasses USD 1 billion per drug, marking a tenfold increase since the 1970s. Given the intensifying market competition and evolving market dynamics, along with patent expirations and generic erosion, R&D is imperative for pharmaceutical companies to maintain a competitive edge and spur future growth. Though Large pharma companies contribute a larger share of the global R&D spending; Small pharma and biotech companies' R&D spend is expected to register the fastest growth over 2023-28F.


Global R&D Spending by Company Type, 2018 - 2028F



Source: Pharmaprojects, Evaluate Pharma

Note: F - Forecast, Large pharma: Pharma companies with revenues > USD 10 Bn, Mid-size pharma: Revenues in range of USD 500 Mn to USD 10 Bn, Small pharma: Revenue lower than USD 500 Bn

Global R&D Spending by Company Type, 2018 - 2028F



Source: Pharmaprojects, Evaluate Pharma


Note: F - Forecast

CROs and CDMOs are crucial players in the Pharma R&D value chain in the pharmaceutical, biotechnology industries. Even as pharma companies experience significant growth, they encounter various obstacles, prompting them to pursue outside collaborations with experts such as CROs and CDMOs. In the past, these companies mainly focused on outsourcing large volumes and forming partnerships with contract service providers to improve their late-stage clinical trials and carry out large-scale manufacturing of established drugs at low cost. However, outsourcing is no longer just about cost. Pharmaceutical sponsors are building closer relationships with contract service providers to get help in R&D, access new markets, share the risk of drug development such as regulatory hurdles, and clinical trials, speed up timelines, and ensure the best quality output at lower costs.

C) Outsourcing Advantages and Global CRDMO Opportunity


Pharma outsourcing offers multifold advantages to innovators, and the need for and importance of CRDMOs is well recognized due to the benefits offered such as reducing in operational cost, access to technical expertise and technology capabilities, integrated offering and improved speed to market.

Benefits for Pharma companies due to Outsourcing



One-stop shop solution: CROs and CDMOs are consolidating and becoming one-stop shops with end-to-end service offerings as CRDMOs. CRDMOs today are positioned as valuable long-term partners to pharma companies, reducing project management costs, sharing risks of product success, mitigating supply chain risks and eliminating scalability challenges. Opportunities for new partnerships are also on the rise. The global R&D outsourcing penetration is projected to increase from 27% in 2018 to 37% in 2028 in terms of value. The development and manufacturing outsourcing penetration value is expected to increase from 23% to 35% during the same period.

Outsourcing penetration in CRDMO



Source: Frost & Sullivan


Traditionally, pharmaceutical companies have relied on CROs for early-stage drug discovery and CDMOs for drug development and production, with some overlapping services such as API and formulation development. However, there is now a clear trend towards collaborating with integrated CRDMOs that offer a comprehensive suite of services covering the entire pharmaceutical value chain. This shift towards integrated CRDMO is especially notable among small pharmaceutical innovators and biotech firms with limited resources and streamlined organizational structures. Collaborating with a CRDMO in an integrated manner offers numerous advantages, including a seamless transition from laboratory to market, access to integrated services, enhanced collaboration, cost savings, improved success rates, and expedited time-to-market for pharmaceutical products.

Additionally, working with CRDMOs eliminates the need and associated risks of transferring molecules between multiple service providers, leading to increased efficiency and reduced complexities. As a result, companies work with the same partner throughout the entire drug lifecycle. CRDMOs also benefit from competitive differentiation, diversified revenue streams, operational efficiency, long-term partnerships, and opportunities for innovation and expertise. It also provides CRDMOs multiple entry points for client engagement, leading to higher customer win rates, increased share of wallet, and enhanced customer retention. Under integrated approach, CRDMOs are incentivized to engage in new drug development programs with existing or new customers and to extend their involvement in these programs from inception to commercialization.

By embracing the integrated CRDMO model, pharmaceutical companies and CRDMOs stand to gain a competitive edge in the dynamic landscape of drug development and manufacturing.

CRDMO Industry Operating Model


D) The Global CRDMO Market



Source: Frost & Sullivan


The Global CRDMO market in 2023 was assessed at an estimated value of USD 196 billion. The industry is anticipated to expand at a CAGR of 9.0% over the forecast period between 2018 and 2028, to reach USD 302 billion by 2028.

The global large molecule CRDMO industry size was estimated at USD 83 billion in 2023 and is expected to expand at a CAGR of



Source: Evaluate Pharma, Frost & Sullivan

Note: F - Forecast




Source: Evaluate Pharma, Frost & Sullivan

Note: F - Forecast


11.4% from 2023 to 2028, to reach USD 143 billion by 2028F, comprising 47% of the overall CRDMO industry globally.

The CRDMO industry offers discovery, preclinical, development, and commercial manufacturing services. In 2023, development



Source: Evaluate Pharma, Frost & Sullivan


Note: F - Forecast



Source: Evaluate Pharma, Frost & Sullivan


Note: F - Forecast

and commercial manufacturing captured about 61% of the CRDMO market. Between 2023 and 2028, both discovery and manufacturing are expected to grow at a faster rate compared to the period between 2018 and 2023. It is estimated that discovery will grow at a CAGR of 8.8% between 2023 and 2028F, reaching USD 55 billion, while manufacturing is projected to grow at 7.5% during the same period, reaching USD 121 billion.




E) The Indian CRDMO Market


The Indian CRDMO industry is one of the fastest-growing globally and is expected to grow at a CAGR of 14.0% from 2023 to 2028 to reach U.S.\$14 billion, which outpaces the global industry rate of 9.0% and other markets such as the PRC due to multiple growth tailwinds in the APAC region, the implementation of the US Biosecure Act, which seeks to block US-based companies from using biotechnology equipment or services from select Chinese firms which potentially reduces demand for Chinese CDMOs, and strong credentials of Indian CRO and CDMO players, which makes India a front runner in the CRDMO outsourcing business.




The Indian CRO market grew 13.9% from USD 1 billion in 2018 to USD 2 billion in 2023, while the CDMO market grew at a CAGR of 12.3% to USD 6 billion in 2023. The Indian CRO market is forecasted to reach USD 3 billion in 2028, while the CDMO is estimated to be USD 11 billion during the same period.



Indian CRDMO industry has largely been dominated by small molecules with their proportion constituting more than 90% of the total industry in 2023. However, the salience of large molecules in Indian CRDMOs is expected to continue to improve given higher growth rates relative to small molecules. Large molecules segment grew rapidly between 2018 and 2023 at a CAGR of 25.2% to reach USD 1 billion and is estimated to grow at 17.9% CAGR from 2023 to 2028.



In the value chain functions, development and commercial manufacturing contribute to more than 76% of the Indian CRDMO market in 2023 and are expected to grow at 14.8% and 13.7% between 2023 and 2028F, respectively. The growth can be attributed to significant improvements in the technical capabilities of Indian companies, which attract manufacturing outsourcing demand from global pharma companies. Indian companies are also growing their integrated offerings with an increased focus on various therapeutic segments, including biologics.



India is fast emerging as the preferred destination for pharma outsourcing; from cost efficiency to quality assurance, Indian CRDMOs are increasingly becoming the preferred partners for Indian and global pharma sponsors. India-based CRDMOs have traditionally been recognized for their cost advantage. However, in recent years, they have made significant investments in advanced technologies and built a broad suite of technical capabilities across various services. Today, Indian CRDMOs are best positioned to take up complex chemistries for global pharma and are now being benchmarked against leading global firms. Some of the key factors contributing to the growth Indian CRDMOs include:

Growth Enablers for Indian CRDMOs




Source: Frost & Sullivan

F) About Anthem

Anthem commenced operations as an export-oriented unit (EOU) and over the years have added new technologies, expanding them from laboratory-scale level to commercial scale cGMP manufacturing units. As of 31st March 2024, there are three manufacturing units, all located in Bangalore, and two land parcels earmarked in Harohalli and Hosur for future expansion. The three manufacturing locations are as below:

- Unit I (Bommasandra industrial area);
- Unit II (Harohalli industrial area);
- Unit III (NeoAnthem @ Harohalli), expected to commence operations in Fiscal 2025.

Anthem: An Integrated Drug Discovery, Development & Manufacturing Company




Anthem Product & Service Offerings: Our business comprises (a) CRDMO services and (b) the manufacture and sale of specialty ingredients. Our CRDMO business caters to customers in regulated markets, while our specialty ingredients business complements our CRDMO business by targeting India and other semi-regulated markets. These businesses enable us to effectively serve a diverse range of customers and address distinct requirements of customers in each market. Our services offered under these businesses are as outlined below:

- **CRDMO Services:** We offer a comprehensive, integrated and highly customizable range of CRDMO services across the NCE and NBE lifecycle, from target identification and lead selection to preclinical development, Phase I, II, III, and commercial manufacturing, with both small molecule and biologics commercial manufacturing capabilities. We also support our customers by manufacturing development batches of molecules used for clinical (Phase I to III) trials, offering capabilities across RNAi, ADC, Peptides, Lipids and Oligonucleotides and in manufacturing across custom synthesis, flow chemistry, biotransformation and fermentation.
- **Specialty Ingredients:** Leveraging on our advanced technological capabilities and our fermentation capacity, we manufacture and sell complex specialized fermentation-based Active Pharmaceutical Ingredient ("APIs"), including Probiotics, Enzymes, Nutritional Actives, Vitamin Analogues, Peptides, Fermentation and Biotransformation Products and Biosimilars. Our specialty ingredients business is complementary to our CRDMO business and serves pharmaceutical companies in India and other semi-regulated markets, contributing to our overall growth and enhancing our manufacturing credentials with global customers.

Anthem has excellent infrastructure to do GMP synthesis ranging from milligram to kilogram, multi-kilogram to multiple ton scale, across both chemistry and biology. A timeline chart of significant milestones at Anthem is as presented below:

A Preferred CRDMO Partner for Big Pharma & Emerging Biotech Innovators Globally



Over the years, Anthem has evolved into a fully integrated CRDMO player with Custom Synthesis & Biologic capabilities

Molecule Size

	Small Molecules	Oligonucleotide / Peptide / RNAi	Small Protein	Fragment Antibody	Antibody	ADC
Anthem's Platform Technologies	<ul style="list-style-type: none">▪ Bio Catalysis▪ Flow Chemistry▪ Photo Chemistry▪ Electro Chemistry▪ Metal / Pincer Catalysis▪ Micellar Chemistry▪ Lipids	Liquid / Solid phase production of nucleotide and peptide <ul style="list-style-type: none">▪ Peptides▪ Oligonucleotides▪ RNAi	Microbial / Mammalian secretory production system for small proteins <ul style="list-style-type: none">▪ Enzymes▪ Peptides▪ Animal fAbs	Mammalian antibody production technology <ul style="list-style-type: none">▪ mAbs▪ Bio-therapeutics	Site Specific conjugation and linker technology <ul style="list-style-type: none">▪ ADCs	
CRDMO Capabilities	Small Molecule API / Intermediate Manufacturing	Solid phase production of Peptides / Oligonucleotide	Recombinant Protein Production		ADC Conjugation	

Anthem has been able to Leverage its Fully Integrated Capabilities Across Both Small and Large Molecules

Manufacturing Facilities:

UNIT 1 – Bommasandra

This facility comprises of a total chemistry R&D Area of 45,000 Sq. Ft. and houses Small Scale GMP Lab – which includes automated peptide synthesizer, dedicated process-engineering laboratory, containment labs for high potent molecules, GMP Quality Control Lab, and associated science desk. Total custom synthesis capacity across 27 reactors is 25 KL and total fermentation capacity is 2 KL. It's a USFDA, ANVISA, PMDA, GLP (OECD) approved facility.

UNIT 2 – Harohalli

This facility is designed to manufacture multiple large-scale products in parallel and has 5 dedicated finishing suites for wet & dry processing and is cGMP compliant. This facility has a large-scale fermentation facility for enzyme and cultures. In FY 22-23, Chemical Synthesis Plant 3, 4 and 5 were commissioned to increase the total production capacity in Unit 2 to 250 KL, spread across 60 reactors. Total fermentation capacity in Unit 2 is 140 KL. The facility is USFDA, ANVISA and TGA approved.

UNIT 3 – NeoAnthem

Currently under construction, this new Greenfield facility housed under a wholly owned subsidiary, Neoanthem Lifesciences Private Limited at Harohalli industrial area is designed to manufacture multiple large scale products in the areas of probiotics, enzymes, high-potent compounds and biosimilar. In phases the facility has commences operations, with the full facility be operational in 2025.

In today's rapidly changing economic landscape, Anthem is focused on strengthening its core capabilities while adjusting its strategic priorities. It continues to create value by expanding our manufacturing capabilities and entering new, high potential markets. Through innovation and the development of new products, we are determined to further enhance our global standing.

Risks, Concerns and Mitigation Strategy

The Company has aligned risk management process with every part of the critical business processes to ensure that the processes are designed and operated effectively towards the achievement of business objectives. Risks are addressed across all business functions in holistic manner:

Risks are identified through discussion with Business heads. Evaluation of risks is done to determine likelihood of occurrence and its impact to priorities risk and mitigate within tolerance limit. Appropriate actions are undertaken by the business heads/ process owners within adequate timelines. Progress of mitigation actions are monitored and reviewed periodically and the Periodic updates are provided to the Board highlighting key risks.

1. Regulatory and Quality Compliances

We are committed to maintaining high quality standard in our R&D and manufacturing operations, which is critical to our growth and success. We have been consistently implementing cGMPs across each of our manufacturing facilities, and our manufacturing facilities are regularly audited by clients and/or inspected by regulatory authorities such as the USFDA, TGA (Australia), ANVISA (Brazil), PMDA (Japan) and Qualified Person (Europe).

As part of our commitment to implement a robust quality system and as part of digital transformation from paper based system to a compliance digital system, we have implemented Veeva Vault Quality for managing quality processes and SAP S4/HANA for material management.

A) Veeva Vault Quality is part of the Vault Development Cloud, built on the Veeva Vault Platform and is focused on unifying quality operations to promote a single source of truth for data and documentation and provide visibility to make accurate, real-time, and comprehensive quality decisions. This integrated cloud based platform collects, tracks, analyses, reports data in our testing and production processes to allow easier data search and management, and ensure integrity, accuracy, and compliance of processes and data. We have implemented the following applications across our operations:

- i. **Veeva Vault Quality Docs:** which enables increased compliance of Quality processes. Veeva Vault is utilized for managing the end-to-end process for creating, reviewing, approving, and storing Quality documents and data. In addition, it is used for managing the document content and metadata. The CMS produces secure and compliant audit trails in accordance with the FDA's 21 CFR Part 11 Electronic Records, Electronic Signatures, and EudraLex Annex 11: Computerized Systems Regulations
- ii. **Veeva Vault Training:** manages role-based qualification and training to support job and audit readiness while demonstrating compliance. Veeva Vault Training allows the configuration and maintenance of a training matrix, which includes Learner Roles, Curricula, Training Assignments and Training Requirements.

- iii. **Veeva QMS:** The QMS monitors our manufacturing practices to ensure our operations comply with the relevant cGMPs, regulations and standards.

B) SAP S4/HANA: All day-to-day operations and regulated transactions are performed in SAP.

Our quality department, comprising 500+ employees, is responsible for ensuring the safety, identity, strength, purity, and quality for each product manufactured by effective implementation of pharmaceutical quality system processes, as well as their sequences, linkages and interdependencies. Our Veeva Vault Quality system and SAP S4/HANA system enables us to monitor all areas of business processes from R&D and raw material procurement to manufacturing to packaging and delivery. As part of quality procedures, we identify and approve multiple vendors to source our key raw materials, in addition to the suppliers approved by our customers, pursuant to a vendor assessment that involves an examination of the potential vendor's regulatory accreditations, and supply strength in terms of delivering large quantities on a consistent basis. Vendor Quality Assessment is performed by Quality Assurance (QA) department using a risk-based approach based on the manufacturing stage in which the material is used and the type of manufacturing batches like development batches, preclinical batches, process performance qualification (PPQ) batches or commercial batches. Due diligence inspections and onsite vendor audits are performed for critical raw materials prior to commercial batch manufacturing. In addition to vendor qualification and vendor audits, incoming raw materials are tested and released by Quality Control (QC) department to approved specifications to maintain quality standards. As part of the current infrastructure, we have established QC testing facilities to perform analytical services including release testing, method development, validations, and stability testing.

In addition, the following controls are in place to maintain data integrity:

- i. Individual user id and password
- ii. Audit trail enabled for analytical instruments
- iii. Validated and calibrated instruments and software
- iv. Individual software with user groups & privileges
- v. Data backup daily, weekly and on a monthly basis
- vi. Data storage direct to the server
- vii. Standalone software backed up on real time

Our facility at Unit I are also compliant with ISO 9001:2015 quality management systems (Certificate Number: IND.23.6168/IM/U Valid until 26th August 2026).

Our facility at Unit II are also compliant with ISO 9001:2015 quality management systems (Certificate Number: IND.23.6168/IM/U Valid until 26th August 2026).

2. Patent Compliance

From the inception of its manufacturing operations, the Company has its stated policy of conforming to intellectual property rights (IPR) and does not violate patents. Anthem continually reviews patent compliance in its process development of active ingredients and has a monitoring mechanism to validate non-infringement of the processes developed.

3. Human Resources

We consider employees as an integral part of our operations and we put in place appropriate compensation plans, feedback process, continuing training and upgradation of skills in their functional areas. Employee relations are affable and harmonious with safe and healthy working environment and all round contribution and participation in the growth.

4. Commercial and Financial Risk

With predominance of its exports, the Company is exposed to a wide spectrum of risks relating to markets, legal disputes relating to contracts, various statutory compliances, credit from suppliers or to customers or from banks/lenders, interest rates, liquidity as well as foreign exchange rate volatility. The Company constantly reviews its systems and processes and takes adequate measures to address these risks or meet its obligations.

5. Insurance

The Company's current and fixed assets as well as products are adequately insured against various risks like transit, fire and allied risks, public liability, the employees insurance, directors & officers' liability etc.

6. Environment, Health and Safety

We are committed to upholding high standards of health and safety measures across our operations. We have put in place various health and safety measures to reduce risks during our operations at the facility. Few of which are listed below:

- Conducting comprehensive process safety evaluations for all projects to address risks during scale-up
- Implementing green chemistry practices wherever possible, including performing multi-stage reactions telescopically and using greener solvents
- Adopting flow chemistry for hazardous processes to lower safety risks and significantly reduce effluent generation compared to batch reactor operations
- Installed state-of-the-art fire hydrant and fire sprinkler system for fire protection, including sprinklers in unmanned areas
- Installed Medium Velocity Water Spray (MVWS) system for external cooling of solvent day tanks
- Employing an earth rite system to mitigate static discharge risks during the safe unloading of solvents from tankers
- Equipped underground solvent storage tanks with nitrogen blanketing and breather cum flame arresters
- Conducting periodic safety training and mock drills to enhance awareness and ensure quick responses in emergencies
- Full-fledged occupational health centre
- Work area monitoring for occupational exposure and implementation of control and mitigation measures

Also, our Unit II and Unit III facilities are designed to be highly automated and equipped with Distributed Control System (DCS), with process controls, scrubbers to contain scrub off gases from the process and well-engineered solvent distribution plate with interlocks for closed system of solvent transfer which significantly reducing human input and exposure to hazardous materials, thereby enhancing safety during the manufacturing process. We also adopt sustainable manufacturing practices such as flow chemistry, which substantially improves the safety of the manufacturing process, as well as enhances reaction efficiency, generates higher yields with fewer by products and reduces hazardous wastes and effluents.

We adhere to a hierarchy of occupational health and safety controls that emphasize elimination, followed by substitution, engineering, and administrative controls, resorting to personal protective equipment only as a final measure. Potential hazards are proactively identified and mitigated through a comprehensive process safety evaluation and other tools such as HAZOP for hazard identification and risk assessment process.] We have a dedicated process safety team comprising of 2 chemical engineers and 2 organic chemists as of 31st March, 2024.

We operate an in-house process safety laboratory tasked with screening for thermal hazards. Our containment systems are qualified for Occupational Exposure Band (OEB) 5 with an Occupational Exposure Limit (OEL) of $1 \mu\text{g}/\text{m}^3$, which ensures the [highest standard of] occupational exposure control. We possess industrial hygiene monitoring capabilities to assess noise levels and personal exposure to gases and solids. Our facilities feature Zero Liquid Discharge (ZLD) effluent treatment facilities at Unit I, II and III.

Our fire protection systems include fire hydrants, sprinkler systems, foam suppression systems and modular extinguishers, among other features.

7. Information Technology

We utilize a wide range of information technology systems in our production processes, in which each of our internal units and divisions are securely connected to one another, including:

i. Enterprise resource planning: We adopt the SAP S/4 HANA as an enterprise resource-planning tool for data processing and analytics support to manage our different business units and our supply chain. These are essential tools that help streamline operations, enhance efficiency, and ensure compliance.

ii. Building management system ("BMS"): We adopt BMS for monitoring, managing and reporting on utility data in our manufacturing units. The BMS monitors and manages the condition of our utility-related equipment to predict and prevent failures, schedules maintenance activities based on equipment condition and performance data, analyzes energy usage patterns for efficiency improvements, and identifies peak load periods and implements load-shifting strategies. BMS monitors and regulates temperature, humidity, and air quality in critical areas like clean rooms and storage facilities, ensuring that conditions remain within specified limits. It optimizes energy consumption, reducing costs while maintaining the necessary environmental conditions for production and storage of the materials, also provides real-

time monitoring and alerts for deviations in critical parameters, enabling rapid response to prevent product spoilage or contamination.

iii. Control process automation system: We implement control process automation systems in our manufacturing units, which monitors critical process parameters such as temperature, pressure, pH value, flow rate on a real-time basis. The control process automation system enables precise and automated controls on our manufacturing processes to ensure efficiency, consistency, and compliance in our production flow.

Our data is stored using in-house data centers which is connected to our information technology infrastructure, applications and virtualized endpoints to ensure seamless connectivity between different business units and divisions within our Company. To ensure data security and regulatory compliance, we employ cybersecurity systems with features such as firewalls to control access to our network based on security rules, intrusion detection and prevention systems to monitor network traffic and antivirus and antimalware to prevent cyberattacks. Further, we have a centralized security operations center to detect, analyze and respond to cybersecurity incidents and conduct vulnerability tests to ensure data production and operational continuity.

We regularly review and update our systems to ensure operation efficiency to align with and support our business needs, and annually assess our IT system as per GxP guidelines to ensure security and quality of our information technology infrastructure.

Internal Control Systems

The Company has an adequate system of internal controls commensurate with the nature, size and complexity of its manufacturing, finance and marketing operations including controls over financial reporting. Appropriate review and control mechanisms are in place for ensuring the internal control systems are operating effectively. The internal control system is supported by qualified personnel and a continuous programme of internal audit.



Financial Statements



Consolidated Financials

Auditors Report (Consolidated Financials)

TO THE MEMBERS OF ANTHEM BIOSCIENCES PRIVATE LIMITED

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying Consolidated Ind AS financial statements of **Anthem Biosciences Private Limited** (hereinafter referred to as “the Holding Company”) and its **subsidiary** (Holding Company and its subsidiary together referred to as “the Group”) which comprise the Consolidated Balance Sheet as at 31st March 2024, the Consolidated Statement of Profit and Loss (including other comprehensive income), Consolidated Statement of Changes in Equity and Consolidated statement of Cash Flows for the year then ended and notes to the Consolidated Financial Statements, including a summary of the significant accounting policies and other explanatory information (hereinafter referred to as “the Ind AS financial statements”).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 (“Act”) in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as amended, (“Ind AS”) and other accounting principles generally accepted in India, of the Consolidated State of Affairs of the Company as at March 31, 2024, the Consolidated profit, the Consolidated total comprehensive income, Consolidated changes in equity and Consolidated cash flows for the year ended.

Basis of Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the Ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the consolidated financial statements.

Board of Directors’ Responsibility for the Consolidated Financial Statements

The Holding Company’s Board of Directors are responsible for the matters stated in section 134(5) of the Companies Act 2013, with respect to the preparation of these consolidated financial statements that give a true and fair view of the financial position and financial performance, of the group in accordance with the Accounting Principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act. The respective Board of Directors of the Companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of each Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Management and Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of the companies included in the group are responsible for overseeing the financial reporting process of each company.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined that there are no key audit matters to be reported for the year 2023-24.

Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on internal financial controls with reference to the consolidated financial statements and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and Board of Directors.
- Conclude on the appropriateness of management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosure are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
 - Obtain sufficient appropriate audit evidence regarding the financial information of entities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial statements. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other Company included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse

consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

As required by the Companies (Independent Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of subsection (11) of Section 143 of the Act, we give in the "Annexure A", a statement on the matter specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143 (3) of the Act, we report that:

- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements..
- b. In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books.
- c. The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss (including other comprehensive income), the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows dealt with by this Report are in agreement with the books of account maintained for the purpose of preparation of the consolidated financial statements.
- d. In our opinion, the aforesaid Consolidated financial statements comply with the Ind AS specified under Section 133 of the Act.
- e. On the basis of the written representations received from the directors of the Holding Company as on 31st March, 2024 taken on record by the Board of Directors of the Holding Company and on the basis of written representations received by the management from directors of its subsidiary which are incorporated in India, as on 31 March 2024, none of the directors of the Group companies incorporated in India is disqualified as on 31 March 2024 from being appointed as a director in terms of Section 164(2) of the Act.
- f. With respect to the adequacy of the internal financial controls with reference to consolidated financial statements of the Holding Company and its subsidiary companies incorporated in India and the operating effectiveness of such controls, refer to our separate report in 'Annexure B'
- g. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act, in our opinion and according to the information and explanations given to us, the limit prescribed by section 197 for maximum permissible managerial remuneration is not applicable to a private limited company.
- h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The consolidated financial statements disclose the impact of pending litigations as at 31 March 2024 on the consolidated financial position of the Group. Refer Note 38 to the consolidated financial statements.
 - ii. The Group did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund.
 - iv. The management has represented in Note 47(ii), that, to the best of its knowledge and belief, no funds have been received by the Holding Company or its subsidiary companies incorporated in India from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Holding Company or its subsidiary companies incorporated in India shall:
 - o directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Parties or
 - o provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries.
 - v. The management has represented in Note 47(i), that, to the best of its knowledge and belief, that no funds have been advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - o directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

- o provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- vi. Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) contain any material mis-statement.
- vii. The Group has neither declared nor paid interim dividend or final dividend during the year. Therefore, reporting under Rule 11(f) of Companies (Audit and Auditors) Rules, 2014 is not applicable.
- viii. Based on our examination which included test checks, the company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with.

For K.P.Rao & Co.

Chartered Accountants

Firm Reg. No. 003135S

Mohan R Lavi

Partner

Membership No. 029340

UDIN:

Place: Bangalore

Date: 5th September 2024

ANNEXURE - A TO THE INDEPENDENT AUDITORS' REPORT

(Referred to in report on other legal and regulatory requirements Section of our report of even date)

There have been no qualifications or adverse remarks by the respective auditors in the Companies (Auditor's Report) Order (CARO) reports of the companies included in the consolidated financial statements. Accordingly, the requirement to report on clause 3(xxi) of the Order is not applicable to the Holding Company.

for K.P.Rao & Co.

Chartered Accountants

Firm Reg. No. 003135S

Mohan R Lavi

Partner

Membership No. 029340

UDIN:

Place: Bangalore

Date: 5th September 2024

ANNEXURE B TO INDEPENDENT AUDITORS' REPORT ON THE CONSOLIDATED FINANCIAL STATEMENTS

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013

Opinion

In conjunction with our audit of the consolidated financial statements of Anthem Biosciences Private Limited (hereinafter referred to as “the Holding Company”) as of and for the year ended 31 March 2024, we have audited the internal financial controls with reference to the consolidated financial statements of the Holding Company and such companies incorporated in India under the Companies Act, 2013 which are its subsidiary companies, as of that date.

In our opinion, the holding company and such Companies incorporated in India which are its subsidiary company, have, in all material respects, an adequate internal financial controls system with reference to consolidated financial statements and such internal financial controls with reference to consolidated financial statements were operating effectively as at 31st March 2024, based on the internal financial controls with reference to consolidated financial statements criteria established by such companies considering the essential components of such internal controls stated in the Guidance Note of Internal Financial Controls With reference to consolidated financial statements issued by the Institute of Chartered Accountants of India. However, the existing policies, systems, procedures and internal controls followed by the Holding Company have to be completely and appropriately documented.

Management’s Responsibility for Internal Financial Controls

The respective Company’s management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls With reference to consolidated financial statements (‘the Guidance Note’) issued by the Institute of Chartered Accountants of India (‘the ICAI’). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required the Companies Act, 2013 (‘the Act’).

Auditor’s Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to consolidated financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing (‘the Standards’), issued by the ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to consolidated financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to consolidated financial statements and their operating effectiveness. Our audit of internal financial controls with reference to consolidated financial statements included obtaining an understanding of internal financial controls with reference to consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to consolidated financial statements.

Meaning of Internal Financial Controls with reference to Consolidated Financial Statements

A Company’s internal financial control with reference to consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting in the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. This includes those policies and procedures that:

- i. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
- ii. provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the company; and
- iii. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition

of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to Consolidated Financial Statements

Because of the inherent limitations of internal financial controls with reference to consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to consolidated financial statements to future periods are subject to the risk that the internal financial control with reference to consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2024, based on the Internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the "Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India".

For K.P.Rao & Co.

Chartered Accountants

Firm Reg. No. 003135S

Mohan R Lavi

Partner

Membership No. 029340

UDIN:

Place: Bangalore

Date: 5th September 2024

Consolidated Financial Statements

Consolidated Balance Sheet as at March 2024				(₹.in Lakhs)
	PARTICULARS	Note	As at 31.03.2024	As a 31.03.2023
I ASSETS				
1) Non-current assets				
a) Property, plant and equipment	3	46,998.65	43,846.54	
b) Capital work-in-progress	3.1	34,469.39	16,407.84	
c) Right of use assets	3.3	628.72	133.76	
d) Intangible assets	3.2	624.32	908.94	
e) Financial Assets				
i) Investment	4.2	1,255.31	616.03	
ii) Trade receivables	5	310.78	310.78	
iii) Loans & Advances	6	505.50	478.60	
iv) Other Financial Asset	7	602.77	460.79	
f) Deferred tax assets (net)	8	4,139.46	2,490.84	
g) Non-Current tax assets (net)	9	140.14	137.49	
h) Other non-current assets	10	1,980.90	3,337.48	
Total Non-Current assets		91,655.95	69,129.08	
2) Current assets				
a) Inventories	11	21,134.74	12,941.63	
b) Financial assets				
i) Investment	4.1	45,907.03	49,287.05	
ii) Trade receivables	5	49,044.78	27,406.78	
iii) Cash and cash equivalents	12	18,385.92	34,223.56	
iv) Bank balances, other than (iii) above	13	49.87	61.13	
v) Other Financial Asset	7	41.97	22.63	
c) Other current assets	14	13,591.10	8,373.92	
Total Current assets		1,48,155.41	1,32,316.71	
TOTAL ASSETS		2,39,811.36	2,01,445.80	
II EQUITY AND LIABILITIES				
Equity				
a) Share capital	15	11,181.54	11,409.74	
b) Other equity	16	1,81,283.91	1,62,657.14	
Total Equity		1,92,465.45	1,74,066.87	
Liabilities				
1) Non-current liabilities				
a) Financial liabilities				
i) Lease liabilities	19	430.59	76.44	
ii) Borrowings	17	11,165.81	9,618.84	
iii) Other financial liabilities	19	1,116.84	616.02	
b) Provisions	20	653.04	538.83	
c) Other non-current liabilities	21	116.93	141.76	
Total non-current liabilities		13,483.21	10,991.89	
2) Current liabilities				
a) Financial liabilities				
i) Lease liabilities	19	168.49	32.22	
i) Borrowings	17	12,086.73	2,887.61	
ii) Trade Payables	18			
(a) total outstanding dues of Micro enterprises & small enterprises		1.32	-	
(b) total outstanding dues to other than Micro enterprises & small enterprises		10,072.79	7,194.13	
iii) Other financial liabilities	19	592.23	449.79	
b) Provisions	20	335.08	335.45	
c) Other current liabilities	21	9965.00	4879.49	
d) Current Tax Liabilities (net)	22	641.08	588.35	
Total current liabilities		33,862.70	16,387.04	
TOTAL EQUITY AND LIABILITIES		2,39,811.36	2,01,445.80	
Corporate information and Significant accounting policies.		1&2		

As per our report of even date attached

For and on behalf of the Board**For K.P. Rao & Co.,**

Chartered Accountants

Firm Registration No. 0031355

Mohan Lavi

Partner

Membership No.029340

Place : Bangalore

Date : September 05, 2024

Gawir Baig
CFO**For and on behalf of the Board****Ajay Bhardwaj**

Managing Director

DIN:00333704

Ravindra K C

Director

DIN:01580534

Ramakrishnan K

Company Secretary

FCS: 11748

Consolidated Statement of Profit and Loss for the period ending on March 31, 2024			(₹.in Lakhs)	
	PARTICULARS	Note	Year Ended 31.03.2024	Year Ended 31.03.2023
I	Revenue from Operations	23	1,41,936.96	1,05,692.43
II	Other Income	24	6,369.92	7,706.85
III	Total Revenue (I + II)		1,48,306.87	1,13,399.27
IV	Expenses			
	Cost of materials consumed	25	64,078.64	34,828.89
	Change in Work in Progress	25.1	(4,123.47)	(901.20)
	Employee benefits expense	26	18,292.69	15,323.70
	Finance costs	27	953.55	676.26
	Depreciation and amortization expense	3	8,182.42	6,369.60
	Other expenses	28	13,191.26	13,552.49
	Total expenses (IV)		1,00,575.09	69,849.75
V	Profit/(Loss) before exceptional items and tax (III-IV)		47,731.79	43,549.53
VI	Exceptional & Extra Ordinary items	33a	-	6,180.24
VII	Profit/(Loss) before tax (V+VI)		47,731.79	49,729.77
VIII	Tax expense	30		
	1) Current tax		12,641.08	12,004.84
	2) Deferred tax		(1,640.29)	(793.58)
			11,000.79	11,211.26
IX	Profit/(Loss) for the year(VII-VIII)		36,731.00	38,518.51
X	Other comprehensive income/(loss)			
	a) Items that will not be reclassified to profit or loss	31		
	Remeasurements of the defined benefit plans		(33.13)	(27.92)
	Deferred Tax on above items		8.34	103.48
	b) Items that will be reclassified to profit or loss		-	-
XI	Total Comprehensive Income for the period (IX+X) (Comprising Profit(Loss) and Other Comprehensive Income for the period)		36,706.21	38,594.07
XII	Earnings per equity share: (In Rs.)			
	2) Basic EPS		6.47	6.77
	3) Diluted EPS		6.47	6.77
	Corporate information and Significant accounting policies	1&2		

As per our report of even date attached

For and on behalf of the Board**For K.P. Rao & Co.,**

Chartered Accountants

Firm Registration No. 0031355

Mohan Lavi

Partner

Membership No.029340

Place : Bangalore

Date : September 05, 2024

For and on behalf of the Board**Ajay Bhardwaj**

Managing Director

DIN:00333704

Ravindra K C

Director

DIN:01580534

Ramakrishnan K

Company Secretary

FCS: 11748

Gawir Baig

CFO

Consolidated Cash flow statement for the period ending March 31, 2024		(₹.in Lakhs)	
Description	As on 31.03.2024	As a 31.03.2023	
A) Cash Flow from operating activities:			
Net Profit before taxation	47,731.79	49,729.77	
Adjustment:(+/-)			
Depreciation/ Amortisation	8,182.42	6,377.41	
Provision for gratuity and leave encashment	93.84	88.50	
Interest and Finance charges	953.55	668.45	
Interest from deposits & advances	(4,086.17)	(2,909.88)	
Dividend/Capital Gain from Mutual Funds	(703.43)	(1,487.33)	
(Profit)/Loss on sale of asset	42.93	(5.33)	
Operating Profit before Working Capital Changes	52,214.92	52,461.58	
Adjustment for changes in working capital:			
Other financial Assets	(161.33)	(22.36)	
Other Current Assets	(5,217.18)	681.57	
Other non-current Assets	1,353.92	(2,394.58)	
Current Financial Liabilities	142.43	213.56	
Trade and other receivables	(21,638.00)	5,213.06	
Inventories	(8,193.11)	(7,118.63)	
Trade payables and other liabilities	2,879.98	710.01	
Other Current Liabilities	4,633.43	(7,645.57)	
Provisions	-	(0.12)	
Cash used in operations	26,015.07	42,098.52	
Income taxes paid	(12,000.00)	(11,500.00)	
Net cash generated in Operating Activities	14,015.07	30,598.52	
B) Cash Flow from Investing Activities:			
Purchase of fixed assets and other capital expenditure	(10,942.51)	(17,867.98)	
Right to use assets-IND AS	(628.93)	70.18	
Sale of Fixed Assets	69.10	7.00	
(Increase)/Decrease in CWIP	(18,061.55)	(1,024.91)	
Purchase of Intangible Assets	(85.45)	(561.71)	
Interest from deposits & advances	4,086.17	2,909.88	
Dividend/capital gain from Mutual Funds	703.43	1,487.33	
Investments in Mutual Fund and Equities	2,740.74	(22,620.15)	
Receipt/(payment) of loans and advances to related party	(26.90)	(1.21)	
Net cash used in Investing activities	(22,145.90)	(37,601.56)	
C) Cash flow from Financing activities:			
Repayment of borrowings	1,546.96	9,029.00	
Other Non-Current liabilities	830.15	(1,836.47)	
IND AS accounting adjustments	(28.53)	(54.99)	
Buy back of equity shares	(14,895.36)	-	
Tax on buy back of equity shares	(3,416.86)	-	
Repayment of short term borrowings	9,199.12	(71.65)	
Interest and finance charges	(953.55)	(668.45)	
Net cash (Used)/ Generated in Financing Activities	(7,718.07)	6,397.45	
Net change in Cash and Cash Equivalents (A+B+C)	(15,848.90)	(605.59)	
Cash and Cash Equivalents (beginning of the year)	34,284.69	34,890.28	
Cash and Cash Equivalents (ending period)	18,435.79	34,284.69	

As per our report of even date attached

For and on behalf of the Board**For K.P. Rao & Co.,**

Chartered Accountants

Firm Registration No. 003135S

Mohan Lavi

Partner

Membership No.029340

Place : Bangalore

Date : September 05, 2024

For and on behalf of the Board**Ajay Bhardwaj**

Managing Director

DIN:00333704

Ravindra K C

Director

DIN:01580534

Ramakrishnan K

Company Secretary

FCS: 11748

Gawir Baig

CFO

Consolidated Statement of Changes In Equity for the period ending March 31, 2024

STATEMENT OF CHANGES IN EQUITY

A - Equity Share Capital

Particulars

(₹.in Lakhs)

Particulars	
Balance as at April 01, 2023	11,410
Changes in equity share capital during the year*consideration	(228.19)
Balance as at March 31, 2024	11,182

* Buy back of equity shares

B - Other Equity

For the year ended March 31, 2024

(₹.in Lakhs)

Particulars	Reserves and Surplus				Items of other comprehensive income/(loss)	Equity Component of Compound Financial Instruments	Total
	Capital Redemption Reserve	General Reserves	Securities Premium	Retained Earnings	Other items of Other Comprehensive Income		
Balance as at April 01, 2023	-	13,690.47	27,185.64	1,22,011.58	(230.55)	0.00	1,62,657.14
Adjustment during the year	-	-	-	4.60	-	-	4.60
Profit for the year	-	-	-	36,731.00	-	-	36,731.00
Other Comprehensive income/(loss) for the year	-	-	-	-	(24.79)	-	(24.79)
Buy-back of equity shares (Refer note 15.4)	228.19	(228.19)	(14,667.17)	-	-	-	(14,667.17)
Tax on buy-back of equity shares (refer note)	-	-	-	(3,416.86)	-	-	(3,416.86)
Additions during the year	-	3,673.10	-	(3,673.10)	-	-	-
Balance as at March 31, 2024	228.19	17,135.37	12,518.47	1,51,657.22	(255.35)	0.00	1,81,283.91

For the year ended March 31, 2023

(₹.in Lakhs)

Particulars	Reserves and Surplus				Items of other comprehensive income/(loss)	Equity Component of Compound Financial Instruments	Total
	Capital Redemption Reserve	General Reserves	Securities Premium	Retained Earnings	Other items of Other Comprehensive Income		
Balance as at April 01, 2022	500.00	9,838.61	27,001.83	97,423.67	(306.11)	164.24	1,34,622.24
Adjustment during the year	(500.00)	-	-	(10,078.75)	-	-	(10,578.75)
Profit for the year	-	-	-	38,518.51	-	-	38,518.51
Other Comprehensive income/(loss) for the year	-	-	-	-	75.56	-	75.56
Dividends & Dividend tax paid	-	-	-	-	-	(164.24)	(164.24)
Additions during the year	-	3,851.85	183.81	(3,851.85)	-	-	183.81
Balance as at March 31, 2023	-	13,690.47	27,185.64	1,22,011.58	(230.55)	0.00	1,62,657.14

As per our report of even date attached

For K.P. Rao & Co.,

Chartered Accountants

Firm Registration No. 0031355

Mohan Lavi

Partner

Membership No.029340

Place : Bangalore

Date : September 05, 2024

For and on behalf of the Board

Ajay Bhardwaj

Managing Director

DIN:00333704

Ravindra K C

Director

DIN:01580534

Ramakrishnan K

Company Secretary

FCS: 11748

Gawir Baig

CFO

Anthem Biosciences Private Limited**Notes forming part of the consolidated financial statements****15) Equity Share Capital**

Particulars	As at 31.03.2024		As at 31.03.2023	
	No. of Shares	(₹.in Lakhs)	No. of Shares	(₹.in Lakhs)
Authorised Share capital				
Equity Shares of Rs. 2/- each	60,00,00,000	12,000	60,00,00,000	12,000
Preference shares of Rs 10/- each	50,00,000	500	50,00,000	500
	60,50,00,000	12,500	60,50,00,000	12,500
Issued, subscribed & fully paid share capital				
Equity Shares of Rs. 2/- each	55,90,77,100	11,182	57,04,86,800	11,410
Total	55,90,77,100	11,182	57,04,86,800	11,410

15.1 The Company has only equity shares having a face value of Rs.2/- each.

15.2 Terms/ Rights attached to equity shares

Each holder of the equity share, as reflected in the records of the Company as of the date of the shareholders meeting, is entitled to one vote in respect of each share held for all matters submitted to vote in the shareholders meeting. In the event of liquidation of the company, the holders of equity shares will be entitled to receive any of the remaining assets of the company after distribution of amounts payable to preference shareholders & any statutory liabilities. The distribution will be in proportion to the number of equity shares held by the shareholders.

15.3 Aggregate number of bonus shares issued during the period of five years immediately preceding the reporting date

Particulars	For the Year ended 31st March				
	2024	2023	2022	2021	2020
Equity shares of Rs. 2/- each	-	52,66,03,200	-	-	-

The Company had allotted 52,66,03,200 equity shares of Rs. 2/- each fully paid up as bonus shares on November 28, 2022 in the ratio of 12:1 (Twelve equity shares of Rs. 2/-each for every one equity share of Rs. 2/- each held in the Company as on the record date i.e. 31st October 2022) by capitalisation of Capital redemption reserve and general reserves of the company.

15.4 Aggregate number of shares bought back during the period of five years immediately preceding the reporting date

Particulars	For the Year ended 31st March				
	2024	2023	2022	2021	2020
Equity shares of Rs. 2/- each	1,14,09,700.00	-	-	-	-

The Board of Directors at its meeting held on December 11, 2023 had approved the buy-back of 1,14,09,700 fully paid up equity shares of face value of Rs.2/- each from the equity shareholders of the Company, at a price of Rs. 130.55/- per equity share (Maximum Buy-Back price) and such aggregate amount not exceeding Rs.148,95,36,335/- (Maximum Buy-back Size, excluding transaction costs and taxes thereon). Buy Back is undertaken through the offer letter on such terms and conditions as the board may deems fit.

15.5 The details of shareholder holding more than 5% shares as at March 31, 2024 and March 31, 2023 set out below:

Sl. No	Name of the shareholder	As at 31.03.2024		As at 31.03.2023	
		No. of Shares held	% holding	No. of Shares held	% holding
1	Mr. Ajay Bhardwaj	29,47,47,175	52.72%	30,13,20,825	52.82%
2	Mr. Ravindra K C	6,60,24,898	11.81%	6,74,97,430	11.83%
3	Mr. Ganesh S	6,80,48,076	12.17%	6,95,65,730	12.19%
4	Viridity Tone LLP	4,74,92,640	8.49%	4,74,92,640	8.32%

15.5 Shareholding of Promoters*

Sl. No	Name of the shareholder	No. of Shares**	% of total shares**	% Change During the year
1	Mr. Ajay Bhardwaj	29,47,47,175	52.72%	(0.00)
2	Mr. Ravindra K C	6,60,24,898	11.81%	(0.00)
3	Mr. Ganesh S	6,80,48,076	12.17%	(0.00)
	Total	42,88,20,149		

16) Other Equity

		(₹.in Lakhs)	
Particulars		31.03.2024	31.03.2023
a) Capital Redemption Reserve		228.19	-
b) General Reserve		17,135.37	13,690.47
c) Share Premium		12,518.47	27,185.64
d) Retained Earnings		1,51,657.22	1,22,011.58
e) Components of Other Comprehensive Income		(255.35)	(230.55)
Balance at the end of the period (a+b+c+d+e)		1,81,283.91	1,62,657.14

Anthem Biosciences Private Limited										
Notes forming part of the consolidated financial statements										
3 Property, Plant and Equipment										
Particulars	Tangible Assets								(₹.in Lakhs)	
	Land - Free Hold *	Road	Buildings	Plant and Equipment	Furniture and Fixtures	Vehicles	Office equipment	Laboratory Equipment	Computers & Accessories	Total
Cost or Deemed cost										
As at April 01,2023	8,361.28	315.04	15,786.63	42,208.81	1,850.47	744.84	564.35	12,898.55	3,102.49	85,832.46
Additions during the year	-	-	4,332.83	4,772.87	483.50	113.78	27.19	1,048.51	163.84	10,942.51
Disposals/adjustments	-	-	-	242.87	-	28.85	46.38	54.79	0.85	373.74
As at March 31,2024	8,361.28	315.04	20,119.45	46,738.81	2,333.97	829.77	545.15	13,892.28	3,265.48	96,401.23
Depreciation										
As at April 01,2023	-	299.39	6,923.20	21,223.16	1,422.06	581.80	415.94	9,014.37	2,106.01	41,985.92
Charge for the period	-	5.59	1,174.42	4,400.16	143.28	66.97	67.61	1,179.89	640.45	7,678.37
Disposals/adjustments	-	-	-	139.04	-	26.40	44.71	50.71	0.85	261.71
As at March 31,2024	-	304.99	8,097.62	25,484.27	1,565.34	622.37	438.84	10,143.55	2,745.61	49,402.58
Net block										
As at March 31,2024	8,361.28	10.05	12,021.83	21,254.53	768.64	207.40	106.32	3,748.73	519.87	46,998.65
As at March 31,2023	8,361.28	15.64	8,863.43	20,985.65	428.41	163.04	148.41	3,884.18	996.49	43,846.54

***All title deeds of Immovable Properties are held in name of the Company except the below mentioned properties.**

'Below title deeds of immovable property not held in name of the company

Relevant line item in the Balance sheet	Description of item of property	Gross carrying value	Title deeds held in the name of	Whether title deed holder is a promoter, director or relative# of promoter*/director or employee of promoter/director	Property held since which date	Reason for not being held in the name of the company
Land	8acre land Plot No. 313-P, 314-P & 318-P, Harohalli Industrial Area, 2nd Phase.	1313.21447	The Karnataka Industrial Areas Development Board (KIADB)	NA	17/05/2018	Lease cum sale basis (99 years lease)
	2acre land Plot Nos. 276-P, 280-P & 281-A Harohalli Industrial Area, 2nd Phase.	367.15414			26/09/2019	
	30acre land Plot no. 527 to 540 & 557 to 570 in Harohalli 3rd Phase Industrial Area.	4737.6864			02/02/2021	

3.1 Capital work-in-progress

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Capital work-in-progress	34,469.39	16,407.84
	34,469.39	16,407.84

Capital work-in-progress ageing schedule**As at 31 March 2024**

CWIP	Amount in capital work in progress for a period of				Total(₹.in Lakhs)
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Project work in progress	23,867.92	8,972.46	1,603.21	25.80	34,469.39
Projects temporarily suspended	-	-	-	-	-

As at 31 March 2023

CWIP	Amount in capital work in progress for a period of				Total(₹.in Lakhs)
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Project work in progress	11,816.54	4,532.90	58.40	-	16,407.84
Projects temporarily suspended	-	-	-	-	-

Capital work-in-progress ageing schedule**As at 31 March 2024**

CWIP	Amount in capital work in progress for a period of				Total(₹.in Lakhs)
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
ETP-Expansion Harohalli	-	-	-	-	-
Biological - Expansion Harohalli	3,535.85	-	-	-	3,535.85
CP 6 Plant Harohalli	-	1,145.08	-	-	1,145.08
NeoAnthem Building	-	9,240.03	-	-	9,240.03
Greenfield projects	-	-	16.15	-	16.15
Neoanthem plant and machineries	16,756.68	3,775.61	-	-	20,532.29
Total	20,292.53	14,160.72	16.15	-	34,469.39

As at 31 March 2023

CWIP	Amount in capital work in progress for a period of				Total(₹.in Lakhs)
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
ETP-Expansion Harohalli	3,642.62	-	-	-	3,642.62
Biological - Expansion Harohalli	-	647.36	-	-	647.36
CP 6 Plant Harohalli	-	-	31.99	-	31.99
NeoAnthem Building	-	-	5,761.48	-	5,761.48
Greenfield projects	481.70	-	-	-	481.70
Others	2,321.31	3,521.39	-	-	5,842.70
Total	6,445.63	4,168.74	5,793.47	-	16,407.84

3.2 Other Intangible assets

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Other Intangible Assets	624.32	908.94
Total	624.32	908.94

Particulars	(₹.in Lakhs)
Cost or Deemed cost	
As at April 01, 2023	2,380.29
Additions during the year	85.45
Disposals	-
As at March 31, 2024	2,465.74
Amortisation	
As at April 01, 2023	1,471.35
Charge for the period	370.07
Disposals	-
As at March 31, 2024	1,841.43
Net block	
As at March 31, 2024	624.32
As at March 31, 2023	908.94

3.3 Right to use assets

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Opening Balance	133.76	248.60
Adjustment during the year	-	-
Additions during the year	628.93	11.44
Deletions during the year	-	(81.62)
Depreciation during the year	(133.97)	(44.66)
Closing Balance	628.72	133.76

Anthem Biosciences Private Limited										
Notes forming part of the consolidated financial statements										
4) 'Investments										
Sl.No.	Particulars	As at 31.03.2024			Total	Amortised Cost	As at 31.03.2023			
		Amortised Cost	Amortised Cost				Through Other Comprehensive Income	Through profit or loss	Through Other Comprehensive Income	Through profit or loss
	Mutual Funds (as per 4.1)	-	-	45,907.03	-	-	-	49,287.05	49,287.05	
	Other investments (as per 4.2)	1,255.31	-	1,255.31	616.03	-	-	-	616.03	
(A)	Total	1,255.31	-	45,907.03	47,162.34	616.03	-	49,287.05	49,903.08	
(i)	Investments outside India									
(ii)	Investments in India	1,255.31	-	45,907.03	47,162.34	616.03	-	49,287.05	49,903.08	
(B)	Total	1,255.31	-	45,907.03	47,162.34	616.03	-	49,287.05	49,903.08	
	(A) - (B)	-	-	-	-	-	-	-	-	
	Less: Impairment Loss Allowance	-	-	-	-	-	-	-	-	
	Total	1,255.31	-	45,907.03	47,162.34	616.03	-	49,287.05	49,903.08	

		(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023
4.1 Trade - Quoted - at fair value		
a) Investments in Mutual Funds; Corporate Bonds & MLDs		
Investment in market linked debentures and corporate bonds	41,842.90	40,990.70
Investment in mutual funds	4,064.13	8,296.36
Total investments at Fair Value	45,907.03	49,287.05

		(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023
4.2 Other Investments		
a) Other Equity Investments		
Investment in Four EF Renewables Private Limited	184.80	205.34
Investment in Ampyr Renewable Energy Resources Eleven Pvt Ltd	166.97	0.02
Investment in Isharays Energy One Pvt Ltd	200.00	-
b) Other Preference Investments		
Investment in Four EF Renewables Private Limited	369.61	410.68
Investment in Ampyr Renewable Energy Resources Eleven Pvt Ltd	333.93	-
Total investments at Fair Value	1,255.31	616.03

Investment in Equity Instrument - Others

- Investment in Four EF Renewables Private Limited, 184804 equity shares of Rs. 100/- each (FY2023: 205338 equity shares of Rs. 100/-each)
- Investment in Ampyr Renewable Energy Resources Eleven Pvt Ltd, 1669668 equity shares of Rs. 10/- each (FY2023: 150 equity shares of Rs.10/-each)
- Investment in Isharays Energy One Pvt Ltd, 2000000 equity shares of Rs. 10/- each

Investment in Preference Shares - Others

- Investment in Four EF Renewables Private Limited, 369609 Preference shares of Rs. 100 each (FY2023: 410677 preference shares of Rs.100/-each)
- Investment in Ampyr Renewable Energy Resources Eleven Pvt Ltd, 3339337 Preference shares of Rs. 10 each

5 Trade Receivables

a) Non-current

		(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023
Unsecured, considered good		
Trade Receivables from Related parties	310.78	310.78
Total	310.78	310.78

Trade Receivables Ageing

(For Current Reporting period)

Particulars	Outstanding for following periods from due date of payment					Total (₹.in Lakhs)
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables – considered good		-			310.78	310.78
(ii) Undisputed Trade receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade receivables– considered good	-	-	-	-	-	-
"(v) Disputed Trade receivables – which have significant increase in credit risk"	-	-	-	-	-	-
(vi) Disputed Trade receivables – credit impaired	-	-	-	-	-	-
Total	-	-	-	-	310.78	310.78

Trade Receivables Ageing
(For Previous Reporting period)

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total (₹.in Lakhs)
(i) Undisputed Trade receivables – considered good		-			310.78	310.78
(ii) Undisputed Trade receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade receivables– considered good	-	-	-	-	-	-
"(v) Disputed Trade receivables – which have significant increase in credit risk"	-	-	-	-	-	-
(vi) Disputed Trade receivables – credit impaired	-	-	-	-	-	-
Total	-	-	-	-	310.78	310.78

b) Current

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Unsecured, considered good		
(i) Trade Receivables	49,044.78	27,406.78
Unsecured, considered doubtful		
(i) Less: Provision for doubtful trade receivables	-	-
Total	49,044.78	27,406.78

Trade Receivables Ageing
(For Current Reporting period)

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total (₹.in Lakhs)
(i) Undisputed Trade receivables – considered good	48,847.25	59.50	116.44	18.16	3.44	49,044.78
(ii) Undisputed Trade receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade receivables– considered good	-	-	-	-	-	-
"(v) Disputed Trade receivables – which have significant increase in credit risk"	-	-	-	-	-	-
(vi) Disputed Trade receivables – credit impaired	-	-	-	-	-	-
Total	48,847.25	59.50	116.44	18.16	3.44	49,044.78

Trade Receivables Ageing
(For Previous Reporting period)

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total (₹.in Lakhs)
(i) Undisputed Trade receivables – considered good	27,387.08	-	-	17.00	2.71	27,406.78
(ii) Undisputed Trade receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade receivables– considered good	-	-	-	-	-	-
"(v) Disputed Trade receivables – which have significant increase in credit risk"	-	-	-	-	-	-
(vi) Disputed Trade receivables – credit impaired	-	-	-	-	-	-
Total	27,387.08	-	-	17.00	2.71	27,406.78

ECL Model

Ind AS 109 requires an impairment assessment to be made for Trade Receivables on an Expected Credit Loss Model. For Trade Receivables.

Ind AS 109 permits a simplified approach of calculating only life time credit losses.

Considering the industry in which the company is operating and the gestation period of its projects, impairment assessment is made annually for the entire block of Trade Receivables and impairment losses are recognised for trade receivables on a case to case basis.

6) Loans & Advances									
Sl.No.	Particulars	As at 31.03.2024				As at 31.03.2023			
		Amortised Cost	Amortised Cost		Total	Amortised Cost	At Fair Value(₹.in Lakhs)		Total
			Through Other Comprehensive Income	Through profit or loss			Through Other Comprehensive Income	Through profit or loss	
	Loan to related party	505.50	-	-	505.50	478.60	-	-	478.60
	Advances to related party	-	-	-	-	-	-	-	-
(A)	Total	505.50	-	-	505.50	478.60	-	-	478.60
(i)	Investments outside India	-	-	-	-	-	-	-	-
(ii)	Investments in India	505.50	-	-	505.50	478.60	-	-	478.60
(B)	Total	505.50	-	-	505.50	478.60	-	-	478.60
	(A) - (B)	-	-	-	-	-	-	-	-
	Less: Impairment Loss Allowance	-	-	-	-	-	-	-	-
	Total	505.50	-	-	505.50	478.60	-	-	478.60

7 Other Financial Asset

a) Non- Current

			(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023	
Unsecured, considered good			
Staff advances	29.88	23.02	
Security Deposits	572.89	437.77	
Total	602.77	460.79	

b) Current

		(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023
Unsecured, considered good		
Accrued interest	18.02	13.67
Staff advances-Current	23.95	8.95
Total	41.97	22.63

c) Fair Value Hierarchy

(₹.in Lakhs)				
Particulars	Carrying value		Fair value	
	31.03.2024	31.03.2023	31.03.2024	31.03.2023
Amortised cost				
(i) Loans	505.50	478.60	505.50	478.60
(ii) Other Investments	1,255.31	616.03	1,255.31	616.03
(iii) Trade Receivables	49,355.56	27,717.57	49,355.56	27,717.57
(iv) Other Financial Assets	644.74	483.42	644.74	483.42
(v) Cash and Cash Equivalents	18,435.79	34,284.69	18,435.79	34,284.69
Fair Value through Profit and Loss				
(i) Investments	45,907.03	49,287.05	45,907.03	49,287.05
Total Financial Assets	1,16,103.94	1,12,867.36	1,16,103.94	1,12,867.36

d) Fair Value Hierarchy

				(₹.in Lakhs)
	Level 1	Level 2	Level 3	Total
Financial Assets				
Mutual Fund Units	45,907.03	0.00	0.00	45,907.03
Other Investments	1,255.31	0.00	0.00	1,255.31
Total	47,162.34	0.00	0.00	47,162.34

8 Deferred Tax Assets (Net)

			(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023	
Deferred tax assets			
Deferred tax assets	2,490.84	1,593.78	
Add: Adjustments during the year	1,648.63	897.06	
Total	4,139.46	2,490.84	

8.1 Components of deferred income tax assets and liabilities arising on account of temporary differences are:

			(₹.in Lakhs)
Deferred tax asset	31.03.2024	31.03.2023	
Expenditure disallowed under Income Tax Act, 1961		7253.03	
Prepaid rent written off	-	1.64	
Property, plant and equipment	1,497.56	5,130.62	
On OCI (Gratuity)	123.13	411.12	
Significant financing component	-	188.46	
Deferred Loan finance cost	1.97	7.81	
Employee benefit expenses on staff loans	0.82	6.62	
Interest on BIRAC Loan	-	44.78	
Lease	46.03	55.03	
Security Deposit	0.34	-	
	1,669.86	13,099.11	
Deferred tax liability			
Interest income due to fair valuation of security deposits	0.25	1.69	
Interest income recognised on Staff loan	1.03	6.64	
Notional interest income on loan to Associate company	1.62	6.32	
Fair Value gain on MF	3.66	-	
Compound financial instruments	-	2.99	
BIRAC Loan grant recognised	14.67	23.64	
Lease	-	53.02	
	21.23	94.31	
Total	1,648.63	13,004.81	

9 Tax Assets (Net)

			(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023	
Income Tax Refundable	140.14	137.49	
Total	140.14	137.49	

10 Other Non-current Assets

			(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023	
Un-secured Considered good			
(i) Capital advances	1,673.66	3,044.65	
(ii) Prepaid Rent	1.77	(1.21)	
(iii) Deferred Employees Benefit	10.87	2.50	
(iv) Deferred Loan - Anthem Biopharma Private Limited	226.57	234.39	
(v) Prepaid Expenses-long term	68.03	57.16	
Total	1,980.90	3,337.48	

11 Inventories

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
(i) Raw materials	14,434.58	10,283.61
(ii) Work in Progress	4,784.81	2,025.16
(iii) Finished goods	1,871.32	507.50
(iv) Goods in transit	44.03	125.36
Total	21,134.74	12,941.63

12 Cash and Cash Equivalents

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Balances with banks:		
(i) in current accounts	2,209.55	808.35
(ii) in deposit accounts	16,176.35	33,415.21
Cash in Hand:		
(i) Cash on hand	0.01	-
Total	18,385.92	34,223.56

13 Other Bank Balances

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Earmarked balances with Banks		
(i) Margin Money & Other Deposits	49.87	61.13
Total	49.87	61.13

14 Other Current Assets

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Un-secured Considered good		
(i) Balances with other statutory authorities	12,003.55	7,760.28
(ii) Prepaid Expenses	316.67	194.34
(iii) Advances to Suppliers	1,269.27	311.35
(iv) Export Incentives Receivable	1.60	107.95
Total	13,591.10	8,373.92

17 Borrowings

a) Non-current

Sl.No.	Particulars	As at 31.03.2024			As at 31.03.2023		
		Amortised Cost	At Fair Value (₹.in Lakhs)		Amortised Cost	At Fair Value(₹.in Lakhs)	
			Through Other Comprehensive Income	Through profit or loss		Through Other Comprehensive Income	Through profit or loss
(a)	Term Loans						
	Secured						
(i)	from Banks	10,893.85	-	-	9,213.27	-	-
(ii)	from other parties	271.95	-	-	405.57	-	-
	Unsecured						
(i)	from Banks	-	-	-	-	-	-
(ii)	from Related parties	-	-	-	-	-	-
(b)	Finance lease obligations	-	-	-	-	-	-
(A)	Total	11,165.81	-	-	9,618.84	-	-
	Borrowings in India	11,165.81	-	-	9,618.84	-	-
	Borrowings outside India	-	-	-	-	-	-
(B)	Total	11,165.81	-	-	9,618.84	-	-
	(A) - (B)	-	-	-	-	-	-

b) Current

Sl.No.	Particulars	As at 31.03.2024			As at 31.03.2023		
		Amortised Cost	At Fair Value (₹.in Lakhs)		Amortised Cost	At Fair Value(₹.in Lakhs)	
			Through Other Comprehensive Income	Through profit or loss		Through Other Comprehensive Income	Through profit or loss
(a)	Term Loans						
	Secured						
(i)	from Banks	3,800.00	-	-	1,900.00	-	-
(ii)	from other parties	107.09	-	-	113.01	-	-
	Unsecured						
(i)	from Banks	-	-	-	-	-	-
(ii)	from Related parties	-	-	-	-	-	-
(b)	Finance lease obligations	-	-	-	-	-	-
(c)	Cash Credit	8,179.63	-	-	874.60	-	-
(A)	Total	12,086.73	-	-	2,887.61	-	-
	Borrowings in India	12,086.73	-	-	2,887.61	-	-
	Borrowings outside India	-	-	-	-	-	-
(B)	Total	12,086.73	-	-	2,887.61	-	-
	(A) - (B)	-	-	-	-	-	-

Break up of Loans- Borrowings with Repayment Terms

Loan Type	Loan Name	Repayment Terms	Total Outstanding (₹.in Lakhs)	
			(For Current Reporting period)	(the previous reporting period)
Term Loan-Project	Citi Bank	20 Quarterly Instalments	8,100	9,000.00
Term Loan-Project	Biotechnology Industry Research Assistance Council	10 Years #	492.47	594.89
Term Loan-Project	Federal Bank	24 Quarterly Instalments	6,593.85	1,113.27
Cash credit	HDFC Bank	Yearly Renewal	1,077.17	-
Cash credit	Citi Bank	Yearly Renewal	1,000.00	1,874.60
PCFC	Citi Bank	Yearly Renewal	6,102.46	-

Excluding IND AS effect

Terms of Security**From Banks**

- 17.1** Term loan from BIRAC (Biotechnology Industry Research Assistance Council), along with interest is secured by Equipment and Machinery which is procured from the sanctioned amount and carry an interest rate of 2.00% p.a (concessional rate)
- 17.2** Term loan from federal bank along with interest is secured by first paripassu charge of EM of lease hold right of Anthem Biosciences Pvt Ltd on 32,932 sqm of land at plot no.313-P;314-P&318-P in Harohalli 2nd Phase Industrial area, and second paripassu charge with the current assets (both present and future);hypothecation of moveable fixed assets of the company procured/to be procured to the extent of Rs.400 crores; Entire cash flow of the company. Term loan carries a fixed rate of interest@6.45% p.a
- 17.3** Cash Credit and other fund and non fund facilities from Citibank & HDFC Bank are secured by the first charge on pari-passu basis on all inventories and receivables, Demand promissory note and letter of continuity. These facilities are payable on demand and carry an interest rate (re-set) in the range of 7.55% to 8.50% p.a.
- 17.4** Term loan from Citi Bank is secured by an exclusive charge on Moveable fixed assets and carry an interest rate which is equivalent to 3Months T bill+125 bps.

Terms of security and repayment

- Mortgage /charge over the company's immovable and movable properties (other than project assets but including all receivables) both present and future;
- Charge/assignment of revenues receivables
- Charge over /assignment of the rights, titles and interests of the company in to and in respect of all project agreements (in accordance with concession agreement).
- Assignment of insurance policies, interest, benefits, claims, guarantees ,performance bonds and liquidated damages;
- The aforesaid charge will rank Pari - Passu with the mortgages and charges created/to be created in favour of participating institutions/banks.

17.5 Obligations towards finance leases

Particulars	(₹.in Lakhs)	
	31.03.2024	31.03.2023
Minimum Lease payments		
(i) Not later than one year	194.63	39.77
(ii) Later than one year but not later than five years	606.43	83.07
Total	801.06	122.84
Less: Amounts representing Interest	-	-
Total	801.06	122.84

18 Trade Payables

Particulars	(₹.in Lakhs)	
	31.03.2024	31.03.2023
Current		
(i) Dues to micro, small and medium enterprises	1.32	-
(ii) Dues to others	9,061.62	6,058.22
(iii) Other Creditors	1,011.16	1,135.90
Total	10,074.10	7,194.13

Trade Payables Ageing
(For Current Reporting period)

Loan Type	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total (₹.in Lakhs)
MSME	1.32	-	-	-	1.32
Others	9,657.05	50.77	201.28	163.69	10,072.79
Disputed dues - MSME	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
Total	9,658.37	50.77	201.28	163.69	10,074.10

Trade Payables Ageing
(For Previous Reporting period)

Loan Type	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total (₹.in Lakhs)
MSME	-	-	-	-	-
Others	6804.42	232.34	84.87	72.50	7,194.13
Disputed dues - MSME	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
Total	6,804.42	232.34	84.87	72.50	7,194.13

19 Other Financial Liabilities

Non Current

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
Lease Liability	430.59	76.44
Performance guarantee deposit	1,116.84	616.02
Total	1,547.43	692.45

Current

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
Retention money	592.23	449.79
Lease Liability	168.49	32.22
Total	760.71	482.01

Note - During the year, the Company made a reassessment of its lease agreements in order to ascertain whether the agreements meet the definition of a lease. The net impact of these changes has been transferred to Retained Earnings.

Fair Value Hierarchy

(₹.in Lakhs)				
Particulars	Carrying value as at		Fair value as at	
	31.03.2024	31.03.2023	31.03.2024	31.03.2023
Amortised cost				
(i) Borrowings	23,252.53	12,506.45	23,252.53	12,506.45
(ii) Trade Payables	10,074.10	7,194.13	10,074.10	7,194.13
(iii) Other financial liabilities	2,308.14	1,174.47	2,308.14	1,174.47
Total Financial Liabilities	35,634.78	20,875.04	35,634.78	20,875.04

20 Provisions

a) Non Current

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
Provision for employee benefits		
(i) Gratuity Payable	397.82	336.04
(ii) Leave encashment	255.22	202.79
Total	653.04	538.83

b) Non Current

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Provision for employee benefits		
(i) Gratuity Payable	228.62	247.07
(ii) Leave encashment	106.46	108.39
Total	335.08	355.45

(i) Movement in provisions

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
a) Provision for Gratuity		
Opening Balance	583.10	523.21
Additional Provisions made	235.78	192.45
Provisions released (paid)	192.45	132.55
Closing Balance	626.43	583.10
b) Leave Encashment		
Opening Balance	311.18	282.58
Additional Provisions made	253.45	218.72
Provisions released (paid)	202.94	190.11
Closing Balance	361.69	311.18

21 Other Liabilities**a) Non- Current**

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Endo Global Biologicals - significant financing component	-	-
Deferred Grant	116.93	141.76
Total	116.93	141.76

b) Current

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Other accrued liabilities	2,239.19	1,878.63
Advances from customers	3,376.69	140.01
Capital creditors	3,843.22	2,558.27
Dues to statutory/government authorities	505.89	264.06
Grants received in advance	-	38.52
Total	9,965.00	4,879.49

22 Current Tax Liability (Net)

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Current		
Income Tax Provision	12,641.08	12,088.35
Less: Advance tax paid	12,000.00	11,500.00
Total	641.08	588.35

23 Revenue From Operations

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Sale of products & services		
Domestic sales	30,961.04	21,302.43
Export sales	1,10,975.91	84,390.00
Total	1,41,936.96	1,05,692.43

23.1 Change in Contract Liabilities:

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Balance at the beginning of the year	-	2,187.39
Add: Interest expense during the year	-	188.46
Less: Invoices raised during the year	-	2,375.86
Balance at the end of the year	-	-
Expected revenue recognition from remaining performance obligations		
-within one year	-	-
-more than one year	-	-

23.2 Performance Obligation

In relation to information about company's performance obligation, the entity satisfies the performance obligation at a point in time.

24 Other Income

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Interest from deposits & advances	4,086.17	2,909.88
Other income	19.53	100.62
Capital Gain and Dividend	703.43	1,487.33
Fair value Gain-Mutual Fund	14.52	(797.61)
Forex gain (net)	1,461.84	1,288.86
RoDTEP/MEIS duty credit incentives	35.83	-
Electricity cross subsidy received (wheeling charges)	-	356.83
Freight and forwarding charges collected	-	70.99
Grant received	44.15	98.11
Fair value SFC written back	-	2,187.39
Lease rent received	4.44	4.44
Total	6,369.92	7,706.85

25 Cost of materials consumed

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Opening stock	10,283.61	3,784.51
Purchases (Chemical and Reagents)	68,229.61	41,328.00
	78,513.22	45,112.51
Less: Closing stock	14,434.58	10,283.61
Cost of material consumed	64,078.64	34,828.89

25.1 Change in Work in Progress

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Opening stock		
Finished goods	507.50	455.36
Work-in-progress	2,025.16	1,176.10
	2,532.66	1,631.46
Less: Closing stock		
Finished goods	1,871.32	507.50
Work-in-progress	4,784.81	2,025.16
Total	(4,123.47)	(901.20)

26 Employee Benefits Expense

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Salaries and allowances	16,296.09	13,945.41
Contribution to provident and other funds	1,152.65	711.08
Staff welfare	840.66	660.58
Employees Benefit Expense	3.28	6.62
Total	18,292.69	15,323.70

27 Finance Costs

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
Interest Expense on		
(i) Interest - Term loans	623.88	355.17
(ii) Interest - Cash credit	198.67	43.68
(iii) Interest - Finance lease	-	18.58
(iv) Interest - IND AS lease	48.93	10.37
(v) Bank charges	38.13	52.19
(vi) Interest on Endo Global-Significant Financing Component	-	188.46
(vii) Amortisation of deferred loan (ABPPL)	7.81	7.81
(viii) Interest on MSME payables	36.13	-
Total	953.55	676.26

28 Other expenses

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
Advertisement and business promotion	106.19	53.53
Auditors' remuneration	26.00	21.00
Bad Debt Written Off	11.94	-
Commission expenses	263.00	415.71
Communication expenses	73.95	80.75
Corporate social responsibility expenses	869.60	601.08
Donation	2.00	2.50
Freight and forwarding charges	423.62	514.96
Health and safety expenses	275.12	286.84
Insurance	456.25	349.17
Interest on statutory dues	12.18	195.90
Internal Audit Fees	8.50	7.50
Legal and professional fees	256.42	222.80
Loss from sale of assets	43.48	0.28
Membership and subscription	79.85	68.75
Miscellaneous expenses	3.93	127.22
Fair value measurement expenses	95.46	46.41
Pollution control expenses	395.87	490.27
Power and fuel	3,212.67	3,901.08
Printing and stationery	228.61	247.19
Processing charges	442.45	295.69
R & D expenses	2,316.05	2,586.13
R & M - Building	96.09	64.43
R & M - Others	864.34	523.95
R & M - Plant and machinery	1,622.55	1,227.02
Rates and taxes	428.34	641.27
Rent	43.10	25.90
Security charges	186.32	152.18
Training and recruitment expenses	12.57	5.37
Travelling and conveyance	334.78	397.60
Total	13,191.26	13,552.49

28.1 As per Section 135 of Companies Act, 2013, a company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities.

29 Auditor's remuneration break-up

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
(i) Statutory audit fees	26.00	21.00
(ii) Certification and other reimbursement	0.67	2.62
(iii) Internal audit fees	8.50	7.50
Total	35.17	31.12

30 Tax Expense

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
A - Current Tax		
Current tax on profits for the year	12,641.08	12,004.84
Total	12,641.08	12,004.84

30.1 Reconciliation of tax expenses to accounting profit

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
A Amount recognised in Statement of profit and loss		
Current tax	12,641.08	12,004.84
Deferred tax expense/(income)	(1,640.29)	(793.58)
Tax expense for the year	11,000.79	11,211.26
B Reconciliation of effective tax rate		
Profit before tax and exceptional item	47,731.79	43,549.53
Add: Exceptional items, net	-	6,180.24
Profit before tax	47,731.79	49,729.77
Tax at statutory income tax rate 25.168%	12,013.14	12,515.99
Tax effects on:		
Inadmissible expenses & Income not included	758.87	-
Deductible expenditure & income to be excluded	(245.44)	-
Deduction under section 80JJA	(16.21)	-
Others	(1,509.56)	(1,304.73)
	11,000.79	11,211.26

31 Other comprehensive income

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Items that will not be reclassified to profit or loss		
(ii) Actuarial gains & losses	(33.13)	(27.92)
(iii) Deferred tax	8.34	103.48
Total	(24.79)	75.56

32 Research and development expenditure

Expenditure on research activities are recognized as expenses and charged to Statement of profit and loss. Development costs of products are also charged to the Statement of profit and loss unless a product's technological feasibility has been established and the ability of the asset to generate future economic benefits, in such case expenditure is capitalized. The amount capitalized comprises expenditure that can be directly attributed or allocated on a reasonable and consistent basis to creating, producing and making the asset ready for its intended use. Fixed assets utilized for research and development are capitalized and depreciated in accordance with the policies stated for Tangible Assets and Intangible Assets. During the year, the below mentioned expenditure is incurred towards research and development:

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Salaries and allowances	1,276.66	1,056.26
Consumables	953.90	1,461.84
Electricity expenses	78.40	63.17
Other expenses	7.09	4.86
Total expenses charged to statement of profit and loss	2,316.05	2,586.13

33 Earnings per share

Particulars	For the year ended	
	31.03.2024	31.03.2023
Earnings:		
Profit for the year attributable to equity shareholders (a)	3,67,06,20,611	3,85,94,06,675
Shares:		
Number of equity shares at the beginning of the year	57,04,86,800	87,76,254
Weighted average number of equity shares issued as share split	-	3,51,07,346
Weighted average number of bonus shares issued during the year	-	52,66,03,200
Weighted average number of equity shares bought back during the year	(34,69,799)	-
Weighted average number of equity shares – Basic (b)	56,70,17,001	57,04,86,800
Dilutive effect of potential equity shares	-	-
Weighted average number of equity shares – Diluted (c)	56,70,17,001	57,04,86,800
EPS: Basic (in Rs.) (a/b)	6.47	6.77
Diluted (in Rs.) (a/c)	6.47	6.77

34 Employee benefit expenses

		(₹.in Lakhs)	
Particulars		For the year ended	
		31.03.2024	31.03.2023
(i) Salaries and Wages		16,296.09	13,945.41
(ii) Contribution to provident and other funds*		1,152.65	711.08
(iii) Staff training and welfare expenses		840.66	660.58
(iv) Employee benefit expenses		3.28	6.62
Total		18,292.69	15,323.70

*Includes contribution to defined contribution plan for the year ended March 31, 2024 Rs. 489.23 lacs (for the year ended March 31, 2023:Rs.411.16 lacs)

Reconciliation of the present value of defined benefit obligation

(₹.in Lakhs)					
Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
Change in projected benefit obligations					
(i)	Obligations at the beginning of the year	1,042.12	909.72	311.18	282.58
(ii)	Service cost	165.99	130.76	63.36	56.03
(iii)	Interest expense	76.75	63.89	15.79	13.86
(iv)	Benefits settled	(45.74)	(90.25)	(202.94)	(190.07)
(v)	Actuarial (gain)/loss	30.78	27.99	174.30	148.79
Obligations at end of the year		1,269.89	1,042.12	361.69	311.18

Reconciliations of present value of plan assets

(₹.in Lakhs)					
Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
Change in plan assets					
(i)	Plan assets at the beginning of the year, at fair value	459.01	386.51	-	-
(ii)	Interest income on plan assets	40.09	30.13	-	-
(iii)	Re-measurement - actuarial gain/ (loss)	(2.35)	0.07	-	-
(iv)	Benefit payments from plan assets	(45.74)	(90.25)	-	-
(v)	Contributions from employers	192.45	132.55	202.94	190.07
(vi)	Benefits settled	-	-	(202.94)	(190.07)
Plan assets at the end of the year at fair value		643.46	459.01	-	

Reconciliation of net defined benefit obligation

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
Change in plan assets					
(i)	Present value of funded obligation	1,269.89	1,042.12	361.69	311.18
(ii)	Fair value of plan assets	(643.46)	(459.01)	-	-
Net Defined Benefit Liability / (Asset)		626.44	583.10	361.69	311.18
Short term Liability		228.62	247.07	106.46	108.39

Expense recognised in the statement of profit and loss under employee benefits expense

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
Change in projected benefit obligations					
(i)	Current Service Cost	165.99	130.76	63.36	56.03
(ii)	Interest Expense on DBO	76.75	63.89	15.79	13.86
(iii)	Interest (Income) on Plan Assets	(40.09)	(30.13)	-	-
(iv)	Actuarial Loss / (Gain) - Other than OCI	-	-	174.30	148.79
Defined Benefit Cost included in P & L		202.65	164.52	253.45	218.68
(i)	Discount rate	7.25%	7.53%	7.53%	7.39%
(ii)	Salary increase	6.00%	6.00%	6.00%	6.00%

Remeasurements recognised in the statement of other comprehensive income

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
(i)	Remeasurements - Gain/ Loss on DBO	30.78	27.99	-	-
(ii)	Return on plan assets, excluding interest income	2.35	(0.07)	-	-
Defined Benefit Cost included in P & L		33.13	27.92	-	-

Bifurcation of present value of obligations at the end of the valuation period as per schedule III of the Companies Act, 2013

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
(i)	Current liabilities	228.62	247.07	106.46	108.39
(ii)	Non-Current liabilities	1,041.28	795.05	255.22	202.79

Plan assets comprises of the following:

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
Insurance Policies		643.46	459.01	-	-

The experience adjustments, meaning difference between changes in plan assets and obligations expected on the basis of actuarial assumption and actual changes in those assets and obligations are as follows:

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
(i)	Experience adjustment on plan liabilities	21.83	31.38	174.10	149.24
	Percentage of opening plan liabilities	2.10%	3.45%	55.95%	52.81%
(ii)	Experience adjustment on plan assets	(2.35)	0.07	-	-
	Percentage of opening plan assets	-0.51%	0.02%	-	-

Maturity profile of defined benefit obligation:

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
	Year 1	229.69	247.78	106.46	108.39
	Year 2	210.93	201.57	81.86	74.55
	Year 3	177.70	184.14	62.30	57.04
	Year 4	162.38	145.72	47.27	40.17
	Year 5	144.72	120.44	35.97	28.10
	Next 5 year Payouts	1,004.79	522.71	127.00	72.25

The weighted average duration of the defined benefit obligation for gratuity is 6 as at 31 March 2024

The weighted average duration of the defined benefit obligation for Leave encashment is 4 as at 31 March 2024

35 Disclosure with respect to Ind AS 116 - Leases

Information about Leases Assets for which the Company is a lessee is presented below:

(₹.in Lakhs)

Particulars	"As at March 31, 2024"	"As at March 31, 2023"
Balance as at beginning of the year	133.76	248.60
Additions	628.93	11.44
Deletions	-	(81.62)
Depreciation*	(133.97)	(44.66)
Balance as at end of the year	628.72	133.76

*The aggregate depreciation expense on Right-of-use assets is included under depreciation expense in Statement of Profit and Loss.

The changes/movement in Lease Liabilities of the Company are as follows:

(₹.in Lakhs)

Particulars	"As at March 31, 2024"	"As at March 31, 2023"
Balance as at beginning of the year	108.66	230.43
Additions	628.93	13.98
Deletions	-	-93.09
Repayment of principal and interest on lease liabilities	-187.45	-53.02
Accreditation of interest	48.93	10.37
Balance as at end of the year	599.08	108.66
Current Liabilities	168.49	32.22
Non-Current Liabilities	430.59	76.44
Total cash outflow for leases	187.45	53.02

The table below provides details regarding amounts recognised in the Standalone Statement of Profit and Loss:

(₹.in Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023
Expenses relating to short-term leases and/or leases of low-value items		
Interest on lease liabilities	48.93	10.37
Depreciation expense	133.97	44.66
Total	182.90	55.03

Contractual maturities of Lease Liabilities on undiscounted basis

(₹.in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
Less than one year	194.63	39.77
One to five years	606.43	83.07
Total	801.06	122.84

36 Financial Risk Management

The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk, foreign currency risk and interest rate risk. The Company's primary focus is to foresee the unpredictability of financial markets and seek to minimize potential adverse effects on its financial performance. The primary market risk to The Company is foreign exchange risk. The Company uses derivative financial instruments to mitigate foreign exchange related risk exposures. All derivative activities for risk management purposes are carried out by specialist teams that have the appropriate skills, experience and supervision. It is The Company's policy that no trading in derivative for speculative purposes may be undertaken. The Board of Directors reviews and agrees policies for managing each of these risks, which are summarised below:

(a) Credit risk:

Credit risk is the risk of financial loss to The Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from The Company's receivables from customers and investment securities. Credit risk arises from cash held with banks and financial institutions, as well as credit exposure to clients, including outstanding accounts receivable. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses in financial assets. The Company assesses the credit quality of the counterparties, taking into account their financial position, past experience and other factors.

(b) Trade and other receivables:

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment.

(c) Investments:

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non-performance by these counterparties, and does not have any significant concentration of exposures to specific industry sectors.

(d) Liquidity risk:

Liquidity risk is the risk that The Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due. Also, the Company has unutilized credit limits with banks.

The Company's corporate treasury department is responsible for liquidity, funding as well as settlement management. In addition, processes and policies related to such risks are overseen by senior management. The working capital position of the Company is given below:

(₹.in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
Cash & cash equivalents	18,385.92	34,223.56
Investments in mutual funds (quoted)	45,907.03	49,287.05

Contractual maturities of significant financial liabilities as at

(₹.in Lakhs)			
Particulars	As at March 31, 2024		
	Less than 1 year	More than 1 year	Total
Borrowings	12,086.73	11,165.81	23,252.53
Lease Liabilities	168.49	430.59	599.08
Trade payables and accrued expenses	10,072.79	-	10,072.79
Other Financial liabilities	592.23	1,116.84	1,709.07

Particulars	As at March 31, 2024		
	Less than 1 year	More than 1 year	Total
Borrowings	2,887.61	9,618.84	12,506.45
Lease Liabilities	32.22	76.44	108.66
Trade payables and accrued expenses	7,194.13	-	7,194.13
Other Financial liabilities	449.79	616.02	1,065.81

(e) Foreign currency risk:

The Company's exchange risk arises from its foreign operations, foreign currency revenues and expenses, (primarily in U.S. Dollars). A significant portion of The Company's revenues are in US Dollars while a significant portion of its costs are in Indian Rupees. As a result, if the value of the Indian Rupee appreciates relative to these foreign currencies, The Company's revenues measured in Rupees may decrease. The exchange rate between the Indian Rupee and these foreign currencies has changed substantially in recent periods and may continue to fluctuate substantially in the future. The Company has an internal committee which meets on a periodic basis to formulate the strategy for foreign currency risk management. When necessary, the Company uses derivative financial instruments, such as foreign exchange forward contracts, to mitigate the risk of changes in foreign currency exchange rates in respect of its forecasted cash flows and trade receivables.

(f) Interest rate risk:

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to The Company's debt obligations with floating interest rates and investments. The Company's borrowings and investments are primarily short-term, which do not expose it to significant interest rate risk.

37 Capital Management Structure

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. The Company monitors the return on capital as well as the level of dividends on its equity shares. The Company's objective when managing capital is to maintain an optimal structure so as to maximize shareholder value. The capital structure is as follows:

The Company is predominantly equity financed which is evident from the capital structure table. Further, The Company has always been a net cash Group with cash and bank balances along with investment which is predominantly investment in liquid and short term mutual funds being far in excess of debt.

(₹.in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
Total equity attributable to the equity share holders of the group	1,92,465.45	1,74,066.87
As percentage of the total capital	100%	100%
current loans & borrowings	12,086.73	2,887.61
Non current loans & borrowings	11,165.81	9,618.84
Total loans & borrowings	23,252.53	12,506.45
As percentage of the total capital	12%	7%
Total capital (loans and borrowings and equity)	2,15,717.99	1,86,573.32

38 Contingent Liabilities & Capital Commitments

(₹.in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
Commitments		
Estimated amount of expected capital commitments	21,156	13,563
Contingent liabilities		
<u>Claims against the company not acknowledged as debts:</u>		
Income tax - AY 2015-16 - CIT Appeals 1, Bengaluru	326	326
Income tax - AY 2016-17 - ACIT, Bengaluru	20	-
Income tax - AY 2017-18 - ITAT , Bengaluru	93	93
Income tax - AY 2018-19 - ACIT, Bengaluru	381	-
Income tax - AY 2020-21 - CIT (A) Bengaluru	51	51
Goods and Service Tax: FY 2017-18-Bengaluru	45	-
Service Tax-Appeal-FY: 2011-2015	12	12
<u>Others:</u>		
Letter of credit	43	286
Bank guarantees	183	70
<u>Corporate guarantees:</u>		
Guarantees given to Federal Bank on behalf of wholly owned subsidiary & associate company for securing financial assistances in the form for term loan and working capital loans.	22,150	21,800

39 Segment information:

Segments are identified in line with Indian Accounting Standard (Ind AS) 108 "Operating Segments", taking into consideration the internal organization and business activities in which it engages and the economic environments in which it operates and separate financial information availability. Company has identified two business segments viz, Contract Manufacturing; Development & Discovery Services and Speciality Ingredients (product business) during the year. Revenue and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reporting segment have been allocated on the basis of associated revenue. All other expenses which are not attributable or allocable to segments have been disclosed as unallocable expenses.

(₹.in Lakhs)

Particulars	Year ended March 31, 2024	Year ended March 31, 2023
Segmental Performance		
Business Vertical:		
A) Contract Research Development & Manufacturing Services (CRDMO)		
Development & Manufacturing	89,759.70	63,495.23
R&D Services	18,557.20	17,314.00
B) Speciality Ingredients	33,620.10	24,883.20
Total	1,41,937.00	1,05,692.43
Revenue wise		
Export	1,11,023.20	84,390.00
Domestic	30,913.80	21,302.43
Total	1,41,937.00	1,05,692.43
Geography wise sales		
North America (USA)	42,930.51	50,020.50
Europe	61,278.29	30,620.00
India	30,913.80	21,302.43
Rest of asia	6,814.40	3,749.50
Total	1,41,937.00	1,05,692.43

40 Corporate Social Responsibility

As per Section 135 of the Companies Act, 2013, a company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities. During the financial year 2023-24 the company has spent below amounts towards various CSR activities undertakes. (viz, Skill development projects; Environmental sustainability; Promoting educations; Contributions towards healthcare; Mid day meals for school children; Construction of government schools etc)

(₹.in Lakhs)

Particulars	Year ended March 31, 2024	Year ended March 31, 2023
Gross amount required to be spent during the year	939.97	688.56
Amount spent during the year	869.60	601.08
Amount spent in local area	867.60	594.08
Shortfall at the end of the year / period.	70.37	87.48
Total of previous years shortfall.	608.71	538.34

As on March 31, 2024, a cumulative amount of Rs.608.71 lakhs is unspent. Total amount spent includes provision of INR. 3.00 crores created and will be spent in the FY2024-25.

41 Trade Payables have been classified as Current and Non-Current. The Management has identified:

Trade Payables have been classified as Current and Non-Current. The Management has identified:

(₹.in Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023
(i) Principal amount remaining unpaid to any supplier as at the end of the accounting year	668.28	-
(ii) Interest due thereon remaining unpaid to any supplier as at the end of the accounting year	36.13	-
(iii) The amount of interest paid along with the amounts of the payment made to the supplier beyond the appointed day	-	-
(iv) The amount of interest due and payable for the year	36.13	-
(v) The amount of interest accrued and remaining unpaid at the end of the accounting year	-	-
(vi) The amount of further interest due and payable even in the succeeding year, until such date when the interest dues as above actually paid	-	-

42 Related Parties

Name of the related party	Nature of relationship with the company	Country of Incorporation/ Residential Status
Ajay Bhardwaj	Managing Director	Indian
Ravindra KC	Director	Indian
Ganesh Sambasivam	Director	Indian
Ramakrishnan K	Company Secretary	Indian
Gawir Baig	Vice President cum CFO	Indian
Ishaan Bhardwaj	Vice President	Indian
Krithika Ganesh	Dp.Manager-II	Indian
Keerthana Ravindra	Dp.Manager-II	Indian
Anthem Biopharma Pvt Ltd	Common Directors	India
Neoanthem Lifesciences Pvt Ltd	Wholly Owned Subsidiary	India

42.1 Transactions with above related parties

(₹.in Lakhs)

Name of the related party	Nature of transaction	Year Ended	
		March 31,2024	March 31,2023
Ishaan Bhardwaj	Remuneration paid	65.43	43.54
Keerthana Ravindra	Remuneration paid	12.80	8.11
Krithika Ganesh	Remuneration paid	15.54	9.70
Anthem Biopharma Pvt Ltd	Business support services	5.79	7.53
	Interest income (Interest charged on loans given)	62.15	60.99

42.2 Balances receivable from related parties are as follows

(₹.in Lakhs)

Name of the related party	Classification	Year Ended	
		March 31,2024	March 31,2023
Anthem Biopharma Pvt Ltd	For sale of goods & services	310.78	310.78
	For loans and advances given	740.44	719.50

43 Remuneration paid to key management personnel

(₹.in Lakhs)

Name	Designation	Remuneration paid for the Year ended	
		March 31,2024	March 31,2023
Ajay Bhardwaj	Managing Director	747.57	467.36
Ravindra K C	Director	741.70	471.40
Ganesh Sambasivam	Director	742.68	471.55
Ramakrishnan K	Company Secretary	39.00	39.00
Gawir Baig	Vice President cum CFO	116.10	104.14

44 Key financial ratios

Particulars	Figures for the current reporting period	Figures for the previous reporting period	Reason if the variance is more than 25%
1. Current Ratio	4.38	8.07	Reduction in short term deposits
2. Debt - Equity Ratio	0.12	0.07	
3. Debt Service Coverage Ratio	2.35	4.31	
4. Return on Equity Ratio	20.03%	24.93%	
5. Inventory turnover ratio	4.59	5.25	
6. Trade Receivables turnover ratio	3.68	3.49	
7. Trade payables turnover ratio	8.47	6.94	
8. Net capital turnover ratio	1.23	1.04	
9. Net profit ratio (Net Profit/Net Sales)	26%	37%	Decrease in profit
10. Return on Capital employed (EBIT/Capital Employed)	32%	49%	

45 Other Statutory Disclosures

- (i) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- (ii) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (iii) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- (iv) No Relationship or Transactions with any struck off companies during the year.
- (v) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (vi) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (vii) The Company has not any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.
- (viii) The Company has not been declared as Willfull Defaulter by any Bank or Financial Institutions or any other lender.
- (ix) The Company has complied with the number of layers prescribed under clause (87) of Section 2 of the Act r.w Companies (Restriction on number of layers) Rules, 2017.
- (x) The Company uses an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the accounting software. There is no instance of audit trail feature being tampered with was noted in respect of the accounting software.

As per our report of even date attached
Notes forming part of consolidated financial statements

For K.P. Rao & Co.,
Chartered Accountants
Firm Registration No. 003135S

Mohan Lavi
Partner
Membership No.029340

Place : Bangalore
Date : September 05, 2024

For and on behalf of the Board

Ajay Bhardwaj
Managing Director
DIN:00333704

Ravindra K C
Director
DIN:01580534

Ramakrishnan K
Company Secretary
FCS: 11748

Gawir Baig
CFO

Accounting Policies (Consolidated Financial Statements)

ANTHEM BIOSCIENCES PRIVATE LIMITED

CIN: U24233KA2006PTC039703

Notes forming part of the Consolidated Financial Statements for the year ended March 31, 2024

1. Corporate information:

Anthem Biosciences Private Limited ("the Company") has been set up as a Life sciences/ Biotechnology based venture specialising in the manufacture of catalytic preparation, other organic compounds such as speciality organic molecules, biologically active peptides etc., which are high-value products used in drug, agrochemical and speciality chemicals industries. During the financial year 2020-21, the company set up a wholly owned subsidiary NeoantheM Lifesciences Private Limited (CIN No. U24239KA2020PTC136337). The company along with its subsidiary are hereby referred to as "The Group".

The Company has received the letter of permission under the 100% EOU scheme for manufacture of catalytic preparation and other organic compounds from the office of the Development Commissioner, CSEZ, sub office in Karnataka, vide letter No. 1/80/2006:PER:EOU:KR:CSEZ/106 dated 19th January 2007, which is further extended vide letter No : 1/80/2006:EOU:CSEZ/1276 dated 11th July 2022, valid till 10th July 2027. In accordance with the said letter of permission, the facilities at the factory located at Bommasandra Industrial Area are with its best in class infrastructure which includes a modern c-GMP kilo lab and a versatile GMP pilot plant. Anthem Biosciences has the capacity to do GMP synthesis from milligram to kilogram and multi-kilogram scale. The projects results are initially transmitted by means of reports followed by the manufacture of small sample quantities that are sent to clients for testing purpose. The Company has received approval from Department of Scientific and Industrial Research Technology for in-house research and development for the purpose of section 35 (2AB) of the Income Tax Act, 1961 beginning 1 April 2011 to 31 March 2017 and further renewed and valid as on 31.03.2024 vide approval letter no:F.No.TU/IV-RD/2954/2021 dated 18th March 2021.

2. Significant accounting policies:

(A) Basis of preparation and presentation:

a) Statement of compliance:

These consolidated financial statements have been prepared in accordance with Indian Accounting Standards ("hereinafter referred to as the "Ind AS") as notified by Ministry of Corporate Affairs pursuant to Section 133 of the companies Act, 2013 read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time.

These consolidated financial statements have been prepared for the Group as a going concern on the basis of relevant Ind AS that are effective at the Group's annual reporting date, March 31, 2024. These consolidated financial statements were approved and authorized for issuance by the Company's Board of Directors on September 05, 2024.

b) Basis of measurement:

The consolidated financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following material items that have been measured at fair value as required by relevant Ind AS:

- i. Certain financial assets and liabilities measured at fair value (refer accounting policy on financial instruments);
- ii. Defined benefit and other long-term employee benefits.

c) Basis of Consolidation

The Company consolidates its entities which are controlled by it. The Company establishes control when; it has power over the entity, is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect the entity's returns by using its power over relevant activities of the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. The financial statements of the Group are consolidated on line-by-line basis. Intra-group transactions, balances and any unrealized gains arising from intra-group transactions, are eliminated. Unrealized losses are eliminated, but only to the extent that there is no evidence of impairment. All temporary differences that arise from the elimination of profits and losses resulting from intra-group transactions are recognized as per Ind AS 12, Income Taxes.

For the purpose of preparing these consolidated financial statements, the accounting policies of the subsidiary have been aligned with the policies adopted by the Parent.

d) Use of estimates and judgements:

The preparation of consolidated financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on a periodic basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the consolidated financial statements is included in the notes.

e) Fair valuation:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Group takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/ or disclosure purposes in these consolidated financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of Ind AS 102, leasing transactions that are within the scope of Ind AS 116, and measurements that have some similarities to fair value but are not fair value, such as a net realisable value in Ind AS 2 or value in use in Ind AS 36.

In addition, for financial reporting purposes, fair value measurements are categorised into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the group can access at the measurement date;
- Level 2 inputs are other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

(i) Functional and presentation currency:

Items included in the consolidated financial statements of the Group are measured using the currency of the primary economic environment in which the Group operates (i.e. the “functional currency”). The consolidated financial statements are presented in Indian Rupee, the national currency of India, which is the functional currency of the Group.

(ii) Foreign currency transactions and balances:

Transactions in foreign currency are translated into the respective functional currencies using the exchange rates prevailing at the dates of the respective transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at the exchange rates prevailing at reporting date of monetary assets and liabilities denominated in foreign currencies are recognized in the consolidated statement of profit and loss and reported within foreign exchange gains/ (losses).

Non-monetary assets and liabilities denominated in a foreign currency and measured at historical cost are translated at the exchange rate prevalent at the date of transaction.

(iii) Financial instruments:

All financial instruments are recognised initially at fair value. Transaction costs that are attributable to the acquisition of the financial asset (other than financial assets recorded at fair value through profit or loss) are included in the fair value of the financial assets. Purchase or sale of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trade) are recognised on trade date. While, loans and borrowings and payables are recognised net of directly attributable transaction costs.

For the purpose of subsequent measurement, financial instruments of the Group are classified in the following categories: non-derivative financial assets comprising amortised cost, debt instruments at fair value through other comprehensive income

(FVTOCI), equity instruments at FVTOCI or fair value through profit and loss account (FVTPL), non-derivative financial liabilities at amortised cost or FVTPL and derivative financial instruments (under the category of financial assets or financial liabilities) at FVTPL. The classification of financial instruments depends on the objective of the business model for which it is held. Management determines the classification of its financial instruments at initial recognition.

(a) Non-derivative financial assets:

(i) Financial assets at amortized cost:

A financial asset shall be measured at amortized cost if both of the following conditions are met:

the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and

the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

They are presented as current assets, except for those maturing later than 12 months after the reporting date which are presented as non-current assets. Financial assets are measured initially at fair value plus transaction costs and subsequently carried at amortized cost using the effective interest rate method, less any impairment loss.

Amortized cost are represented by trade receivables, security deposits, cash and cash equivalents, employee and other advances and eligible current and non-current assets. Cash and cash equivalents comprise cash in hand and in banks and demand deposits with banks which can be withdrawn at any time without prior notice or penalty on the principal.

For the purposes of the cash flow statement, cash and cash equivalents include cash in hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand, book overdraft and are considered part of the Group's cash management system.

(ii) Financial assets at FVTPL:

FVTPL is a residual category for financial assets. Any financial asset which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as FVTPL. In addition the Group may elect to designate the financial asset, which otherwise meets amortized cost or FVTOCI criteria, as FVTPL if doing so eliminates or significantly reduces a measurement or recognition inconsistency. Financial assets included within the FVTPL category are measured at fair values with all changes in the consolidated statement of profit and loss.

(b) Non-derivative financial liabilities:

(i) Financial liabilities at amortized cost:

Financial liabilities at amortized cost represented by borrowings, trade and other payables are initially recognized at fair value, and subsequently carried at amortized cost using the effective interest rate method.

(B) Property, plant and equipment:

a) Recognition and measurement:

Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Cost includes expenditures directly attributable to the acquisition of the asset.

b) Depreciation

The Group depreciates property, plant and equipment over the estimated useful life on a written down value basis from the date the assets are ready for intended use. Assets acquired under finance lease and leasehold improvements are amortized over the lower of estimated useful life and lease term. The estimated useful lives of assets for the current and comparative period of significant items of property, plant and equipment are as follows:

Category	Useful Life (years)
Roads	5-10
Buildings	5-60
Plant and machinery	15-20
Electrical installations	10
Furniture and fittings	10

Category	Useful Life (years)
Laboratory equipments	10
Office equipment	5
Pipelines	15
Computers and DP units	3-6
Motor vehicles	8

Depreciation methods, useful lives and residual values are reviewed at each reporting date. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Subsequent expenditure relating to property, plant and equipment is capitalized only when it is probable that future economic benefits associated with these will flow to the Group and the cost of the item can be measured reliably. Repairs and maintenance costs are recognized in the consolidated statement of profit and loss when incurred. The cost and related accumulated depreciation are eliminated from the consolidated financial statements upon sale or disposition of the asset and the resultant gains or losses are recognized in the consolidated statement of profit and loss.

Amounts paid towards the acquisition of property, plant and equipment outstanding as of each reporting date and the cost of property, plant and equipment not ready for intended use before such date are disclosed under capital advances and capital work- in-progress respectively.

(C Intangible assets:

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective estimated useful lives on a written down value basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

The estimated useful lives of intangibles are as follows:

Category	Useful Life
Software licenses	Earlier of license period or 1-3 years

(D) Leases:

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Group accounts for each lease component within the contract as a lease separately from non-lease components of the contract and allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.

The Group recognizes right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right-of- use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred and an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset or restoring the underlying asset or site on which it is located. The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any re-measurement of the lease liability. The right-of-use asset is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. Right-of- use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the consolidated statement of profit and loss.

The Group measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the incremental borrowing rate, if that rate can be readily determined. If that rate cannot be readily determined, the Group uses incremental borrowing rate. The lease payments shall include fixed payments, variable lease payments, residual value guarantees, exercise price of a purchase option where the Group is reasonably certain to exercise that option and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease. The lease liability is subsequently re-measured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and re-measuring the carrying

amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments.

The Group recognises the amount of the re-measurement of lease liability due to modification as an adjustment to the right-of-use asset and consolidated statement of profit and loss depending upon the nature of modification. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Group recognises any remaining amount of the re-measurement in consolidated statement of profit and loss.

The Group has elected not to apply the requirements of Ind AS 116 Leases to short-term leases of all assets that have a lease term of 12 months or less and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognised as an expense on a straight-line basis over the lease term.

(E) Impairment:

(a) Financial assets:

In accordance with Ind AS 109, the Group applies expected credit loss (ECL) model for measurement and recognition of impairment loss. The Group follows 'simplified approach' for recognition of impairment loss allowance on trade receivable. The application of simplified approach does not require the Group to track changes in credit risk.

Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition. For recognition of impairment loss on other financial assets and risk exposure, the Group determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If in subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the Group reverts to recognising impairment loss allowance based on 12-month ECL. Lifetime ECLs are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12-month ECL is a portion of the lifetime ECL which results from default events that are possible within 12-months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Group in accordance with the contract and all the cash flows that the group expects to receive (i.e. all shortfalls), discounted at the original effective interest rate (EIR). When estimating the cash flows, the group is required to consider:

- (i) All contractual terms of the financial instrument (including prepayment, extension etc.) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the group is required to use the remaining contractual term of the financial instrument.
- (ii) Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

As a practical expedient, the Group uses a provision matrix to determine impairment loss on portfolio of its trade receivable. The provision matrix is based on its historically observed default rates over the expected life of the trade receivable. At every reporting date, the historically observed default rates are updated. ECL impairment loss allowance (or reversal) recognised during the period is recognised as income/expense in the consolidated statement of profit and loss.

The balance sheet presentation for various financial instruments is described below:

Financial assets measured at amortized cost, contractual revenue receivable. ECL is presented as an allowance, i.e. as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write off criteria, the Group does not reduce impairment allowance from the gross carrying amount.

(b Non-financial assets:

The Group assesses at each reporting date whether there is any objective evidence that a non-financial asset or a group of non-financial assets is impaired. If any such indication exists, the Group estimates the amount of impairment loss. An impairment loss is calculated as the difference between an asset's carrying amount and recoverable amount. Losses are recognised in profit or loss and reflected in an allowance account. When the Group considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, then the previously recognised impairment loss is reversed through profit or loss. The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the "cash-generating unit").

(F) Employee benefits:

The Company participates in various employee benefit plans. Post-employment benefits are classified as either defined contribution plans or defined benefit plans. Under a defined contribution plan, the Company's only obligation is to pay a fixed amount with no obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits. The related actuarial and investment risks fall on the employee. The expenditure for defined contribution plans is recognized as expense during the period when the employee provides service. Under a defined benefit plan, it is the Company's obligation to provide agreed benefits to the employees. The related actuarial and investment risks fall on the Company. The present value of the defined benefit obligations is calculated using the projected unit credit method.

The Company has the following employee benefit plans:

a) Provident Fund:

Retirement benefit in the form of Provident Fund is a defined contribution scheme and the contributions are charged to the consolidated statement of profit and loss for the year when the employee renders the related service and the contributions to the government funds are due. The Company has no obligation other than the contribution payable to provident fund authorities.

b) Gratuity:

For the purpose of administration of gratuity of the employees of the Company, the Company has established Anthem Biosciences Private Limited Employees Gratuity Trust. In accordance with the Payment of Gratuity Act, 1972, the Company provides for a lump sum payment to eligible employees, at retirement or termination of employment based on the last drawn salary and years of employment with the Company. Company's obligation in respect of the gratuity plan, which is a defined benefit plan, is provided for based on actuarial valuation using the projected unit credit method.

Actuarial gains or losses are recognized in other comprehensive income. Further, the profit or loss does not include an expected return on plan assets. Instead net interest recognized in profit or loss is calculated by applying the discount rate used to measure the defined benefit obligation to the net defined benefit liability or asset. The actual return on the plan assets above or below the discount rate is recognized as part of re-measurement of net defined liability or asset through other comprehensive income.

Re-measurements comprising actuarial gains or losses and return on plan assets (excluding amounts included in net interest on the net defined benefit liability) are not reclassified to profit or loss in subsequent periods.

c) Compensated absences:

The employees of the Company are entitled to compensated absences. The employees can carry forward a portion of the unutilized accumulating compensated absences and utilize it in future periods or receive cash at retirement or termination of employment. The Company records an obligation for compensated absences in the period in which the employee renders the services that increases this entitlement.

The Company measures the expected cost of compensated absences as the additional amount that the Group expects to pay as a result of the unused entitlement that has accumulated at the end of the reporting period. The Company recognizes accumulated compensated absences based on actuarial valuation. Non-accumulating compensated absences are recognized in the period in which the absences occur. The Company recognizes actuarial gains and losses immediately in the consolidated statement of profit and loss.

(G) Provisions:

Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset, if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Provisions for onerous contracts are recognized when the expected benefits to be derived by the Group from a contract are lower than the unavoidable costs of meeting the future obligations under the contract. Provisions for onerous contracts are measured at the present value of lower of the expected net cost of fulfilling the contract and the expected cost of terminating the contract.

(H) Revenue :**a) Sale of goods & services:**

Groups earns revenue primarily from sale of goods, providing scientific & technical consultancy services. Revenue is recognised upon transfer of control of promised products or services (performance obligation) to the customers in an amount that reflects the consideration which the company expects to receive in exchange for those products or services.

The amount of revenue to be recognised (transaction price) is based on the consideration expected to be received in exchange for goods, excluding amounts collected on behalf of third parties such as sales tax or other taxes directly linked to sales. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on their relative stand-alone selling prices.

Revenue from product sales are recorded net of allowances for estimated rebates, cash discounts and estimates of product returns, all of which are established at the time of sale.

The Group adjusts the promised amount of consideration for the effects of time value of money if the timing of payments agreed to by the parties to the contract provides the customer with a significant benefit of financing the transfer of goods or services to the customer. The impact of the time value of money is shown as Contract Liability.

b) Rental income:

Rental income is recognised in consolidated statement of profit and loss on a straight-line basis over the term of the lease except where the rentals are structured to increase in line with expected general inflation. Lease incentives granted are recognised as an integral part of the total rental income, over the term of the lease.

c) Dividend & interest income :

Dividend income is recorded when the right to receive payment is established. Interest income is recognised using the effective interest method.

(I) Finance expense:

Finance expenses consist of interest expense on loans and borrowings. Borrowing costs are recognized in the consolidated statement of profit and loss using the effective interest method.

Foreign currency gains and losses are reported on a net basis. This includes changes in the fair value of foreign exchange derivative instruments, which are accounted at fair value through profit or loss.

(J) Income tax:

Income tax comprises current and deferred tax. Income tax expense is recognized in the consolidated statement of profit and loss except to the extent it relates to items directly recognized in equity or in other comprehensive income.

a) Current income tax:

Current income tax for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the taxable income for the period.

The tax rates and tax laws used to compute the current tax amount are those that are enacted or substantively enacted by the reporting date and applicable for the period. The Group offsets current tax assets and current tax liabilities, where it has a legally enforceable right to set off the recognized amounts and where it intends either to settle on a net basis or to realize the asset and liability simultaneously.

b) Deferred income tax:

Deferred income tax is recognized using the balance sheet approach. Deferred income tax assets and liabilities are recognized for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount in consolidated financial statements, except when the deferred income tax arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profits or loss at the time of the transaction.

Deferred income tax asset is recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. Deferred income tax liabilities are recognized for all taxable temporary differences.

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no

longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date

(K) Earnings per share (EPS):

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the period. Diluted EPS is computed by dividing the net profit after tax by the weighted average number of equity shares considered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date. Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for bonus shares, as appropriate.

(L) Research and development costs :

Research costs are expensed as incurred. Development costs are expensed as incurred unless technical and commercial feasibility of the project is demonstrated, future economic benefits are probable, the Group has an intention and ability to complete and use or sell the software and the costs can be measured reliably.

(M) Government grants:

Grants from the government are recognised when there is reasonable assurance that:

- (i) the Group will comply with the conditions attached to them; and
- (ii) the grant will be received.

Government grants related to revenue are recognised on a systematic basis in the consolidated statement of profit and loss over the periods necessary to match them with the related costs which they are intended to compensate. Such grants are deducted in reporting the related expense. When loan or similar assistance is provided by government or related institutions, with an interest rate below the current applicable market rate, the effect of this favorable interest is recognized as government grant. The loan or assistance is initially recognized and measured at fair value and the government grant is measured as the difference between the initial carrying value of the loan and the proceeds received.

(N) Inventories:

Inventories consist of (a) Raw materials, (b) Work-in-progress and (d) Finished goods. Inventories are carried at lower of cost and net realizable value. The cost of raw materials is determined on a weighted average basis and/specific cost wherever applicable. Cost of work in progress & finished goods produced includes direct material, labour cost and a proportion of manufacturing overheads.

(O) Previous year's figures have been re-grouped or re-classified to conform to the present year's presentation.

Standalone Financials

Auditors Report (Standalone Financials)

TO THE MEMBERS OF ANTHEM BIOSCIENCES PRIVATE LIMITED

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying Standalone Ind AS financial statements of **Anthem Biosciences Private Limited** which comprise the Standalone Balance Sheet as at 31 March 2024, the Standalone Statement of Profit and Loss (including other comprehensive income), Standalone Statement of Changes in Equity and the Standalone Statement of Cash Flows for the year then ended and notes to the standalone financial statements including a summary of the significant accounting policies and other explanatory information (hereinafter referred to as “the Standalone Ind AS financial statements”).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 (“Act”) in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as amended, (“Ind AS”) and other accounting principles generally accepted in India, of the Standalone State of Affairs of the Company as at March 31, 2024, and its profit and the total comprehensive income, the cash flows and the changes in equity for the year ended on that date.

Basis of Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the Ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

Board of Directors’ Responsibility for the Standalone Financial Statements

The Board of Directors are responsible for the matters stated in section 134(5) of the Companies Act 2013, with respect to the preparation of these financial statements that give a true and fair view of the financial position and financial performance, of the company in accordance with the Accounting Principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Board of Directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company’s financial reporting process.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined that there are no key audit matters to be reported for the year 2023-24.

Auditor’s Responsibility for the audit of Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable

assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosure are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We also communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

As required by the Companies (Independent Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of subsection (11) of Section 143 of the Act, we give in the "Annexure A", a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143 (3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

- c) The Standalone Balance Sheet, the Standalone Statement of Profit and Loss (including other comprehensive income), Standalone Statement of Changes in Equity and the Standalone Statement of Cash Flows dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended.
- e) On the basis of the written representations received from the directors as on 31st March, 2024 taken on record by the Board of Directors, none of the directors are disqualified as on 31st March, 2024 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in **"Annexure B"**.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements – Refer Note 38 to the standalone financial statements;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund.
 - iv. The Management has represented in Note 45(i) that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - v. The Management has represented in Note 45(ii) that, to the best of its knowledge and belief, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - vi. Based on the audit procedures as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) contain any material mis-statement.
 - vii. The company has neither declared nor paid interim dividend or final dividend during the year. Therefore, reporting under Rule 11(f) of Companies (Audit and Auditors) Rules, 2014 is not applicable.
 - h) With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act, in our opinion and according to the information and explanations given to us, the limit prescribed by section 197 for maximum permissible managerial remuneration is not applicable to a private limited company.
 - i) Based on our examination which included test checks, the company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with.

For K.P.Rao & Co.

Chartered Accountants

Firm Reg. No. 003135S

Mohan R Lavi

Partner

Membership No. 029340

UDIN:

Place: Bangalore

Date: 5th September 2024

ANNEXURE - A TO THE INDEPENDENT AUDITORS' REPORT

(Referred to in report on other legal and regulatory requirements Section of our report of even date)

- i.
- a.
 - A. The company has maintained showing proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment;
 - B. the company has maintained proper records showing full particulars of intangible assets;
- b. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Property, Plant and Equipment have been physically verified by the management during the year.
- c. Except for the property tabulated below, the title deeds of immovable properties held by the company are in the name of the Company.

Description	Gross Carrying Value (In Lakhs)	Held in name of	Whether promoter/ director or their relative or employee	Period held	Reason for not being in name of company
PPE	1313.21	The Karnataka Industrial Areas Development Board (KIADB)	No	17/05/2018	Lease cum sale basis (99 years lease)
PPE	367.15	The Karnataka Industrial Areas Development Board (KIADB)	No	26/09/2019	Lease cum sale basis (99 years lease)
PPE	4737.69	The Karnataka Industrial Areas Development Board (KIADB)	No	02/02/2021	Lease cum sale basis (99 years lease)

- d. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment or Intangible Assets during the year.
- e. According to the information and explanations given to us, no proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.
- ii.
- a. According to the information and explanations given to us and on the basis of our examination of the records of the Company, physical verification of inventory has been conducted at reasonable intervals by the management, the coverage and procedure of such verification by the management is appropriate; No discrepancies of 10% or more in the aggregate for each class of inventory were noticed.
- b. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks on the basis of security of current assets. In our opinion, the quarterly returns or statements filed by the Company with such banks are generally in agreement with the books of account of the Company. Differences if any, are immaterial.
- iii. According to the information and explanations given to us and on the basis of our examination of the records of the Company, The Company has granted advances to one of its subsidiary during the year & the company has granted loans & stood guarantee for two companies during the year, details of the loan & guarantee is stated in sub-clause(a) below.

- a. A. Based on the audit procedures carried on by us and as per the information and explanations given to us, the Company has granted advances to its wholly-owned subsidiary (Neoanthem Lifesciences Private Limited) during the year ended 31st March 2024.

Particulars	Amount (in lakhs)
Aggregate amount of advances during the year	15141.35
Balance of loan outstanding as at balance sheet date	17460.32

- b. The company also stood guarantee for wholly owned subsidiary Neoanthem Lifesciences Private Limited during the year ended 31st March 2024:

Particulars	Amount (in lakhs)
Aggregate amount of Guarantee for Neoanthem Lifesciences Private Limited during the year	21400.00

- C. Based on the audit procedures carried on by us and as per the information and explanations given to us, the Company has stood guarantee for a company other than its subsidiary during the year ended 31st March 2024:

Particulars	Amount (in lakhs)
Aggregate amount of Guarantee stood for Anthem Biopharma Private Limited during the year	750.00

- c. to the information and explanations given to us and based on the audit procedures conducted by us, we are of the opinion that the terms and conditions of the loans given are prima facie, not prejudicial to the interest of the Company.
- d. According to the information and explanations given to us and on the basis of our examination of the records of the Company, in the case of loans given, the repayment of principal and payment of interest has been stipulated and the repayments or receipts have been regular.
- e. According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no overdue amount for more than ninety days in respect of loans given.
- f. According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan given falling due during the year, which has been renewed or extended or fresh loans given to settle the over dues of existing loans given to the same party.
- g. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not given any loans either repayable on demand or without specifying any terms or period of repayment.
- iv. According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, or provided any guarantee or security as specified under Section 185 of the Companies Act, 2013 and the Company has not provided any guarantee or security as specified under Section 186 of the Companies Act, 2013. Further, the Company has complied with the provisions of Section 186 of the Companies Act, 2013 in relation to loans given and investments made.
- v. The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable
- vi. According to the information and explanations given to us and on the basis of our examination of the records, the Company is not required to maintain cost records under sub-section (1) of section 148 of the Companies Act, 2013. Accordingly, clause 3(vi) of the Order is not applicable.
- vii.
- a. The company has been regular in depositing undisputed statutory dues including Income Tax, Cess and other statutory dues with the appropriate authorities during the year.
- b. According to the information and explanations given to us, there are no dues of GST, Provident fund, Employees' State Insurance, Income-tax, Sales tax, Service tax, Duty of Customs, Value added tax, Cess or other statutory dues which have not been deposited by the Company on account of disputes, except for the following:

Nature of the statute	Nature of the Dues	Amount (In Lakhs)	Period	Forum where dispute is pending
Income Tax Act, 1961	Income Tax	92.91	AY 2017-18	CIT (A)- Bangalore
Income Tax Act, 1961	Income Tax	50.88	AY 2020-21	CIT (A)-Bangalore
Income Tax Act, 1961	Income Tax	19.76	AY 2016-17	ACIT-Bangalore
Income Tax Act, 1961	Income Tax	381.48	AY 2018-19	ACIT-Bangalore
Goods and Service Tax	GST	45.46	FY 2017-18	JCCT-Appeals-4-Bangalore
The Finance Act, 1994	Service Tax	12.25	FY 2012 to FY 2015	CESTAT- Bangalore

viii. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year.

ix.

- a. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not defaulted in repayment of dues to banks, financial institutions.
- b. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the company has not been declared wilful defaulter by any bank or financial institution or other lender.
- c. According to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained
- d. According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the financial statements of the company, we report that no funds raised on short-term basis have been used for long-term purposes by the company.
- e. According to the information and explanations given to us and procedures performed by us, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.
- f. According to the information and explanations given to us and procedures performed by us, the company has not raised any loans during the year on the pledge of securities held in its subsidiary.

x.

- a. The Company has not raised any money by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3 (x)(a) of the Order is not applicable.
- b. Based on examination of the books and records of the Company and according to the information and explanations given to us, the company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year.

xi.

- a. Based on examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.
- b. According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- c. As represented to us by the Management, constituting whistle-blower policy is not required by the company. Accordingly, clause 3(xi)(c) of the Order is not applicable

xii. According to the information and explanations given to us, the company is not a Nidhi Company and therefore the provisions of Para 3(xii) of the Companies (Auditors Report), 2020 are not applicable.

xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc., as required by the applicable accounting standards.

xiv.

- a. The company has an internal audit system commensurate with the size and nature of its business.
- b. We have considered the internal audit reports of the company issued till date, for the period under audit.

xv. In our opinion and according to the information and explanation given to us, the Company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, clause 3(xv) of the Order is not applicable.

xvi.

- a. The company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, paragraph 3(xvi)(a) of the Order is not applicable.
- b. The Company is not a Non-Banking Financial or Housing Finance activities as defined in regulations made by the Reserve Bank of India. Accordingly, paragraph 3(xvi)(b) of the Order is not applicable.
- c. The company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly the provisions of Para 3(xvi)(c) is not applicable.
- d. As per the information and explanations given to us, there are no Core Investment Companies as part of the Group. Accordingly the provisions of Para 3(xvi)(d) is not applicable.

xvii. The company has not incurred cash losses in the current and in the immediately preceding financial year.

xviii. There has been no resignation of the statutory auditors during the year and accordingly this clause is not applicable.

xix. According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

xx. In our opinion and according to the information and explanations given to us, the Company has transferred the amount to be spent on CSR to a specific bank account.

For K.P.Rao & Co.

Chartered Accountants

Firm Reg. No. 003135S

Mohan R Lavi

Partner

Membership No. 029340

UDIN:

Place: Bangalore

Date: 5th September 2024

ANNEXURE B TO INDEPENDENT AUDITORS' REPORT ON THE STANDALONE FINANCIAL STATEMENTS

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013

Opinion

We have audited the internal financial controls with reference to standalone financial statements of the Company as of 31 March 2024 in conjunction with our audit of the standalone financial statements of the Company as at and for the year ended on that date.

In our opinion, the Company has maintained, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2024, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. However, the existing policies, systems, procedures and internal controls followed by the Company have to be completely and appropriately documented.

Board of Directors' Responsibility for Internal Financial Controls

The Board of Directors are responsible for establishing and maintaining internal financial controls based on the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ('the Guidance Note') issued by the Institute of Chartered Accountants of India ('the ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required the Companies Act, 2013 ('the Act').

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing ('the Standards'), issued by the ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. This includes those policies and procedures that:

- i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
- ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the company; and
- iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2024, based on the Internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the "Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India".

For K.P.Rao & Co.

Chartered Accountants

Firm Reg. No. 003135S

Mohan R Lavi

Partner

Membership No. 029340

UDIN:

Place: Bangalore

Date: 5th September 2024

Standalone Financial Statements

Balance Sheet as at March 2024		(₹.in Lakhs)		
	PARTICULARS	Note	As at 31.03.2024	As a 31.03.2023
I	ASSETS			
1)	Non-current assets			
a)	Property, plant and equipment	3	46,541.68	43,846.54
b)	Capital work-in-progress	3.3	15,591.35	14,340.76
c)	Right of use assets	3.1	628.72	133.76
d)	Intangible assets	3.2	600.17	908.94
e)	Financial Assets			
i)	Investment	4.2	1,270.31	631.03
ii)	Trade receivables	5	310.78	310.78
iii)	Loans & Advances	6	17,873.41	2,797.57
iv)	Other Financial Asset	7	499.22	460.79
f)	Deferred tax assets (net)	8	4,141.02	2,490.80
g)	Non-Current tax assets (net)	9	140.14	137.49
h)	Other non-current assets	10	277.10	1,280.93
	Total Non-Current assets		87,873.91	67,339.39
2)	Current assets			
a)	Inventories	11	21,130.92	12,941.63
b)	Financial assets			
i)	Investment	4.1	45,907.03	49,287.05
ii)	Trade receivables	5	48,983.38	27,406.78
iii)	Cash and cash equivalents	12	18,334.86	34,218.21
iv)	Bank balances, other than (iii) above	13	49.87	61.13
v)	Other Financial Asset	7	41.72	22.63
c)	Other current assets	14	10,100.92	8,025.05
	Total Current assets		1,44,548.69	1,31,962.49
	TOTAL ASSETS		2,32,422.60	1,99,301.88
II	EQUITY AND LIABILITIES			
	Equity			
a)	Share capital	15	11,181.54	11,409.74
b)	Other equity	16	1,82,125.94	1,62,752.09
	Total Equity		1,93,307.48	1,74,161.83
	Liabilities			
1)	Non-current liabilities			
a)	Financial liabilities			
i)	Lease liabilities	19	430.59	76.44
ii)	Borrowings	17	6,571.95	8,505.57
iii)	Other financial liabilities	19	1,116.84	616.02
b)	Provisions	20	653.04	538.83
c)	Other non-current liabilities	21	116.93	141.76
	Total non-current liabilities		8,889.35	9,878.61
2)	Current liabilities			
a)	Financial liabilities			
i)	Lease liabilities	19	168.49	32.22
i)	Borrowings	17	10,086.73	2,887.61
ii)	Trade Payables	18		
	(a) Dues of Micro enterprises & small enterprises		-	-
	(b) Dues to other than Micro enterprises & small enterprises		10,043.53	7,192.07
iii)	Other financial liabilities	19	592.23	449.79
b)	Other current liabilities	21	8,358.64	3,755.95
c)	Provisions	20	335.08	355.45
d)	Current Tax Liabilities (net)	22	641.08	588.35
	Total current liabilities		30,225.77	15,261.44
	TOTAL EQUITY AND LIABILITIES		2,32,422.60	1,99,301.88
Corporate information and Significant accounting policies.		1&2		

As per our report of even date attached

For and on behalf of the Board**For K.P. Rao & Co.,**

Chartered Accountants

Firm Registration No. 003135S

Mohan Lavi

Partner

Membership No.029340

Place : Bangalore

Date : September 05, 2024

Gawir Baig
CFO**For and on behalf of the Board****Ajay Bhardwaj**

Managing Director

DIN:00333704

Ravindra K C

Director

DIN:01580534

Ramakrishnan K

Company Secretary

FCS: 11748

Statement of Profit and Loss for the period ending on March 31, 2024				(₹.in Lakhs)
	PARTICULARS	Note	Year Ended 31.03.2024	Year Ended 31.03.2023
I	Revenue from Operations	23	1,41,753.90	1,05,692.43
II	Other Income	24	7051.98	7737.17
III	Total Revenue (I + II)		1,48,805.88	1,13,429.60
IV	Expenses			
	Cost of materials consumed	25	64,076.68	34,828.89
	Change in Work in Progress	25.1	(4,123.47)	(901.20)
	Employee benefits expense	26	18,265.38	15,323.70
	Finance costs	27	914.30	675.33
	Depreciation and amortization expense	3	8,149.02	6,369.60
	Other expenses	28	13,046.71	13,553.24
	Total expenses (IV)		1,00,328.61	69,831.57
V	Profit/(Loss) before exceptional items and tax (III-IV)		48,477.27	43,598.03
VI	Exceptional & Extra Ordinary items	33a	-	6,180.24
VII	Profit/(Loss) before tax (V+VI)		48,477.27	49,778.27
VIII	Tax expense	30		
	1) Current tax		12,641.08	12,004.84
	2) Deferred tax		(1,641.88)	(793.68)
			10,999.20	11,211.16
IX	Profit/(Loss) for the year(VII-VIII)		37,478.07	38,567.11
X	Other comprehensive income/(loss)			
	a) Items that will not be reclassified to profit or loss	31		
	Remeasurements of the defined benefit plans		(33.13)	(27.92)
	Deferred Tax on above items		8.34	103.48
	b) Items that will be reclassified to profit or loss		-	-
XI	Total Comprehensive Income for the period (IX+X) (Comprising Profit(Loss) and Other Comprehensive Income for the period)		37,453.28	38,642.67
XII	Earnings per equity share: (In Rs.)			
	2) Basic PES		6.61	6.77
	3) Diluted EPS		6.61	6.77
	Corporate information and Significant accounting policies	1&2		

As per our report of even date attached

For and on behalf of the Board**For K.P. Rao & Co.,**

Chartered Accountants

Firm Registration No. 0031355

Mohan Lavi

Partner

Membership No.029340

Place : Bangalore

Date : September 05, 2024

For and on behalf of the Board**Ajay Bhardwaj**

Managing Director

DIN:00333704

Ravindra K C

Director

DIN:01580534

Ramakrishnan K

Company Secretary

FCS: 11748

Gawir Baig

CFO

Standalone Cash flow statement for the period ending March 31, 2024		(₹.in Lakhs)	
Description	As on 31.03.2024	As a 31.03.2023	
A) Cash Flow from operating activities:			
Net Profit before taxation	48,477.27	49,778.27	
Adjustment:(+/-)			
Depreciation/ Amortisation	8,149.02	6,377.41	
Provision for gratuity and leave encashment	93.84	88.50	
Interest and Finance charges	914.30	667.52	
Interest from deposits & advances	(4,779.57)	(2,949.56)	
Dividend/Capital Gain from Mutual Funds	(703.43)	(1,487.33)	
(Profit)/Loss on sale of asset	42.93	(5.33)	
Operating Profit before Working Capital Changes	52,194.34	52,469.48	
Adjustment for changes in working capital:			
Other financial Assets	(57.52)	(22.36)	
Other Current Assets	(2,075.86)	1,027.02	
Other non-current Assets	1,001.18	(338.04)	
Current Financial Liabilities	142.43	213.56	
Trade and other receivables	(21,576.59)	5,213.06	
Inventories	(8,189.29)	(7,118.63)	
Trade payables and other liabilities	2,851.46	720.32	
Other Current Liabilities	4,150.61	(8,765.97)	
Provisions	-	(0.12)	
Cash used in operations	28,440.76	43,398.33	
Income taxes paid	(12,000.00)	(11,500.00)	
Net cash generated in Operating Activities	16,440.76	31,898.33	
B) Cash Flow from Investing Activities:			
Purchase of fixed assets and other capital expenditure	(10,454.21)	(17,867.98)	
Right to use assets-IND AS	(628.93)	70.18	
Sale of Fixed Assets	69.10	7.00	
(Increase)/Decrease in CWIP	(1,250.59)	926.86	
Purchase of Intangible Assets	(59.23)	(561.71)	
Interest from deposits & advances	4,779.57	2,949.56	
Dividend/capital gain from Mutual Funds	703.43	1,487.33	
Investments in Mutual Fund and Equities	2,740.74	(22,620.15)	
Receipt/(payment) of loans and advances to related party	(15,075.84)	(2,181.71)	
Net cash used in Investing activities	(19,175.96)	(37,790.62)	
C) Cash flow from Financing activities:			
Proceeds from issue of equity shares	(1,933.62)	7,915.73	
Repayment of Borrowings	830.15	(1,836.47)	
Other Non-Current liabilities	(28.53)	(54.99)	
IND AS fair value adjustment	(14,895.36)	-	
Repayment of short term borrowings	(3,416.86)	-	
Interest and Finance charges	7,199.12	(71.65)	
Preference dividend (inclusive of tax)	(914.30)	(667.52)	
Net cash (Used)/ Generated in Financing Activities	(13,159.40)	5,285.10	
Net change in Cash and Cash Equivalents (A+B+C)	(15,894.61)	(607.18)	
Cash and Cash Equivalents (beginning of the year)	34,279.34	34,886.52	
Cash and Cash Equivalents (ending period)	18,384.73	34,279.34	

As per our report of even date attached

For and on behalf of the Board**For K.P. Rao & Co.,**

Chartered Accountants

Firm Registration No. 003135S

Mohan Lavi

Partner

Membership No.029340

Place : Bangalore

Date : September 05, 2024

For and on behalf of the Board**Ajay Bhardwaj**

Managing Director

DIN:00333704

Ravindra K C

Director

DIN:01580534

Ramakrishnan K

Company Secretary

FCS: 11748

Gawir Baig

CFO

Standalone Statement of Changes In Equity for the period ending March 31, 2024

STATEMENT OF CHANGES IN EQUITY

A - Equity Share Capital

Particulars

(₹.in Lakhs)

Particulars	
Balance as at April 01, 2023	11,410
Changes in equity share capital during the year*consideration	(228.19)
Balance as at March 31, 2024	11,182

* Buy back of equity shares

B - Other Equity

For the year ended March 31, 2024

(₹.in Lakhs)

Particulars	Reserves and Surplus				Items of other comprehensive income/(loss)	Equity Component of Compound Financial Instruments	Total
	Capital Redemption Reserve	General Reserves	Securities Premium	Retained Earnings	Other items of Other Comprehensive Income		
Balance as at April 01, 2023	-	13,699.97	27,185.64	1,22,097.04	(230.55)	0.00	1,62,752.09
Adjustment during the year	-	-	-	4.60	-	-	4.60
Profit for the year	-	-	-	37,478.07	-	-	37,478.07
Other Comprehensive income/(loss) for the year	-	-	-	-	(24.79)	-	(24.79)
Buy-back of equity shares (Refer note 15.4)	228.19	(228.19)	(14,667.17)	-	-	-	(14,667.17)
Tax on buy-back of equity shares (refer note)	-	-	-	(3,416.86)	-	-	(3,416.86)
Additions during the year	-	3,747.81	-	(3,747.81)	-	-	-
Balance as at March 31, 2024	228.19	17,219.58	12,518.47	1,52,415.04	(255.35)	0.00	1,82,125.94

For the year ended March 31, 2023

(₹.in Lakhs)

Particulars	Reserves and Surplus				Items of other comprehensive income/(loss)	Equity Component of Compound Financial Instruments	Total
	Capital Redemption Reserve	General Reserves	Securities Premium	Retained Earnings	Other items of Other Comprehensive Income		
Balance as at April 01, 2023	500.00	9,843.25	27,001.83	97,465.38	(306.11)	164.24	1,34,668.60
Adjustment during the year	(500.00)	-	-	(10,078.75)	-	-	(10,578.75)
Profit for the year	-	-	-	38,567.11	-	-	38,567.11
Other Comprehensive income/(loss) for the year	-	-	-	-	75.56	-	75.56
Dividends & Dividend tax paid	-	-	-	-	-	(164.24)	(164.24)
Additions during the year	-	3,856.71	183.81	(3,856.71)	-	-	183.81
Balance as at March 31, 2023	-	13,699.97	27,185.64	1,22,097.04	(230.55)	0.00	1,62,752.09

As per our report of even date attached

For K.P. Rao & Co.,

Chartered Accountants

Firm Registration No. 003135S

Mohan Lavi

Partner

Membership No.029340

Place : Bangalore

Date : September 05, 2024

For and on behalf of the Board

Ajay Bhardwaj

Managing Director

DIN:00333704

Ravindra K C

Director

DIN:01580534

Ramakrishnan K

Company Secretary

FCS: 11748

Gawir Baig

CFO

Anthem Biosciences Private Limited**Notes forming part of the Standalone financial statements****15) Equity Share Capital**

Particulars	As at 31.03.2024		As at 31.03.2023	
	No. of Shares	(₹.in Lakhs)	No. of Shares	(₹.in Lakhs)
Authorised Share capital				
Equity Shares of Rs. 2/- each	60,00,00,000	12,000	60,00,00,000	12,000
Preference shares of Rs 10/- each	50,00,000	500	50,00,000	500
	60,50,00,000	12,500	60,50,00,000	12,500
Issued, subscribed & fully paid share capital				
Equity Shares of Rs. 2/- each	55,90,77,100	11,182	57,04,86,800	11,410
Total	55,90,77,100	11,182	57,04,86,800	11,410

15.1 The Company has only equity shares having a face value of Rs.2/- each.

15.2 Terms/ Rights attached to equity shares

Each holder of the equity share, as reflected in the records of the Company as of the date of the shareholders meeting, is entitled to one vote in respect of each share held for all matters submitted to vote in the shareholders meeting. In the event of liquidation of the company, the holders of equity shares will be entitled to receive any of the remaining assets of the company after distribution of amounts payable to preference shareholders & any statutory liabilities. The distribution will be in proportion to the number of equity shares held by the shareholders.

15.3 Aggregate number of bonus shares issued during the period of five years immediately preceding the reporting date

Particulars	For the Year ended 31st March				
	2024	2023	2022	2021	2020
Equity shares of Rs. 2/- each	-	52,66,03,200	-	-	-

The Company had allotted 52,66,03,200 equity shares of Rs. 2/- each fully paid up as bonus shares on November 28, 2022 in the ratio of 12:1 (Twelve equity shares of Rs. 2/-each for every one equity share of Rs. 2/- each held in the Company as on the record date i.e. 31st October 2022) by capitalisation of Capital redemption reserve and general reserves of the company.

15.4 Aggregate number of shares bought back during the period of five years immediately preceding the reporting date

Particulars	For the Year ended 31st March				
	2024	2023	2022	2021	2020
Equity shares of Rs. 2/- each	1,14,09,700.00	-	-	-	-

The Board of Directors at its meeting held on December 11, 2023 had approved the buy-back of 1,14,09,700 fully paid up equity shares of face value of Rs.2/- each from the equity shareholders of the Company, at a price of Rs. 130.55/- per equity share (Maximum Buy-Back price) and such aggregate amount not exceeding Rs.148,95,36,335/- (Maximum Buy-back Size, excluding transaction costs and taxes thereon). Buy Back is undertaken through the offer letter on such terms and conditions as the board may deems fit.

15.5 The details of shareholder holding more than 5% shares as at March 31, 2024 and March 31, 2023 set out below:

Sl. No	Name of the shareholder	As at 31.03.2024		As at 31.03.2023	
		No. of Shares held	% holding	No. of Shares held	% holding
1	Mr. Ajay Bhardwaj	29,47,47,175	52.72%	30,13,20,825	52.82%
2	Mr. Ravindra K C	6,60,24,898	11.81%	6,74,97,430	11.83%
3	Mr. Ganesh S	6,80,48,076	12.17%	6,95,65,730	12.19%
4	Viridity Tone LLP	4,74,92,640	8.49%	4,74,92,640	8.32%

15.5 Shareholding of Promoters*

Sl. No	Name of the shareholder	No. of Shares**	% of total shares**	% Change During the year
1	Mr. Ajay Bhardwaj	29,47,47,175	52.72%	(0.00)
2	Mr. Ravindra K C	6,60,24,898	11.81%	(0.00)
3	Mr. Ganesh S	6,80,48,076	12.17%	(0.00)
	Total	42,88,20,149		

16) Other Equity

		(₹.in Lakhs)	
Particulars		31.03.2024	31.03.2023
a) Capital Redemption Reserve		228.19	-
b) General Reserve		17,219.58	13,699.97
c) Share Premium		12,518.47	27,185.64
d) Retained Earnings		1,52,415.04	1,22,097.04
e) Components of Other Comprehensive Income		(255.35)	(230.55)
Balance at the end of the period (a+b+c+d+e)		1,82,125.94	1,62,752.09

Anthem Biosciences Private Limited										
Notes forming part of the standalone financial statements										
3 Property, Plant and Equipment										
Particulars	Tangible Assets								(₹.in Lakhs)	
	Land - Free Hold *	Road	Buildings	Plant and Equipment	Furniture and Fixtures	Vehicles	Office equipment	Laboratory Equipment	Computers & Accessories	Total
Cost or Deemed cost										
As at April 01,2023	8,361.28	315.04	15,786.63	42,208.81	1,850.47	744.84	564.35	12,898.55	3,102.49	85,832.46
Additions during the year	-	-	4,332.83	4,772.87	110.37	113.78	27.19	1,006.03	91.15	10,454.21
Disposals/adjustments	-	-	-	242.87	-	28.85	46.38	54.79	0.85	373.74
As at March 31,2024	8,361.28	315.04	20,119.45	46,738.81	1,960.84	829.77	545.15	13,849.79	3,192.79	95,912.93
Depreciation										
As at April 01,2023	-	299.39	6,923.20	21,223.16	1,422.06	581.80	415.94	9,014.37	2,106.01	41,985.92
Charge for the period	-	5.59	1,174.42	4,400.16	120.37	66.97	67.61	1,177.96	633.96	7,647.04
Disposals/adjustments	-	-	-	139.04	-	26.40	44.71	50.71	0.85	261.71
As at March 31,2024	-	304.99	8,097.62	25,484.27	1,542.43	622.37	438.84	10,141.62	2,739.11	49,371.25
Net block										
As at March 31,2024	8,361.28	10.05	12,021.83	21,254.53	418.42	207.40	106.32	3,708.17	453.68	46,541.68
As at March 31,2023	8,361.28	15.64	8,863.43	20,985.65	428.41	163.04	148.41	3,884.18	996.49	43,846.54

*All title deeds of Immovable Properties are held in name of the Company except the below mentioned properties.

'Below title deeds of immovable property not held in name of the company

Relevant line item in the Balance sheet	Description of item of property	Gross carrying value	Title deeds held in the name of	Whether title deed holder is a promoter, director or relative# of promoter*/director or employee of promoter/director	Property held since which date	Reason for not being held in the name of the company
Land	8acre land Plot No. 313-P, 314-P & 318-P, Harohalli Industrial Area, 2nd Phase.	1313.21447	The Karnataka Industrial Areas Development Board (KIADB)	NA	17/05/2018	Lease cum sale basis (99 years lease)
	2acre land Plot Nos. 276-P, 280-P & 281-A Harohalli Industrial Area, 2nd Phase.	367.15414			26/09/2019	
	30acre land Plot no. 527 to 540 & 557 to 570 in Harohalli 3rd Phase Industrial Area.	4737.6864			02/02/2021	

3.1 Capital work-in-progress

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Capital work-in-progress	15,591.35	14,340.76
	15,591.35	14,340.76

Capital work-in-progress ageing schedule**As at 31 March 2024**

CWIP	Amount in capital work in progress for a period of				Total(₹.in Lakhs)
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Project work in progress	8,765.49	5,196.85	1,603.21	25.80	15,591.35
Projects temporarily suspended	-	-	-	-	-

As at 31 March 2023

CWIP	Amount in capital work in progress for a period of				Total(₹.in Lakhs)
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Project work in progress	9,864.78	4,417.59	41.40	16.99	14,340.76
Projects temporarily suspended	-	-	-	-	-

As at 31 March 2024

CWIP	Amount in capital work in progress for a period of				Total(₹.in Lakhs)
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Biological - Expansion Harohalli	3535.85	-	-	-	3,535.85
CP 6 Plant Harohalli	-	1,145.08	-	-	1,145.08
NeoAnthem Building	-	9,240.03	-	-	9,240.03
Greenfield projects	-	-	16.15	-	16.15
Others	1,654.24	-	-	-	1,654.24
Total	5190.09	10,385.11	16.15	-	15,591.35

As at 31 March 2023

CWIP	Amount in capital work in progress for a period of				Total(₹.in Lakhs)
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
ETP-Expansion Harohalli	3,642.62	-	-	-	3,642.62
Biological - Expansion Harohalli	-	647.36	-	-	647.36
CP 6 Plant Harohalli	-	-	31.99	-	31.99
NeoAnthem Building	-	-	5,761.48	-	5,761.48
Greenfield projects	481.70	-	-	-	481.70
Others	2,321.31	1,454.31	-	-	3,775.62
Total	6,445.63	2,101.66	5,793.47	-	14,340.76

3.2 Other Intangible assets

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Other Intangible Assets	600.17	908.94
Total	600.17	908.94

Particulars	(₹.in Lakhs)
Cost or Deemed cost	
As at April 01, 2023	2,380.29
Additions during the year	59.23
Disposals	-
As at March 31, 2024	2,439.53
Amortisation	
As at April 01, 2023	1,471.35
Charge for the period	368.00
Disposals	-
As at March 31, 2024	1,839.36
Net block	
As at March 31, 2024	600.17
As at March 31, 2023	908.94

3.3 Right to use assets

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Opening Balance	133.76	248.60
Adjustment during the year	-	-
Additions during the year	628.93	11.44
Deletions during the year	-	(81.62)
Depreciation during the year	(133.97)	(44.66)
Closing Balance	628.72	133.76

Anthem Biosciences Private Limited									
Notes forming part of the standalone financial statements									
4) 'Investments'									
Sl.No.	Particulars	As at 31.03.2024			As at 31.03.2023			At Fair Value(₹ in Lakhs)	
		Amortised Cost	Amortised Cost		Total	Amortised Cost	Through Other Comprehensive Income	Through profit or loss	Total
			Through Other Comprehensive Income	Through profit or loss					
	Mutual Funds (as per 4.1)	-	-	45,907.03	45,907.03	-	-	49,287.05	49,287.05
	Other investments (as per 4.2)	1,270.31	-	-	1,270.31	631.03	-	-	631.03
(A)	Total	1,270.31	-	45,907.03	47,177.34	631.03	-	49,287.05	49,918.08
(i)	Investments outside India								
(ii)	Investments in India	1,270.31	-	45,907.03	47,177.34	631.03	-	49,287.05	49,918.08
(B)	Total	1,270.31	-	45,907.03	47,177.34	631.03	-	49,287.05	49,918.08
	(A) - (B)	-	-	-	-	-	-	-	-
	Less: Impairment Loss Allowance	-	-	-	-	-	-	-	-
	Total	1,270.31	-	45,907.03	47,177.34	631.03	-	49,287.05	49,918.08

		(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023
4.1 Trade - Quoted - at fair value		
a) Investments in Mutual Funds; Corporate Bonds & MLDs		
Investment in market linked debentures and corporate bonds	41,842.90	40,990.70
Investment in mutual funds	4,064.13	8,296.36
Total investments at Fair Value	45,907.03	49,287.05

		(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023
4.1 Other Investments		
a) Investments in wholly owned subsidiary		
Neo Anthem Life Sciences Private Limited	15.00	15.00
b) Other Equity Investments		
Investment in Four EF Renewables Private Limited	184.80	205.34
Investment in Ampyr Renewable Energy Resources Eleven Pvt Ltd	166.97	0.02
Investment in Isharays Energy One Pvt Ltd	200.00	-
c) Other Preference Investments		
Investment in Four EF Renewables Private Limited	369.61	410.68
Investment in Ampyr Renewable Energy Resources Eleven Pvt Ltd	333.93	-
Total investments at Fair Value	1,270.31	631.03

Investment in Equity Instrument- wholly owned Subsidiary company

1. Investment in Neoanthem Life Sciences Private Limited, 1,50,000 equity shares of Rs. 10 each (FY2023: 150,000 equity shares of Rs. 10/- each), constitutes 100% of the capital of that company

Investment in Equity Instrument - Others

- Investment in Four EF Renewables Private Limited, 184804 equity shares of Rs. 100/- each (FY2023: 205338 equity shares of Rs. 100/-each)
- Investment in Ampyr Renewable Energy Resources Eleven Pvt Ltd, 1669668 equity shares of Rs. 10/- each (FY2023: 150 equity shares of Rs.10/-each)
- Investment in Isharays Energy One Pvt Ltd, 2000000 equity shares of Rs. 10/- each

Investment in Preference Shares - Others

- Investment in Four EF Renewables Private Limited, 369609 Preference shares of Rs. 100 each (FY2023: 410667 preference shares of Rs.100/-each)
- Investment in Ampyr Renewable Energy Resources Eleven Pvt Ltd, 3339337 Preference shares of Rs. 10 each

5 Trade Receivables

a) Non-current

		(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023
Unsecured, considered good		
Trade Receivables from Related parties	310.78	310.78
Total	310.78	310.78

Trade Receivables Ageing (For Current Reporting period)

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total (₹.in Lakhs)
(i) Undisputed Trade receivables – considered good		-			310.78	310.78
(ii) Undisputed Trade receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade receivables– considered good	-	-	-	-	-	-
"(v) Disputed Trade receivables – which have significant increase in credit risk"	-	-	-	-	-	-
(vi) Disputed Trade receivables – credit impaired	-	-	-	-	-	-
Total	-	-	-	-	310.78	310.78

Trade Receivables Ageing
(For Previous Reporting period)

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total (₹.in Lakhs)
(i) Undisputed Trade receivables – considered good		-			310.78	310.78
(ii) Undisputed Trade receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade receivables– considered good	-	-	-	-	-	-
"(v) Disputed Trade receivables – which have significant increase in credit risk"	-	-	-	-	-	-
(vi) Disputed Trade receivables – credit impaired	-	-	-	-	-	-
Total	-	-	-	-	310.78	310.78

b) Current

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Unsecured, considered good		
(i) Trade Receivables	48,983.38	27,406.78
Unsecured, considered doubtful		
(i) Less: Provision for doubtful trade receivables	-	-
Total	48,983.38	27,406.78

Trade Receivables Ageing
(For Current Reporting period)

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total (₹.in Lakhs)
(i) Undisputed Trade receivables – considered good	48,785.84	59.50	116.44	18.16	3.44	48,983.38
(ii) Undisputed Trade receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade receivables– considered good	-	-	-	-	-	-
"(v) Disputed Trade receivables – which have significant increase in credit risk"	-	-	-	-	-	-
(vi) Disputed Trade receivables – credit impaired	-	-	-	-	-	-
Total	48,785.84	59.50	116.44	18.16	3.44	48,983.38

Trade Receivables Ageing
(For Previous Reporting period)

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total (₹.in Lakhs)
(i) Undisputed Trade receivables – considered good	27,387.08	-	-	17.00	2.71	27,406.78
(ii) Undisputed Trade receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade receivables – credit impaired	-	-	-	-	-	-
(iv) Disputed Trade receivables– considered good	-	-	-	-	-	-
"(v) Disputed Trade receivables – which have significant increase in credit risk"	-	-	-	-	-	-
(vi) Disputed Trade receivables – credit impaired	-	-	-	-	-	-
Total	27,387.08	-	-	17.00	2.71	27,406.78

ECL Model

Ind AS 109 requires an impairment assessment to be made for Trade Receivables on an Expected Credit Loss Model. For Trade Receivables, Ind AS 109 permits a simplified approach of calculating only life time credit losses.

Considering the industry in which the company is operating and the gestation period of its projects, impairment assessment is made annually for the entire block of Trade Receivables and impairment losses are recognised for trade receivables on a case to case basis.

6) Loans & Advances									
Sl.No.	Particulars	As at 31.03.2024				As at 31.03.2023			
		Amortised Cost	Amortised Cost		Total	Amortised Cost	At Fair Value(₹.in Lakhs)		Total
			Through Other Comprehensive Income	Through profit or loss			Through Other Comprehensive Income	Through profit or loss	
	Loans & advances to related party	17,873.41	-	-	17,873.41	478.60	-	-	478.60
	Advances to related party	-	-	-	-	2,318.97	-	-	2,318.97
(A)	Total	17,873.41	-	-	17,873.41	2,797.57	-	-	2,797.57
(i)	Investments outside India	-	-	-	-	-	-	-	-
(ii)	Investments in India	17,873.41	-	-	17,873.41	2,797.57	-	-	2,797.57
(B)	Total	17,873.41	-	-	17,873.41	2,797.57	-	-	2,797.57
	(A) - (B)	-	-	-	-	-	-	-	-
	Less: Impairment Loss Allowance	-	-	-	-	-	-	-	-
	Total	17,873.41	-	-	17,873.41	2,797.57	-	-	2,797.57

7 Other Financial Asset

a) Non- Current

		(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023
Unsecured, considered good		
Staff advances	29.88	23.02
Security Deposits	469.34	437.77
Total	499.22	460.79

b) Current

		(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023
Unsecured, considered good		
Accrued interest	17.77	13.67
Staff advances-Current	23.95	8.95
Total	41.72	22.63

c) Fair Value Hierarchy

(₹.in Lakhs)				
Particulars	Carrying value		Fair value	
	31.03.2024	31.03.2023	31.03.2024	31.03.2023
Amortised cost				
(i) Loans	17,873.41	2,797.57	17,873.41	2,797.57
(ii) Other Investments	1,270.31	631.03	1,270.31	631.03
(iii) Trade Receivables	49,294.16	27,717.57	49,294.16	27,717.57
(iv) Other Financial Assets	540.94	483.42	540.94	483.42
(v) Cash and Cash Equivalents	18,384.73	34,279.34	18,384.73	34,279.34
Fair Value through Profit and Loss				
(i) Investments	45,907.03	49,287.05	45,907.03	49,287.05
Total Financial Assets	1,33,270.58	1,15,195.97	1,33,270.58	1,15,195.97

d) Fair Value Hierarchy

				(₹.in Lakhs)
	Level 1	Level 2	Level 3	Total
Financial Assets				
Mutual Fund Units	45,907.03	0.00	0.00	45,907.03
Investment in Wholly Owned Subsidiary	15.00	0.00	0.00	15.00
Other Investments	1,255.31	0.00	0.00	1,255.31
Total	47,177.34	0.00	0.00	47,177.34

8 Deferred Tax Assets (Net)

			(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023	
Deferred tax assets			
Deferred tax assets	2,490.80	1,593.65	
Add: Adjustments during the year	1,650.22	897.16	
Total	4,141.02	2,490.80	

8.1 Components of deferred income tax assets and liabilities arising on account of temporary differences are:

			(₹.in Lakhs)
Deferred tax asset	31.03.2024	31.03.2023	
Expenditure disallowed under Income Tax Act, 1961	-	7,253.03	
Prepaid rent written off	-	1.64	
Property, plant and equipment	1,499.15	5,130.62	
On OCI (Gratuity)	123.13	411.12	
Significant financing component	-	188.46	
Deferred Loan finance cost	1.97	7.81	
Employee benefit expenses on staff loans	0.82	6.62	
Interest on BIRAC Loan	-	44.78	
Lease	46.03	55.03	
Security Deposit	0.34	-	
	1,671.45	13,099.11	
Deferred tax liability			
Interest income due to fair valuation of security deposits	0.25	1.69	
Interest income recognised on Staff loan	1.03	6.64	
Notional interest income on loan to Associate company	1.62	6.32	
Actuarial gain/loss (OCI)	3.66	-	
Compound financial instruments	-	2.99	
BIRAC Loan grant recognised	14.67	23.64	
Lease	-	53.02	
	21.23	94.31	
Total	1,650.22	13,004.81	

9 Tax Assets (Net)

			(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023	
Income Tax Refundable	140.14	137.49	
Total	140.14	137.49	

10 Other Non-current Assets

			(₹.in Lakhs)
Particulars	31.03.2024	31.03.2023	
Un-secured Considered good			
(i) Capital advances	1.90	988.10	
(ii) Prepaid Rent	1.77	(1.21)	
(iii) Deferred Employees Benefit	10.87	2.50	
(iv) Deferred Loan - Anthem Biopharma Private Limited	226.57	234.39	
(v) Prepaid Expenses-long term	35.98	57.16	
Total	277.10	1,280.93	

11 Inventories

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
(i) Raw materials	14,430.76	10,283.61
(ii) Work in Progress	4,784.81	2,025.16
(iii) Finished goods	1,871.32	507.50
(iv) Goods in transit	44.03	125.36
Total	21,130.92	12,941.63

12 Cash and Cash Equivalents

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Balances with banks:		
(i) in current accounts	2,163.13	803.00
(ii) in deposit accounts	16,171.72	33,415.21
Cash in Hand:		
(i) Cash on hand	0.01	-
Total	18,334.86	34,218.21

13 Other Bank Balances

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Earmarked balances with Banks		
(i) Margin Money & Other Deposits	49.87	61.13
Total	49.87	61.13

14 Other Current Assets

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Un-secured Considered good		
(i) Balances with other statutory authorities	8,522.31	7,411.54
(ii) Prepaid Expenses	307.73	194.22
(iii) Advances to Suppliers	1,269.27	311.35
(iv) Export Incentives Receivable	1.60	107.95
Total	10,100.92	8,025.05

17 Borrowings
a) Non-current

Sl.No.	Particulars	As at 31.03.2024			As at 31.03.2023		
		Amortised Cost	At Fair Value (₹.in Lakhs)		Amortised Cost	At Fair Value(₹.in Lakhs)	
			Through Other Comprehensive Income	Through profit or loss		Through Other Comprehensive Income	Through profit or loss
(a)	Term Loans						
	Secured						
(i)	from Banks	6,300.00	-	-	8,100.00	-	-
(ii)	from other parties	271.95	-	-	405.57	-	-
	Unsecured						
(i)	from Banks	-	-	-	-	-	-
(ii)	from Related parties	-	-	-	-	-	-
(b)	Finance lease obligations	-	-	-	-	-	-
(A)	Total	6,571.95	-	-	8,505.57	-	-
	Borrowings in India	6,571.95	-	-	8,505.57	-	-
	Borrowings outside India	-	-	-	-	-	-
(B)	Total	6,571.95	-	-	8,505.57	-	-
	(A) - (B)	-	-	-	-	-	-

b) Current

Sl.No.	Particulars	As at 31.03.2024			As at 31.03.2023		
		Amortised Cost	At Fair Value (₹.in Lakhs)		Amortised Cost	At Fair Value(₹.in Lakhs)	
			Through Other Comprehensive Income	Through profit or loss		Through Other Comprehensive Income	Through profit or loss
(a)	Term Loans						
	Secured						
(i)	from Banks	1,800.00	-	-	1,900.00	-	-
(ii)	from other parties	107.09	-	-	113.01	-	-
	Unsecured						
(i)	from Banks	-	-	-	-	-	-
(ii)	from Related parties	-	-	-	-	-	-
(b)	Finance lease obligations	-	-	-	-	-	-
(c)	Cash Credit	8,179.63	-	-	874.60	-	-
(A)	Total	10,086.73	-	-	2,887.61	-	-
	Borrowings in India	10,086.73	-	-	2,887.61	-	-
	Borrowings outside India	-	-	-	-	-	-
(B)	Total	10,086.73	-	-	2,887.61	-	-
	(A) - (B)	-	-	-	-	-	-

Break up of Loans- Borrowings with Repayment Terms				
Loan Type	Loan Name	Repayment Terms	Total Outstanding (₹.in Lakhs)	
			(For Current Reporting period)	(The previous reporting period)
Term Loan-Project	Citi Bank	20 Quarterly Instalments	8,100	9,000.00
Term Loan-Project	Biotechnology Industry Research Assistance Council	10 Years #	492.47	594.89
Cash credit	HDFC Bank	Yearly Renewal	1,077.17	-
Cash credit	Citi Bank	Yearly Renewal	1,000.00	1874.60
PCFC	Citi Bank	Yearly Renewal	6,102.46	-

Excluding IND AS effect

Terms of Security**From Banks**

17.1 Term loan from BIRAC (Biotechnology Industry Research Assistance Council), along with interest is secured by Equipment and Machinery which is procured from the sanctioned amount and carry an interest rate of 2.00% p.a (concessional rate)

17.2 Cash Credit and other fund and non fund facilities from Citibank & HDFC Bank are secured by the first charge on pari-passu basis on all inventories and receivables, Demand promissory note and letter of continuity. These facilities are payable on demand and carry an interest rate (re-set) in the range of 7.55% to 8.50% p.a.

17.3 Term loan from Citi Bank is secured by an exclusive charge on Moveable fixed assets and carry an interest rate which is equivalent to 3Months T bill+125 bps.

Terms of security and repayment

- Mortgage /charge over the company's immovable and movable properties (other than project assets but including all receivables) both present and future;
- Charge/assignment of revenues receivables
- Charge over /assignment of the rights, titles and interests of the company in to and in respect of all project agreements (in accordance with concession agreement).
- Assignment of insurance policies, interest, benefits, claims, guarantees ,performance bonds and liquidated damages;
- The aforesaid charge will rank Pari - Passu with the mortgages and charges created/to be created in favour of participating institutions/banks.

17.4 Obligations towards finance leases

Particulars	(₹.in Lakhs)	
	31.03.2024	31.03.2023
Minimum Lease payments		
(i) Not later than one year	194.63	39.77
(ii) Later than one year but not later than five years	606.43	83.07
Total	801.06	122.84
Less: Amounts representing Interest	-	-
Total	801.06	122.84

18 Trade Payables

Particulars	(₹.in Lakhs)	
	31.03.2024	31.03.2023
Current		
(i) Dues to micro, small and medium enterprises	-	-
(ii) Dues to others	9,032.37	6,058.22
(iii) Other Creditors	1,011.16	1,133.85
Total	10,043.53	7,192.07

Trade Payables Ageing
(For Current Reporting period)

Loan Type	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total (₹.in Lakhs)
MSME	-	-	-	-	-
Others	9,626.96	50.77	201.28	164.51	10,043.52
Disputed dues - MSME	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
Total	9,626.96	50.77	201.28	164.51	10,043.52

Trade Payables Ageing
(For Current Reporting period)

Loan Type	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total (₹.in Lakhs)
MSME	-	-	-	-	-
Others	6802.36	232.34	84.87	72.50	7,192.07
Disputed dues - MSME	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
Total	6,802.36	232.34	84.87	72.50	7,192.07

19 Other Financial Liabilities

Non Current

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
Lease Liability	430.59	76.44
Performance guarantee deposit	1,116.84	616.02
Total	1,547.43	692.45

Current

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
Retention money	592.23	449.79
Lease Liability	168.49	32.22
Total	760.71	482.01

Note - During the year, the Company made a reassessment of its lease agreements in order to ascertain whether the agreements meet the definition of a lease. The net impact of these changes has been transferred to Retained Earnings.

Fair Value Hierarchy

(₹.in Lakhs)				
Particulars	Carrying value as at		Fair value as at	
	31.03.2024	31.03.2023	31.03.2024	31.03.2023
Amortised cost				
(i) Borrowings	16,658.68	11,393.18	16,658.68	11,393.18
(ii) Trade Payables	10,043.53	7,192.07	10,043.53	7,192.07
(iii) Other financial liabilities	2,308.14	1,174.47	2,308.14	1,174.47
Total Financial Liabilities	29,010.35	19,759.71	29,010.35	19,759.71

20 Provisions

a) Non Current

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
Provision for employee benefits		
(i) Gratuity Payable	397.82	336.04
(ii) Leave encashment	255.22	202.79
Total	653.04	538.83

b) Non Current

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Provision for employee benefits		
(i) Gratuity Payable	228.62	247.07
(ii) Leave encashment	106.46	108.39
Total	335.08	355.45

(i) Movement in provisions

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
a) Provision for Gratuity		
Opening Balance	583.10	523.21
Additional Provisions made	235.78	192.45
Provisions released (paid)	192.45	132.55
Closing Balance	626.43	583.10
b) Leave Encashment		
Opening Balance	311.18	282.58
Additional Provisions made	253.45	218.72
Provisions released (paid)	202.94	190.11
Closing Balance	361.69	311.18

21 Other Liabilities**a) Non- Current**

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Endo Global Biologicals - significant financing component	-	0.00
Deferred Grant	116.93	141.76
Total	116.93	141.76

b) Current

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Other accrued liabilities	2,181.55	1,877.63
Advances from customers	3,376.69	140.01
Capital creditors	2,366.27	1,443.73
Dues to statutory/government authorities	434.13	256.05
Grants received in advance	-	38.52
Total	8,358.64	3,755.95

22 Current Tax Liability (Net)

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Current		
Income Tax Provision	12,641.08	12,088.35
Less: Advance tax paid	12,000.00	11,500.00
Total	641.08	588.35

23 Revenue From Operations

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Sale of products & services		
Domestic sales	30,973.01	21,302.43
Export sales	1,10,780.89	84,390.00
Total	1,41,753.90	1,05,692.43

23.1 Change in Contract Liabilities:

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Balance at the beginning of the year	-	2,187.39
Add: Interest expense during the year	-	188.46
Less: Invoices raised during the year	-	2,375.86
Balance at the end of the year	-	-

Expected revenue recognition from remaining performance obligations

-within one year	-	-
-more than one year	-	-

23.2 Performance Obligation

In relation to information about company's performance obligation, the entity satisfies the performance obligation at a point in time.

24 Other Income

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Interest from deposits & advances	4,779.57	2,949.56
Other income	19.53	100.62
Capital Gain and Dividend	703.43	1,487.33
Fair value Gain-Mutual Fund	14.52	(797.61)
Forex gain (net)	1,450.50	1,279.51
RoDTEP/MEIS duty credit incentives	35.83	-
Electricity cross subsidy received (wheeling charges)	-	356.83
Freight and forwarding charges collected	-	70.99
Grant received	44.15	98.11
Fair value SFC written back	-	2,187.39
Lease rent received	4.44	4.44
Total	7,051.98	7,737.17

25 Cost of materials consumed

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Opening stock	10,283.61	3,784.51
Purchases (Chemical and Reagents)	68,223.82	41,328.00
	78,507.43	45,112.51
Less: Closing stock	14,430.76	10,283.61
Cost of material consumed	64,076.68	34,828.89

25.1 Change in Work in Progress

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Opening stock		
Finished goods	507.50	455.36
Work-in-progress	2,025.16	1,176.10
	2,532.66	1,631.46
Less: Closing stock		
Finished goods	1,871.32	507.50
Work-in-progress	4,784.81	2,025.16
Total	(4,123.47)	(901.20)

26 Employee Benefits Expense

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Salaries and allowances	16,269.16	13,945.41
Contribution to provident and other funds	1,152.65	711.08
Staff welfare	840.29	660.58
Employees Benefit Expense	3.28	6.62
Total	18,265.38	15,323.70

27 Finance Costs

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
Interest Expense on		
(i) Interest - Term loans	623.88	355.17
(ii) Interest - Cash credit	198.67	43.68
(iii) Interest - Finance lease	-	18.58
(iv) Interest - IND AS lease	48.93	10.37
(v) Bank charges	35.01	51.25
(vi) Interest on Endo Global-Significant Financing Component	-	188.46
(vii) Amortisation of deferred loan (ABPPL)	7.81	7.81
Total	914.30	675.33

28 Other expenses

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
Advertisement and business promotion	106.19	53.53
Auditors' remuneration	25.00	20.00
Bad Debt Written Off	11.94	-
Commission expenses	263.00	415.71
Communication expenses	73.95	80.75
Corporate social responsibility expenses	869.60	601.08
Donation	2.00	2.50
Freight and forwarding charges	423.41	514.96
Health and safety expenses	258.86	286.34
Insurance	448.94	349.17
Interest on statutory dues	12.18	195.90
Internal Audit Fees	8.50	7.50
Legal and professional fees	251.32	217.72
Loss from sale of assets	43.48	0.28
Membership and subscription	79.85	68.75
Miscellaneous expenses	2.63	127.22
Fair value measurement expenses	95.46	46.41
Pollution control expenses	395.87	490.27
Power and fuel	3,129.27	3,894.63
Printing and stationery	227.81	247.19
Processing charges	441.55	295.69
R & D expenses	2,316.05	2,586.13
R & M - Building	96.09	64.43
R & M - Others	856.84	523.83
R & M - Plant and machinery	1,622.55	1,227.02
Rates and taxes	425.56	638.10
Rent	43.10	25.90
Security charges	168.36	151.25
Training and recruitment expenses	12.57	5.37
Travelling and conveyance	334.78	397.60
Total	13,046.71	13,535.24

28.1 As per Section 135 of Companies Act, 2013, a company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities.

29 Auditor's remuneration break-up

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
(i) Statutory audit fees	25.00	20.00
(ii) Certification and other reimbursement	0.67	2.62
(iii) Internal audit fees	8.50	7.50
Total	34.17	30.12

30 Tax Expense

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
A - Current Tax		
Current tax on profits for the year	12,641.08	12,004.84
Total	12,641.08	12,004.84

30.1 Reconciliation of tax expenses to accounting profit

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
A Amount recognised in Statement of profit and loss		
Current tax	12,641.08	12,004.84
Deferred tax expense/(income)	(1,641.88)	(793.68)
Tax expense for the year	10,999.20	11,211.16
B Reconciliation of effective tax rate		
Profit before tax and exceptional item	48,477.27	43,598.03
Add: Exceptional items, net	-	6,180.24
Profit before tax	48,477.27	49,778.27
Tax at statutory income tax rate 25.168%	12,200.76	12,528.20
Tax effects on:		
Inadmissible expenses & Income not included	758.87	-
Deductible expenditure & income to be excluded	(245.44)	-
Deduction under section 80JJA	(16.21)	-
Others	(1,698.78)	(1,317.03)
	10,999.20	11,211.16

31 Other comprehensive income

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
Items that will not be reclassified to profit or loss		
(ii) Actuarial gains & losses	(33.13)	(27.92)
(iii) Deferred tax	8.34	103.48
Total	(24.79)	75.56

32 Research and development expenditure

Expenditure on research activities are recognized as expenses and charged to Statement of profit and loss. Development costs of products are also charged to the Statement of profit and loss unless a product's technological feasibility has been established and the ability of the asset to generate future economic benefits, in such case expenditure is capitalized. The amount capitalized comprises expenditure that can be directly attributed or allocated on a reasonable and consistent basis to creating, producing and making the asset ready for its intended use. Fixed assets utilized for research and development are capitalized and depreciated in accordance with the policies stated for Tangible Assets and Intangible Assets. During the year, the below mentioned expenditure is incurred towards research and development:

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
Salaries and allowances	1,276.66	1,056.26
Consumables	953.90	1,461.84
Electricity expenses	78.40	63.17
Other expenses	7.09	4.86
Total expenses charged to statement of profit and loss	2,316.05	2,586.13

33 Earnings per share

Particulars	For the year ended	
	31.03.2024	31.03.2023
Earnings:		
Profit for the year attributable to equity shareholders (a)	3,74,53,27,722	3,86,42,66,715
Shares:		
Number of equity shares at the beginning of the year	57,04,86,800	87,76,254
Weighted average number of equity shares issued as share split	-	3,51,07,346
Weighted average number of bonus shares issued during the year	-	52,66,03,200
Weighted average number of equity shares bought back during the year	(34,69,799)	-
Weighted average number of equity shares – Basic (b)	56,70,17,001	57,04,86,800
Dilutive effect of potential equity shares	-	-
Weighted average number of equity shares – Diluted (c)	56,70,17,001	57,04,86,800
EPS: Basic (in Rs.) (a/b)	6.61	6.77
Diluted (in Rs.) (a/c)	6.61	6.77

34 Employee benefit expenses

		(₹.in Lakhs)	
Particulars		For the year ended	
		31.03.2024	31.03.2023
(i) Salaries and Wages		16,269.16	13,945.41
(ii) Contribution to provident and other funds*		1,152.65	711.08
(iii) Staff training and welfare expenses		840.29	660.58
(iv) Employee benefit expenses		3.28	6.62
Total		18,265.38	15,323.70

*Includes contribution to defined contribution plan for the year ended March 31, 2024 Rs. 489.23 lacs (for the year ended March 31, 2023:Rs.411.16 lacs)

Reconciliation of the present value of defined benefit obligation

(₹.in Lakhs)					
Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
Change in projected benefit obligations					
(i)	Obligations at the beginning of the year	1,042.12	909.72	311.18	282.58
(ii)	Service cost	165.99	130.76	63.36	56.03
(iii)	Interest expense	76.75	63.89	15.79	13.86
(iv)	Benefits settled	(45.74)	(90.25)	(202.94)	(190.07)
(v)	Actuarial (gain)/loss	30.78	27.99	174.30	148.79
Obligations at end of the year		1,269.89	1,042.12	361.69	311.18

Reconciliations of present value of plan assets

(₹.in Lakhs)					
Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
Change in plan assets					
(i)	Plan assets at the beginning of the year, at fair value	459.01	386.51	-	-
(ii)	Interest income on plan assets	40.09	30.13	-	-
(iii)	Re-measurement - actuarial gain/ (loss)	(2.35)	0.07	-	-
(iv)	Benefit payments from plan assets	(45.74)	(90.25)	-	-
(v)	Contributions from employers	192.45	132.55	202.94	190.07
(vi)	Benefits settled	-	-	(202.94)	(190.07)
Plan assets at the end of the year at fair value		643.46	459.01	-	

Reconciliation of net defined benefit obligation

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
Change in plan assets					
(i)	Present value of funded obligation	1,269.89	1,042.12	361.69	311.18
(ii)	Fair value of plan assets	(643.46)	(459.01)	-	-
Net Defined Benefit Liability / (Asset)		626.44	583.10	361.69	311.18
Short term Liability		228.62	247.07	106.46	108.39

Expense recognised in the statement of profit and loss under employee benefits expense

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
Change in projected benefit obligations					
(i)	Current Service Cost	165.99	130.76	63.36	56.03
(ii)	Interest Expense on DBO	76.75	63.89	15.79	13.86
(iii)	Interest (Income) on Plan Assets	(40.09)	(30.13)	-	-
(iv)	Actuarial Loss / (Gain) - Other than OCI	-	-	174.30	148.79
Defined Benefit Cost included in P & L		202.65	164.52	253.45	218.68
(i)	Discount rate	7.25%	7.53%	7.53%	7.39%
(ii)	Salary increase	6.00%	6.00%	6.00%	6.00%

Remeasurements recognised in the statement of other comprehensive income

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
(i)	Remeasurements - Gain/ Loss on DBO	30.78	27.99	-	-
(ii)	Return on plan assets, excluding interest income	2.35	(0.07)	-	-
Defined Benefit Cost included in P & L		33.13	27.92	-	-

Bifurcation of present value of obligations at the end of the valuation period as per schedule III of the Companies Act, 2013

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
(i)	Current liabilities	228.62	247.07	106.46	108.39
(ii)	Non-Current liabilities	1,041.28	795.05	255.22	202.79

Plan assets comprises of the following:

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
Insurance Policies		643.46	459.01	-	-

The experience adjustments, meaning difference between changes in plan assets and obligations expected on the basis of actuarial assumption and actual changes in those assets and obligations are as follows:

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
(i)	Experience adjustment on plan liabilities	21.83	31.38	174.10	149.24
	Percentage of opening plan liabilities	2.10%	3.45%	55.95%	52.81%
(ii)	Experience adjustment on plan assets	(2.35)	0.07	-	-
	Percentage of opening plan assets	-0.51%	0.02%	-	-

Maturity profile of defined benefit obligation:

(₹.in Lakhs)

Particulars		Gratuity		Leave Encashment	
		For the year ended		For the year ended	
		31.03.2024	31.03.2023	31.03.2024	31.03.2023
	Year 1	229.69	247.78	106.46	108.39
	Year 2	210.93	201.57	81.86	74.55
	Year 3	177.70	184.14	62.30	57.04
	Year 4	162.38	145.72	47.27	40.17
	Year 5	144.72	120.44	35.97	28.10
	Next 5 year Payouts	1,004.79	522.71	127.00	72.25

The weighted average duration of the defined benefit obligation for gratuity is 6 as at 31 March 2024

The weighted average duration of the defined benefit obligation for Leave encashment is 4 as at 31 March 2024

35 Disclosure with respect to Ind AS 116 - Leases

Information about Leases Assets for which the Company is a lessee is presented below:

(₹.in Lakhs)

Particulars	"As at March 31, 2024"	"As at March 31, 2023"
Balance as at beginning of the year	133.76	248.60
Additions	628.93	11.44
Deletions	-	(81.62)
Depreciation*	(133.97)	(44.66)
Balance as at end of the year	628.72	133.76

*The aggregate depreciation expense on Right-of-use assets is included under depreciation expense in Statement of Profit and Loss.

The changes/movement in Lease Liabilities of the Company are as follows:

(₹.in Lakhs)

Particulars	"As at March 31, 2024"	"As at March 31, 2023"
Balance as at beginning of the year	108.66	230.43
Additions	628.93	13.98
Deletions	-	-93.09
Repayment of principal and interest on lease liabilities	-187.45	-53.02
Accreditation of interest	48.93	10.37
Balance as at end of the year	599.08	108.66
Current Liabilities	168.49	32.22
Non-Current Liabilities	430.59	76.44
Total cash outflow for leases	187.45	53.02

The table below provides details regarding amounts recognised in the Standalone Statement of Profit and Loss:

(₹.in Lakhs)

Particulars	As at March 31, 2024	As at March 31, 2023
Expenses relating to short-term leases and/or leases of low-value items		
Interest on lease liabilities	48.93	10.37
Depreciation expense	133.97	44.66
Total	182.90	55.03

Contractual maturities of Lease Liabilities on undiscounted basis

(₹.in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
Less than one year	194.63	39.77
One to five years	606.43	83.07
Total	801.06	122.84

36 Financial Risk Management

The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk, foreign currency risk and interest rate risk. The Company's primary focus is to foresee the unpredictability of financial markets and seek to minimize potential adverse effects on its financial performance. The primary market risk to The Company is foreign exchange risk. The Company uses derivative financial instruments to mitigate foreign exchange related risk exposures. All derivative activities for risk management purposes are carried out by specialist teams that have the appropriate skills, experience and supervision. It is The Company's policy that no trading in derivative for speculative purposes may be undertaken. The Board of Directors reviews and agrees policies for managing each of these risks, which are summarised below:

(a) Credit risk:

Credit risk is the risk of financial loss to The Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from The Company's receivables from customers and investment securities. Credit risk arises from cash held with banks and financial institutions, as well as credit exposure to clients, including outstanding accounts receivable. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses in financial assets. The Company assesses the credit quality of the counterparties, taking into account their financial position, past experience and other factors.

(b) Trade and other receivables:

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment.

(c) Investments:

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non-performance by these counterparties, and does not have any significant concentration of exposures to specific industry sectors.

(d) Liquidity risk:

Liquidity risk is the risk that The Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due. Also, the Company has unutilized credit limits with banks.

The Company's corporate treasury department is responsible for liquidity, funding as well as settlement management. In addition, processes and policies related to such risks are overseen by senior management. The working capital position of the Company is given below:

(₹.in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
Cash & cash equivalents	18,334.86	34,218.21
Investments in mutual funds (quoted)	45,907.03	49,287.05

Contractual maturities of significant financial liabilities as at

(₹.in Lakhs)			
Particulars	As at March 31, 2024		
	Less than 1 year	More than 1 year	Total
Borrowings	10,086.73	6,571.95	16,658.68
Lease Liabilities	168.49	430.59	599.08
Trade payables and accrued expenses	10,043.53	-	10,043.53
Other Financial liabilities	592.23	1,116.84	1,709.07

Particulars	As at March 31, 2024		
	Less than 1 year	More than 1 year	Total
Borrowings	2,887.61	8,505.57	11,393.18
Lease Liabilities	32.22	76.44	108.66
Trade payables and accrued expenses	7,192.07	-	7,192.07
Other Financial liabilities	449.79	616.02	1,065.81

(e) Foreign currency risk:

The Company's exchange risk arises from its foreign operations, foreign currency revenues and expenses, (primarily in U.S. Dollars). A significant portion of The Company's revenues are in US Dollars while a significant portion of its costs are in Indian Rupees. As a result, if the value of the Indian Rupee appreciates relative to these foreign currencies, The Company's revenues measured in Rupees may decrease. The exchange rate between the Indian Rupee and these foreign currencies has changed substantially in recent periods and may continue to fluctuate substantially in the future. The Company has an internal committee which meets on a periodic basis to formulate the strategy for foreign currency risk management. When necessary, the Company uses derivative financial instruments, such as foreign exchange forward contracts, to mitigate the risk of changes in foreign currency exchange rates in respect of its forecasted cash flows and trade receivables.

(f) Interest rate risk:

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to The Company's debt obligations with floating interest rates and investments. The Company's borrowings and investments are primarily short-term, which do not expose it to significant interest rate risk.

37 Capital Management Structure

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. The Company monitors the return on capital as well as the level of dividends on its equity shares. The Company's objective when managing capital is to maintain an optimal structure so as to maximize shareholder value.

The capital structure is as follows:

The Company is predominantly equity financed which is evident from the capital structure table. Further, The Company has always been a net cash Group with cash and bank balances along with investment which is predominantly investment in liquid and short term mutual funds being far in excess of debt.

(₹.in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
Total equity attributable to the equity share holders of the group	1,93,307.48	1,74,161.83
As percentage of the total capital	100%	100%
current loans & borrowings	10,086.73	2,887.61
Non current loans & borrowings	6,571.95	8,505.57
Total loans & borrowings	16,658.68	11,393.18
As percentage of the total capital	9%	7%
Total capital (loans and borrowings and equity)	2,09,966.16	1,85,555.00

(₹.in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
Commitments		
Estimated amount of expected capital commitments	21,156	13,563
Contingent liabilities		
<u>Claims against the company not acknowledged as debts:</u>		
Income tax - AY 2015-16 - CIT Appeals 1, Bengaluru	326	326
Income tax - AY 2016-17 - ACIT, Bengaluru	20	-
Income tax - AY 2017-18 - ITAT, Bengaluru	93	93
Income tax - AY 2018-19 - ACIT, Bengaluru	381	-
Income tax - AY 2020-21 - CIT (A) Bengaluru	51	51
Goods and Service Tax: FY 2017-18-Bengaluru	45	-
Service Tax-Appeal-FY: 2011-2015	12	12
<u>Others:</u>		
Letter of credit	43	286
Bank guarantees	183	70
<u>Corporate guarantees:</u>		
Guarantees given to Federal Bank on behalf of wholly owned subsidiary & associate company for securing financial assistances in the form for term loan and working capital loans.	22,150	21,800

39 Segment information:

Segments are identified in line with Indian Accounting Standard (Ind AS) 108 "Operating Segments", taking into consideration the internal organization and business activities in which it engages and the economic environments in which it operates and separate financial information availability. Company has identified two business segments viz, Contract Manufacturing; Development & Discovery Services and Speciality Ingredients (product business) during the year. Revenue and expenses directly attributable to segments are reported under each reportable segment. Expenses which are not directly identifiable to each reporting segment have been allocated on the basis of associated revenue. All other expenses which are not attributable or allocable to segments have been disclosed as unallocable expenses.

(₹.in Lakhs)		
Particulars	Year ended March 31, 2024	Year ended March 31, 2023
Segmental Performance		
Business Vertical:		
A) Contract Research Development & Manufacturing Services (CRDMO):		
Development & Manufacturing	89,576.60	63,495.23
R&D Services	18,557.20	17,314.00
B) Speciality Ingredients	33,620.10	24,883.20
Total	1,41,753.90	1,05,692.43
Revenue wise		
Export	1,10,780.89	84,390.00
Domestic	30,973.01	21,302.43
Total	1,41,753.90	1,05,692.43
Geography wise sales		
North America (USA)	42,665.80	50,020.50
Europe	61,347.96	30,620.00
India	30,925.77	21,302.43
Rest of asia	6,814.40	3,749.50
Total	1,41,753.90	1,05,692.43

40 Corporate Social Responsibility

As per Section 135 of the Companies Act, 2013, a company, meeting the applicability threshold, needs to spend at least 2% of its average net profit for the immediately preceding three financial years on corporate social responsibility (CSR) activities. During the financial year 2023-24 the company has spent below amounts towards The Akshaya Patra Foundation for serving mid day meals; The Art & Photography Foundation; Sri Sringeri Sharada Peetham Charitable Trust; Janseva Trust Param; Construction of schools at Rampura, Anumanahalli & Aadnakupee Urdu School, Government primary school at Hebbidarametlu; Government Primary School-Kitchen & Dinning hall at Jakkasandra karnataka and consutruction of government higher primary school at Bannikuppe etc. Also company has undertaken various CSR initiatives to construct more schools and other social welfare measures.

(₹.in Lakhs)		
Particulars	Year ended March 31, 2024	Year ended March 31, 2023
Gross amount required to be spent during the year	939.97	688.56
Amount spent during the year	869.60	601.08
Amount spent in local area	867.60	594.08
Shortfall at the end of the year / period.	70.37	87.48
Total of previous years shortfall.	608.71	538.34

As on March 31, 2024, a cumulative amount of Rs.608.71 lakhs is unspent. Total amount spent includes provision of INR. 3.00 crores created and will be spent in the FY2024-25.

41 Trade Payables have been classified as Current and Non-Current. The Management has identified:

Trade Payables have been classified as Current and Non-Current. The Management has identified:

(₹.in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
(i) Principal amount remaining unpaid to any supplier as at the end of the accounting year	-	-
(ii) Interest due thereon remaining unpaid to any supplier as at the end of the accounting year	-	-
(iii) The amount of interest paid along with the amounts of the payment made to the supplier beyond the appointed day	-	-
(iv) The amount of interest due and payable for the year	-	-
(v) The amount of interest accrued and remanining unpaid at the end of the accounting year	-	-
(vi) The amount of further interest due and payable even in the succeeding year, until such date when the interest dues as above actually paid	-	-

42 Related Parties

Name of the related party	Nature of relationship with the company	Country of Incorporation/ Residential Status
Ajay Bhardwaj	Managing Director	Indian
Ravindra KC	Director	Indian
Ganesh Sambasivam	Director	Indian
Ramakrishnan K	Company Secretary	Indian
Gawir Baig	Vice President cum CFO	Indian
Ishaan Bhardwaj	Vice President	Indian
Krithika Ganesh	Dp.Manager-II	Indian
Keerthana Ravindra	Dp.Manager-II	Indian
Anthem Biopharma Pvt Ltd	Common Directors	India
Neoanthem Lifesciences Pvt Ltd	Wholly Owned Subsidiary	India

42.1 Transactions with above related parties

(₹.in Lakhs)

Name of the related party	Nature of transaction	Year Ended	
		March 31,2024	March 31,2023
Ishaan Bhardwaj	Remuneration paid	65.43	43.54
Keerthana Ravindra	Remuneration paid	12.80	8.11
Krithika Ganesh	Remuneration paid	15.54	9.70
Anthem Biopharma Pvt Ltd	Business support services	5.79	7.53
	Interest income (Interest charged on loans given)	62.15	60.99
Neoanthem Lifesciences Pvt Ltd	Interest income (Interest charged on loans & advances given)	693.79	39.68
	Sale of goods and services	112.77	-
	Purchase of goods and services	79.04	-

42.2 Balances receivable from related parties are as follows

(₹.in Lakhs)

Name of the related party	Classification	Year Ended	
		March 31,2024	March 31,2023
Anthem Biopharma Pvt Ltd	For sale of goods & services	310.78	310.78
	For loans and advances given	740.44	719.50
Neoanthem Lifesciences Pvt Ltd	For loans and advances given	17,367.90	2,318.97

43 Remuneration paid to key management personnel

(₹.in Lakhs)

Name	Designation	Remuneration paid for the Year ended	
		March 31,2024	March 31,2023
Ajay Bhardwaj	Managing Director	747.57	467.36
Ravindra K C	Director	741.70	471.40
Ganesh Sambasivam	Director	742.68	471.55
Ramakrishnan K	Company Secretary	39.00	39.00
Gawir Baig	Vice President cum CFO	116.10	104.14

44 Key financial ratios

Particulars	Figures for the current reporting period	Figures for the previous reporting period	Reason if the variance is more than 25%
1. Current Ratio (in times)	4.78	8.65	Reduction in short term deposits
2. Debt - Equity Ratio (in times)	0.09	0.07	
3. Debt Service Coverage Ratio (in times)	3.28	4.71	
4. Return on Equity Ratio (%)	20.38%	25%	
5. Inventory turnover ratio (in times)	4.59	5.25	
6. Trade Receivables turnover ratio (in times)	3.68	3.49	
7. Trade payables turnover ratio (in times)	8.95	7.08	
8. Net capital turnover ratio (in times)	1.23	1.04	
9. Net profit ratio (%)	26%	37%	Decrease in profit
10. Return on Capital employed (%)	25%	29%	

45 Other Statutory Disclosures

- (i) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- (ii) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (iii) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- (iv) No Relationship or Transactions with any struck off companies during the year.
- (v) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (vi) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (vii) The Company has not any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.
- (viii) The Company has not been declared as Willfull Defaulter by any Bank or Financial Institutions or any other lender.
- (ix) The Company has complied with the number of layers prescribed under clause (87) of Section 2 of the Act r.w Companies (Restriction on number of layers) Rules, 2017.
- (x) The Company uses an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the accounting software. There is no instance of audit trail feature being tampered with was noted in respect of the accounting software.

As per our report of even date attached
Notes forming part of standalone financial statements

For K.P. Rao & Co.,
Chartered Accountants
Firm Registration No. 003135S

Mohan Lavi
Partner
Membership No.029340

Place : Bangalore
Date : September 05, 2024

For and on behalf of the Board

Ajay Bhardwaj
Managing Director
DIN:00333704

Ravindra K C
Director
DIN:01580534

Ramakrishnan K
Company Secretary
FCS: 11748

Gawir Baig
CFO

Accounting Policies (Standalone Financial Statements)

ANTHEM BIOSCIENCES PRIVATE LIMITED

CIN: U24233KA2006PTC039703

Notes forming part of the Standalone Financial Statements for the year ended March 31, 2024

1. Corporate information:

Anthem Biosciences Private Limited has been set up as a Life sciences/ Biotechnology based venture specialising in the manufacture of catalytic preparation, other organic compounds such as speciality organic molecules, biologically active peptides etc., which are high-value products used in drug, agrochemical and speciality chemicals industries. The Company has received the letter of permission under the 100% EOU scheme for manufacture of catalytic preparation and other organic compounds from the office of the Development Commissioner, CSEZ, sub office in Karnataka, vide letter No. 1/80/2006:PER:EOU:KR:CSEZ/106 dated 19th January 2007, which is further extended vide letter No : 1/80/2006:EOU:CSEZ/1276 dated 11th July 2022 valid till 10th July 2027 . In accordance with the said letter of permission, the facilities at the factory located at Bommasandra Industrial Area are with its best in class infrastructure which includes a modern c-GMP kilo lab and a versatile GMP pilot plant. Anthem Biosciences has the capacity to do GMP synthesis from milligram to kilogram and multi-kilogram scale. The projects results are initially transmitted by means of reports followed by the manufacture of small sample quantities that are sent to clients for testing purpose. The Company has received approval from Department of Scientific and Industrial Research Technology for in-house research and development activities, beginning 1 April 2011 to 31 March 2017 and further renewed and valid as on 31.03.2024 vide approval letter No. :F.No.TU/IV-RD/2954/2021 dated 18th March 2021.

Significant accounting policies:

(A) Basis of preparation and presentation:

a) Statement of compliance:

These standalone financial statements have been prepared in accordance with Indian Accounting Standards ("hereinafter referred to as the "Ind AS") as notified by Ministry of Corporate Affairs pursuant to Section 133 of the companies Act, 2013 read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time

These standalone financial statements have been prepared for the Company as a going concern on the basis of relevant Ind AS that are effective at the Company's annual reporting date, March 31, 2024. These standalone financial statements were approved and authorized for issuance by the Company's Board of Directors on their meeting held on September 05, 2024.

b) Basis of measurement:

The financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following material items that have been measured at fair value as required by relevant Ind AS:

- i. Certain financial assets and liabilities measured at fair value (refer accounting policy on financial instruments);
- ii. Defined benefit and other long-term employee benefits.

c) Use of estimates and judgements:

The preparation of financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on a periodic basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the notes.

d) Fair valuation:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/ or disclosure purposes in these financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of Ind AS 102, leasing transactions that are within the scope of Ind AS 116, and measurements that have some similarities to fair value but are not fair value, such as a net realisable value in Ind AS 2 or value in use in Ind AS 36.

In addition, for financial reporting purposes, fair value measurements are categorised into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the company can access at the measurement date;
- Level 2 inputs are other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

(i) Functional and presentation currency:

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the Company operates (i.e. the “functional currency”). The financial statements are presented in Indian Rupee, the national currency of India, which is the functional currency of the Company.

(ii) Foreign currency transactions and balances:

Transactions in foreign currency are translated into the respective functional currencies using the exchange rates prevailing at the dates of the respective transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at the exchange rates prevailing at reporting date of monetary assets and liabilities denominated in foreign currencies are recognized in the statement of profit and loss and reported within foreign exchange gains/ (losses).

Non-monetary assets and liabilities denominated in a foreign currency and measured at historical cost are translated at the exchange rate prevalent at the date of transaction.

(iii) Financial instruments:

All financial instruments are recognised initially at fair value. Transaction costs that are attributable to the acquisition of the financial asset (other than financial assets recorded at fair value through profit or loss) are included in the fair value of the financial assets. Purchase or sale of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trade) are recognised on trade date. While, loans and borrowings and payables are recognised net of directly attributable transaction costs.

For the purpose of subsequent measurement, financial instruments of the Company are classified in the following categories: nonderivative financial assets comprising amortised cost, debt instruments at fair value through other comprehensive income (FVTOCI), equity instruments at FVTOCI or fair value through profit and loss account (FVTPL), non-derivative financial liabilities at amortised cost or FVTPL and derivative financial instruments (under the category of financial assets or financial liabilities) at FVTPL. The classification of financial instruments depends on the objective of the business model for which it is held. Management determines the classification of its financial instruments at initial recognition.

(a) Non-derivative financial assets:**(i) Financial assets at amortized cost:**

A financial asset shall be measured at amortised cost if both of the following conditions are met:

- (a) the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and
- (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

They are presented as current assets, except for those maturing later than 12 months after the reporting date which are presented as non-current assets. Financial assets are measured initially at fair value plus transaction costs and subsequently carried at amortized cost using the effective interest rate method, less any impairment loss.

Amortized cost are represented by trade receivables, security deposits, cash and cash equivalents, employee and other advances and eligible current and non-current assets. Cash and cash equivalents comprise cash on hand and in banks and demand deposits with banks which can be withdrawn at any time without prior notice or penalty on the principal.

For the purposes of the cash flow statement, cash and cash equivalents include cash on hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand, book overdraft and are considered part of the Company's cash management system.

(ii) Financial assets at FVTPL:

FVTPL is a residual category for financial assets. Any financial asset which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as FVTPL. In addition the Company may elect to designate the financial asset, which otherwise meets amortized cost or FVTOCI criteria, as FVTPL if doing so eliminates or significantly reduces a measurement or recognition inconsistency. Financial assets included within the FVTPL category are measured at fair values with all changes in the statement of profit and loss.

(b) Non-derivative financial liabilities:

(i) Financial liabilities at amortized cost:

Financial liabilities at amortized cost represented by borrowings, trade and other payables are initially recognized at fair value, and subsequently carried at amortized cost using the effective interest rate method.

(B) Property, plant and equipment:

a) Recognition and measurement:

Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Cost includes expenditures directly attributable to the acquisition of the asset.

b) Depreciation:

The Company depreciates property, plant and equipment over the estimated useful life on a written down value basis from the date the assets are ready for intended use. Assets acquired under finance lease and leasehold improvements are amortized over the lower of estimated useful life and lease term. The estimated useful lives of assets for the current and comparative period of significant items of property, plant and equipment are as follows:

Category	Useful Life (years)
Roads	5-10
Buildings	5-60
Plant and machinery	15-20
Electrical installations	10
Furniture and fittings	10
Laboratory equipments	10
Office equipment	5
Pipelines	15
Computers and DP units	3-6
Motor vehicles	8

Depreciation methods, useful lives and residual values are reviewed at each reporting date. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Subsequent expenditure relating to property, plant and equipment is capitalized only when it is probable that future economic benefits associated with these will flow to the Company and the cost of the item can be measured reliably. Repairs and maintenance costs are recognized in the statement of profit and loss when incurred. The cost and related accumulated depreciation are eliminated from the financial statements upon sale or disposition of the asset and the resultant gains or losses are recognized in the statement of profit and loss.

Amounts paid towards the acquisition of property, plant and equipment outstanding as of each reporting date and the cost of property, plant and equipment not ready for intended use before such date are disclosed under capital advances and capital work- in-progress respectively.

(C) Intangible assets:

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective estimated useful lives on a written down value basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

The estimated useful lives of intangibles are as follows:

Category	Useful Life
Software licenses	Earlier of license period or 1-3 years

(D) Leases:

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Company accounts for each lease component within the contract as a lease separately from non-lease components of the contract and allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.

The Company recognises right-of-use asset representing its right to use the underlying asset for the lease term at the lease commencement date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred and an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset or restoring the underlying asset or site on which it is located. The right-of-use assets is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any re-measurement of the lease liability. The right-of-use assets is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the statement of profit and loss.

The Company measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the incremental borrowing rate, if that rate can be readily determined. If that rate cannot be readily determined, The Company uses incremental borrowing rate. The lease payments shall include fixed payments, variable lease payments, residual value guarantees, exercise price of a purchase option where The Company is reasonably certain to exercise that option and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease. The lease liability is subsequently re-measured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and re-measuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments.

The Company recognises the amount of the re-measurement of lease liability due to modification as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the

measurement of the lease liability, The Company recognises any remaining amount of the re-measurement in statement of profit and loss.

The Company has elected not to apply the requirements of Ind AS 116 Leases to short-term leases of all assets that have a lease term of 12 months or less and leases for which the underlying asset is of low value. The lease payments associated with these leases are recognised as an expense on a straight-line basis over the lease term.

(E) Impairment:**(a) Financial assets:**

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss. The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivable. The application of simplified approach does not require the Company to track changes in credit risk.

Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition. For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If in subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the company reverts to recognising impairment loss allowance based on 12-month ECL. Lifetime ECLs are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12-month ECL is a portion of the lifetime ECL which results from default events that are possible within 12-months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the company expects to receive (i.e. all shortfalls), discounted at the original effective interest rate (EIR). When estimating the cash flows, company is required to consider:

- (i) All contractual terms of the financial instrument (including prepayment, extension etc.) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the company is required to use the remaining contractual term of the financial instrument.
- (ii) Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

As a practical expedient, the Company uses a provision matrix to determine impairment loss on portfolio of its trade receivable. The provision matrix is based on its historically observed default rates over the expected life of the trade receivable. At every reporting date, the historically observed default rates are updated. ECL impairment loss allowance (or reversal) recognised during the period is recognised as income/expense in the statement of profit and loss.

The balance sheet presentation for various financial instruments is described below:

Financial assets measured at amortized cost, contractual revenue receivable. ECL is presented as an allowance, i.e. as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

(b) Non-financial assets:

Assesses at each reporting date whether there is any objective evidence that a non-financial asset or a group of non-financial assets is impaired. If any such indication exists, the Company estimates the amount of impairment loss. An impairment loss is calculated as the difference between an asset's carrying amount and recoverable amount. Losses are recognised in profit or loss and reflected in an allowance account. When the Company considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, then the previously recognised impairment loss is reversed through profit or loss. The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the "cash-generating unit").

(F) Employee benefits:

The Company participates in various employee benefit plans. Post-employment benefits are classified as either defined contribution plans or defined benefit plans. Under a defined contribution plan, the Company's only obligation is to pay a fixed amount with no obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits. The related actuarial and investment risks fall on the employee. The expenditure for defined contribution plans is recognized as expense during the period when the employee provides service. Under a defined benefit plan, it is the Company's obligation to provide agreed benefits to the employees. The related actuarial and investment risks fall on the Company. The present value of

the defined benefit obligations is calculated using the projected unit credit method.

The Company has the following employee benefit plans:

a) Provident Fund:

Retirement benefit in the form of Provident Fund is a defined contribution scheme and the contributions are charged to the statement of profit and loss for the year when the employee renders the related service and the contributions to the government funds are due. The Company has no obligation other than the contribution payable to provident fund authorities.

b) Gratuity:

For the purpose of administration of gratuity of the employees of the Company, the Company has established Anthem Biosciences Private Limited Employees Gratuity Trust. In accordance with the Payment of Gratuity Act, 1972, the Company provides for a lump sum payment to eligible employees, at retirement or termination of employment based on the last drawn salary and years of employment with the Company. Company's obligation in respect of the gratuity plan, which is a defined benefit plan, is provided for based on actuarial valuation using the projected unit credit method.

Actuarial gains or losses are recognized in other comprehensive income. Further, the profit or loss does not include an expected return on plan assets. Instead net interest recognized in profit or loss is calculated by applying the discount rate used to measure the defined benefit obligation to the net defined benefit liability or asset. The actual return on the plan assets above or below the discount rate is recognized as part of re-measurement of net defined liability or asset through other comprehensive income.

Re-measurements comprising actuarial gains or losses and return on plan assets (excluding amounts included in net interest on the net defined benefit liability) are not reclassified to profit or loss in subsequent periods.

c) Compensated absences:

The employees of the Company are entitled to compensated absences. The employees can carry forward a portion of the unutilized accumulating compensated absences and utilize it in future periods or receive cash at retirement or termination of employment. The Company records an obligation for compensated absences in the period in which the employee renders the services that increases this entitlement.

The Company measures the expected cost of compensated absences as the additional amount that the Company expects to pay as a result of the unused entitlement that has accumulated at the end of the reporting period. The Company recognizes accumulated compensated absences based on actuarial valuation. Non-accumulating compensated absences are recognized in the period in which the absences occur. The Company recognizes actuarial gains and losses immediately in the statement of profit and loss.

(G) Provisions:

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset, if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Provisions for onerous contracts are recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable costs of meeting the future obligations under the contract. Provisions for onerous contracts are measured at the present value of lower of the expected net cost of fulfilling the contract and the expected cost of terminating the contract.

(H) Revenue :

a) Sale of goods & services:

Company earns revenue primarily from sale of goods, providing scientific & technical consultancy services. Revenue is recognised upon transfer of control of promised products or services (performance obligation) to the customers in an amount that reflects the consideration which the company expects to receive in exchange for those products or services.

The amount of revenue to be recognised (transaction price) is based on the consideration expected to be received in exchange for goods, excluding amounts collected on behalf of third parties such as sales tax or other taxes directly linked to sales. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on their relative stand-alone selling prices.

Revenue from product sales are recorded net of allowances for estimated rebates, cash discounts and estimates of product returns, all of which are established at the time of sale.

The company adjusts the promised amount of consideration for the effects of time value of money if the timing of payments agreed to by the parties to the contract provides the customer with a significant benefit of financing the transfer of goods or services to the customer. The impact of the time value of money is shown as Contract Liability.

b) Rental income:

Rental income is recognised in statement of profit and loss on a straight-line basis over the term of the lease except where the rentals are structured to increase in line with expected general inflation. Lease incentives granted are recognised as an integral part of the total rental income, over the term of the lease.

c) Dividend & interest income :

Dividend income is recorded when the right to receive payment is established. Interest income is recognised using the effective interest method.

(I) Finance expense:

Finance expenses consist of interest expense on loans and borrowings. Borrowing costs are recognized in the statement of profit and loss using the effective interest method.

Foreign currency gains and losses are reported on a net basis. This includes changes in the fair value of foreign exchange derivative instruments, which are accounted at fair value through profit or loss.

(J) Income tax:

Income tax comprises current and deferred tax. Income tax expense is recognized in the statement of profit and loss except to the extent it relates to items directly recognized in equity or in other comprehensive income.

a) Current income tax:

Current income tax for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the taxable income for the period.

The tax rates and tax laws used to compute the current tax amount are those that are enacted or substantively enacted by the reporting date and applicable for the period. The Company offsets current tax assets and current tax liabilities, where it has a legally enforceable right to set off the recognized amounts and where it intends either to settle on a net basis or to realize the asset and liability simultaneously.

b) Deferred income tax:

Deferred income tax is recognized using the balance sheet approach. Deferred income tax assets and liabilities are recognized for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount in financial statements, except when the deferred income tax arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profits or loss at the time of the transaction.

Deferred income tax asset is recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. Deferred income tax liabilities are recognized for all taxable temporary differences.

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date

(K) Earnings per share (EPS):

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the period. Diluted EPS is computed by dividing the net profit after tax by the weighted average number of equity shares considered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date. Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for bonus shares, as appropriate.

(L) Research and development costs :

Research costs are expensed as incurred. Development costs are expensed as incurred unless technical and commercial feasibility of the project is demonstrated, future economic benefits are probable, the Company has an intention and ability to complete and use or sell the software and the costs can be measured reliably.

(M) Government grants:

Grants from the government are recognised when there is reasonable assurance that:

- (i) the Company will comply with the conditions attached to them; and
- (ii) the grant will be received.

Government grants related to revenue are recognised on a systematic basis in the statement of profit and loss over the periods necessary to match them with the related costs which they are intended to compensate. Such grants are deducted in reporting the related expense. When loan or similar assistance is provided by government or related institutions, with an interest rate below the current applicable market rate, the effect of this favorable interest is recognized as government grant. The loan or assistance is initially recognized and measured at fair value and the government grant is measured as the difference between the initial carrying value of the loan and the proceeds received.

(N) Inventories:

Inventories consists of (a) Raw materials, (b) Work-in-progress and (d) Finished goods. Inventories are carried at lower of cost and net realizable value. The cost of raw materials are determined on a moving average basis and/specific cost wherever applicable. Cost of work in progress & finished goods produced includes direct material, labour cost and a proportion of manufacturing overheads.

(O) Previous year's figures have been re-grouped or re-classified to conform to the present year's presentation.



NeoAnthem Financials

Auditors Report (NeoAnthem Financials)

INDEPENDENT AUDITOR'S REPORT

To

The Members of

Neoanthem Lifesciences Private Limited

Bengaluru

Report on the Indian Accounting Standard (Ind AS) Financial Statements

Opinion

We have audited the accompanying standalone financial statements of **Neo anthem Lifesciences Private Limited** ("the Company"), which comprise the standalone Balance Sheet as at March 31, 2024, and the standalone Statement of Profit and Loss and statement of cash flows for the period then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the **Companies Act, 2013** (Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, its losses and cash flows for the year ended on that date.

Basis for opinion

We conducted our audit in accordance with the standards on auditing specified under section 143 (10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the auditor's responsibilities for the audit of the standalone financial statements section of our report. We are independent of the Company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management Responsibilities for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act 2013, with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position and financial performance, and the cash flows of the Company in accordance with the Accounting Principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error..

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has not realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually

or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosure are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards,

Report on Other Legal and Regulatory Requirements

As the Companies (Independent Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of subsection (11) of Section 143 of the Act is not applicable to the company we are not reporting on the matters specified in paragraphs 3 and 4 of the Order.

As required by Section 143 (3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act.
- e) On the basis of the written representations received from the directors as on 31st March, 2024 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2024 from being appointed as a director in terms of Section 164 (2) of the Act.

- f) Since the Company's turnover as per last audited financial statements is less than Rs.50 Crores and no borrowings from banks and financial institutions at any time. during the year, the Company is exempted from getting an audit opinion with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls vide notification dated June 13, 2017.
- g) The provisions of section 197 of the Act does not apply to the Company, hence reporting under Section 143(3)(g) is not required.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company has no litigation pending against it.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund.
 - iv.
 - a. The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall:
 - directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company or,
 - provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
 - b. The management has represented, that, to the best of its knowledge and belief, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall:
 - directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Party or
 - provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries; and
 - c. Based on such audit procedures as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under subclause (iv) (a) and (iv) (b) contain any material mis-statement.
 - i) Based on our examination, the company, has used accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with.

For K.P.Rao & Co.

Chartered Accountants

Firm Reg. No. 003135S

Mohan R. Lavi

Partner

Membership No. 029340

UDIN :

Place: Bangalore

Date: 05th September 2024

NeoAnthem Financial Statements

Balance Sheet as at March 31, 2024				(₹.in Lakhs)
	PARTICULARS	Note	As at 31.03.2024	As at 31.03.2023
I	ASSETS			
1)	Non-current assets			
a)	Property, plant and equipment	2	481.11	-
b)	Capital work in progress	2.1	18,878.04	2,067.08
c)	Financial Assets			
i)	Trade receivables	4	93.24	-
d)	Deferred tax assets (net)	3	-	0.03
e)	Other non-current assets	4.3	103.55	-
	Total Non-Current assets		19,555.94	2,067.11
2)	Current assets			
a)	Inventories	4.2	3.82	-
b)	Financial assets			
i)	Trade receivables	4	61.40	-
ii)	Cash and cash equivalents	4.1	51.06	5.35
iii)	Other Financial assets	4.2	0.25	-
c)	Other current assets		5,193.99	2,405.41
	Total Current assets		5,310.52	2,410.77
	TOTAL ASSETS		24,866.46	4,477.88
II	EQUITY AND LIABILITIES			
	Equity			
a)	Equity Share capital	5	15.00	15.00
b)	Other equity	5.4	(842.02)	(94.95)
	Total Equity		(827.02)	(79.95)
	Liabilities			
1)	Non-current liabilities			
a)	Financial liabilities		-	-
b)	i) Borrowings	6	22,054.17	3,432.24
c)	Deferred tax liability (net)	3	1.56	-
	Total non-current liabilities		22,055.73	3,432.24
2)	Current liabilities			
a)	Provisions		-	-
b)	Other current liabilities			
i)	Borrowings	6	2,000.00	-
ii)	Trade Payables			
(a)	total outstanding dues of Micro enterprises & small enterprises	6.2	1.32	-
(b)	total outstanding dues to other than Micro enterprises & small enterprises		30.09	2.05
iii)	Other financial liabilities	6.3	1,513.08	1,114.54
b)	Provisions			
c)	Other current liabilities	6.4	93.28	9.00
	Total current liabilities		3,637.76	1,125.60
	TOTAL EQUITY AND LIABILITIES		24,866.46	4,477.88
	Corporate information and Significant accounting policies.	1		

See accompanying notes forming part of financial statements
As per our report of even date attached

For K.P. Rao & Co.,
Chartered Accountants
Firm Registration No. 003135S

Mohan Lavi
Partner
Membership No.029340

Place : Bangalore
Date : September 05, 2024

For and on behalf of the Board

Ajay Bhardwaj
Director
DIN:00333704

Ravindra K C
Director
DIN:01580534

Statement of Profit and Loss for the period ending on March 31, 2024			(₹.in Lakhs)	
	PARTICULARS	Note	Year ended 31.03.2024	Year ended 31.03.2023
I	Revenue from Operations		195.03	-
II	Other income	7	11.73	9.35
III	Total Revenue (I + II)		206.75	9.35
IV	Expenses			
	Cost of materials consumed	9	13.94	-
	Employee benefits expense	10	27.31	-
	Finance costs	11	733.04	40.61
	Depreciation and amortization expense	2	33.40	-
	Other expenses	12	144.55	17.25
	Total expenses (IV)		952.23	57.85
V	Profit/(Loss) before exceptional items and tax (III-IV)		(745.48)	(48.50)
VI	Exceptional items		-	-
VII	Profit/(Loss) before tax (V-VI)		(745.48)	(48.50)
VIII	Tax expense			
	1) Current tax		-	-
	2) Deferred tax	13	1.59	0.10
IX	Profit/(Loss) for the year (VII-VIII)		(747.07)	(48.60)
X	Other comprehensive income/(loss)			
	a) Items that will not be reclassified to profit or loss			
	Remeasurements of the defined benefit plans		-	-
	Deferred Tax on above items		-	-
	b) Items that will be reclassified to profit or loss			
XI	Total Comprehensive Income for the period (IX+X) (Comprising Profit(Loss) and Other Comprehensive Income for the period)		(747.07)	(48.60)
XII	Earnings per equity share: (In Rs.)			
	1) Basic		(0.00)	(0.00)
	2) Diluted		(0.00)	(0.00)
	Corporate information and Significant accounting policies. . Note.	1		

See accompanying notes forming part of financial statements
As per our report of even date attached

For K.P. Rao & Co.,
Chartered Accountants
Firm Registration No. 0031355

Mohan Lavi
Partner
Membership No.029340

Place : Bangalore
Date : September 05, 2024

For and on behalf of the Board

Ajay Bhardwaj
Director
DIN:00333704

Ravindra K C
Director
DIN:01580534

Cash flow statement for the period ending March 31, 2024		(₹.in Lakhs)
Description	Year ended 31.03.2024	Year ended 31.03.2023
A) Cash Flow from operating activities:		
Net Profit before taxation	(745.48)	(48.50)
Adjustment:(+/-)		
Depreciation/ Amortisation	33.40	-
Operating Profit before Working Capital Changes	(712.08)	(48.50)
Adjustment for changes in working capital:		
Other financial Assets	(154.90)	-
Other current Assets	(2,792.39)	(2,402.00)
Other non current Assets	(103.55)	-
Other Current Liabilities	512.16	1,110.08
Cash used in operations	(3,250.76)	(1,340.42)
Income taxes paid	-	-
Net cash generated in Operating Activities	(3,250.76)	(1,340.42)
B) Cash Flow from Investing Activities:		
Purchase of fixed assets	(514.51)	-
Increase in CWIP	(16,810.96)	(1,951.76)
Net cash used in Investing activities	(17,325.48)	(1,951.76)
C) Cash flow from Financing activities:		
Proceeds from bank borrowings	5,480.58	1,113.27
Proceeds from working capital funding from holding co	15,141.35	2,180.50
Net cash (Used)/ Generated in Financing Activities	20,621.93	3,293.78
Net change in Cash and Cash Equivalents (A+B+C)	45.70	1.59
Cash and Cash Equivalents (beginning of the year)	5.35	3.77
Cash and Cash Equivalents (ending period)	51.06	5.35

See accompanying notes forming part of financial statements
As per our report of even date attached

For K.P. Rao & Co.,
Chartered Accountants
Firm Registration No. 0031355

Mohan Lavi
Partner
Membership No.029340

Place : Bangalore
Date : September 05, 2024

For and on behalf of the Board

Ajay Bhardwaj
Director
DIN:00333704

Ravindra K C
Director
DIN:01580534

Statement of Changes In Equity for the period ending March 31, 2024**A - Equity Share Capital
Particulars**

Particulars	(₹.in Lakhs)	
	Number	Amount
Equity shares at the beginning of the year	150000	15.00
ADD: Issued during the year	-	-
Balance as at March 31, 2024	150000	15.00

B - Other Equity as on March 31, 2024

	General Reserves	Securities Premium	Retained Earnings	Other items of Other Comprehensive Income	Total
Balance as at April 01, 2023	-	-	(94.95)	-	(94.95)
Other Comprehensive income/(loss) for the year	-	-	-	-	-
Profit/(loss) for the year	-	-	(747.07)	-	(747.07)
Balance as at March 31, 2024	-	-	(842.02)	-	(842.02)

Other Equity as on 31.03.2023

	General Reserves	Securities Premium	Retained Earnings	Other items of Other Comprehensive Income	Total
Balance as at April 01, 2022	-	-	(46.35)	-	(46.35)
Other Comprehensive income/(loss) for the year	-	-	-	-	-
Profit/(loss) for the year	-	-	(48.60)	-	(48.60)
Balance as at March 31, 2023	-	-	(94.95)	-	(94.95)

See accompanying notes forming part of financial statements
As per our report of even date attached

For K.P. Rao & Co.,
Chartered Accountants
Firm Registration No. 0031355

Mohan Lavi
Partner
Membership No.029340

Place : Bangalore
Date : September 05, 2024

For and on behalf of the Board

Ajay Bhardwaj
Director
DIN:00333704

Ravindra K C
Director
DIN:01580534

5) Equity Share Capital

Particulars	As at 31.03.2024		As at 31.03.2023	
	No. of Shares	(₹.in Lakhs)	No. of Shares	(₹.in Lakhs)
Authorised Share capital				
Equity Shares of Rs. 10/- each	1,50,000	15.00	1,50,000	15.00
	1,50,000	15.00	1,50,000	15.00
Issued, subscribed & fully paid share capital				
Equity Shares of Rs. 10/- each	1,50,000	15.00	1,50,000	15.00
Total	1,50,000	15.00	1,50,000	15.00

5.1 The Company has equity share having a face value of Rs.10/- each.

5.2 Terms/ Rights attached to equity shares

Each holder of the equity share, as reflected in the records of the Company as of the date of the shareholders meeting, is entitled to one vote in respect of each share held for all matters submitted to vote in the shareholders meeting. In the event of liquidation of the company, the holders of equity shares will be entitled to receive any of the remaining assets of the company after distribution of amounts payable to preference shareholders if any. The distribution will be in proportion to the number of equity shares held by the shareholders

5.3 The details of shareholder holding more than 5% shares as at March 31, 2024 set out below:

Sl. No	Name of the shareholder	As at 31.03.2024		As at 31.03.2023	
		No. of Shares held	% holding	No. of Shares held	% holding
1	Anthem Biosciences Private Limited (Holding Co.,)	150000	100	150000	100

5.4 Other Equity

(₹.in Lakhs)

Particulars	As at March 31,2024	As at March 31,2023
a) Retained Earnings	(842.02)	(94.95)
Balance at the end of the period (a+b+c)	(842.02)	(94.95)

2 Property, Plant and Equipment

Particulars	Tangible			(₹.in Lakhs)
	Furniture and Fixtures	Laboratory Equipment	Computers & Accessories	Total
Cost or Deemed cost				
As at April 01,2023	-	-	-	-
Additions during the year	373.13	42.48	72.69	488.30
Disposals/adjustments	-	-	-	-
As at March 31,2024	373.13	42.48	72.69	488.30
Depreciation				
As at April 01,2023	-	-	-	-
Charge for the period	22.91	1.93	6.50	31.33
Disposals/adjustments	-	-	-	-
As at March 31,2024	22.91	1.93	6.50	31.33
Net block				
As at March 31,2024	350.22	40.56	66.19	456.96
As at March 31,2024	-	-	-	-

2.1 Capital work-in-progress

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Capital work-in-progress	18,878.04	2,067.08
	18,878.04	2,067.08

Capital work-in-progress ageing schedule**As at 31 March 2024**

CWIP	Amount in capital work in progress for a period of				Total(₹.in Lakhs)
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Project work in progress	17,184.45	1,578.28	105.88	9.44	18,878.04
Projects temporarily suspended	-	-	-	-	-

As at 31 March 2023

CWIP	Amount in capital work in progress for a period of				Total(₹.in Lakhs)
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Project work in progress	1,951.76	115.32	-	-	2,067.08
Projects temporarily suspended	-	-	-	-	-

2.2 Other Intangible assets

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Other Intangible Assets	24.15	-
Total	24.15	-

(₹.in Lakhs)

Particulars	31.03.2023
Cost or Deemed cost	
	-
Additions during the year	26.22
Disposals	-
As at March 31, 2024	26.22
Amortisation	
As at April 01, 2023	-
Charge for the period	2.07
Disposals	-
As at March 31, 2024	2.07
Net block	
As at March 31, 2024	24.15
As at March 31, 2024	-

6.2 Trade Payables Ageing as on 31.03.2024

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total(₹.in Lakhs)
MSME	1.32	-	-	-	1.32
Others	30.09	-	-	-	30.09
Disputed dues - MSME	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
Total	31.40	-	-	-	31.40

Trade Payables Ageing as on 31.03.2023

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total(₹.in Lakhs)
MSME	-	-	-	-	-
Others	2.05	-	-	-	2.05
Disputed dues - MSME	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
Total	2.05	-	-	-	2.05

3 . Deferred Tax Assets

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Deferred tax assets		
Deferred tax assets	0.03	0.13
Add: Adjustments during the year	(1.59)	(0.10)
Total	(1.56)	0.03

4. Trade receivable**a) Non current asset**

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Unsecured, considered good		
Trade Receivables from Related parties	93.24	-
Total	93.24	-

b) Current asset

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Unsecured, considered good		
Trade Receivables	61.40	-
Total	61.40	-

4.1 Cash and Cash Equivalents

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Deferred tax assets		
(i) in current accounts	46.43	5.35
(ii) in deposit accounts	4.63	-
Total	51.06	5.35

4.2 Other Financial Asset

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Raw Material stock	0.25	-
Total	0.25	-

i) Inventories

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Raw Material stock	3.82	-
Total	3.82	-

ii) Other current assets

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Balances with other statutory authorities	3,481.24	348.75
Pre-paid expenses	40.99	0.12
Capital advances	1,671.76	2,056.55
Total	5,193.99	2,405.41

4.3 Other non current assets

	(₹.in Lakhs)	
Particulars	31.03.2024	31.03.2023
Security deposits	103.55	-
Total	103.55	-

6. Borrowings**Non current liabilities**

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Term Loan	4,593.85	1,113.27
Related party payable-ABPL (intercorporate loans)	17,460.32	2,318.97
Total	22,054.17	3,432.24

Current liabilities

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Term Loan-short term portion	2,000	-
Total	2,000	-

6.1 Break up of loans- Borrowings with repayment of terms

Loan Type	Loan Name	Repayment Terms	Total Outstanding (₹.in Lakhs)	
			(For Current Reporting period)	(the previous reporting period)
Term Loan-Project	Federal Bank	24 Quarterly Instalments	6,593.85	1,113.27

Term loan from federal bank along with interest is secured by first paripassu charge of EM of lease hold right of Anthem Biosciences Pvt Ltd on 32,932 sqm of land at plot no.313-P;314-P&318-P in Harohalli 2nd Phase Industrial area, and second paripassu charge with the current assets (both present and future);hypothecation of moveable fixed assets of the company procured/to be procured to the extent of Rs.400 crores; Entire cash flow of the company. Term loan carries a fixed rate of interest@6.45% p.a

6.2 Trade Payables

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
(i) Dues to micro, small and medium enterprises	1.32	-
(ii) Dues to others	30.09	2.05
Total	31.40	2.05

6.3 Other Financial Liabilities

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Capital Creditors	1,476.95	1,114.54
Interest Payable to MSME	36.13	-
Total	1,513.08	1,114.54

6.4 Other current liabilities

(₹.in Lakhs)

Particulars	31.03.2024	31.03.2023
Dues to statutory/government authorities	71.76	8.00
Other accrued liabilities	21.52	1.00
Total	93.28	9.00

7. Revenue from operations

Particulars	31.03.2024	31.03.2023
Export sales	195.03	-
Total	195.03	-

8. Other Income

Particulars	31.03.2024	31.03.2023
Forex Gain/(Loss)	11.34	9.35
Interest received	0.39	-
Total	11.73	9.35

9. Cost of material consumed

Particulars	31.03.2024	31.03.2023
Opening stock	-	-
Add:Purchases	17.76	-
Closing stock	3.82	-
Total	13.94	-

10. Employee benefit expenses

Particulars	31.03.2024	31.03.2023
Salaries and allowances	26.94	-
Staff welfare	0.37	-
Total	27.31	-

11. Finance cost

Particulars	31.03.2024	31.03.2023
Bank charges	3.12	0.93
Interest paid-Related Party Loans and Advances	693.79	39.68
Interest on MSME dues outstanding	36.13	-
Total	733.04	40.61

12. Other Expenses

Particulars	31.03.2024	31.03.2023
Auditors' remuneration	1.00	1.00
Legal and professional fees	5.10	5.08
Rates and taxes	2.78	3.17
Environmental, Health & Safety	16.26	0.50
Freight and forwarding charges	0.20	-
Insurance	7.32	-
Repairs and maintenance	7.51	0.12
Testing and analysis charges	0.90	-
Power and fuel	83.40	6.45
Miscellaneous expenses	1.30	-
Printing & Stationery	0.81	-
Security Charges	17.97	0.93
Total	144.55	17.25

13. Tax Expense

Particulars	31.03.2024	31.03.2023
A - Current Tax		
Current tax on profits for the year	-	-
Total	-	-

13.1 Reconciliation of tax expenses to accounting profit

Particulars	31.03.2024	31.03.2023
Accounting profit before tax	-745.48	-48.50
Tax @17.16 %	-127.92	-8.32
Adjustments:		
Expenses that are disallowed as per Income Tax Act	-	-
Expenses that are specifically allowed as per the Income Tax Act	-	-
Effect of deduction under section 35(2AB) of the Income Tax Act	-	-
Others	-	-
Tax Expenses recognised in the statement of profit and loss	-127.92	-8.32
Income tax credit/(expense) recognised in Other Comprehensive Income :	-	-
Tax effect on actuarial gains/losses on defined benefit obligations	-	-

13.2 Auditors Remuneration Break up

Particulars	Year ended 31st March 2023	Year ended 31st March 2022
Statutory audit fees	1.00	1.00
Other matters	-	-
Total	1.00	1.00

13.3 Earning Per Share

Particulars	31.03.2024		31.03.2023	
	Basic EPS	Diluted EPS	Basic EPS	Diluted EPS
Equity shares outstanding during the year	1,50,000	1,50,000	1,50,000	1,50,000
Weighted average number of equity shares for calculation of earnings per share	1,50,000	1,50,000	1,50,000	1,50,000

14 Financial Risk Management

The Company's activities expose it to a variety of financial risks: credit risk, liquidity risk, foreign currency risk and interest rate risk. The Company's primary focus is to foresee the unpredictability of financial markets and seek to minimize potential adverse effects on its financial performance. The Board of Directors reviews and agrees policies for managing each of these risks, which are summarised below:

(a) Credit risk:

Credit risk is the risk of financial loss to The Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from The Company's receivables from customers and investment securities. Credit risk arises from cash held with banks and financial institutions, as well as credit exposure to clients, including outstanding accounts receivable. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses in financial assets. The Company assesses the credit quality of the counterparties, taking into account their financial position, past experience and other factors.

(b) Trade and other receivables:

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer.

(c) Investments:

The Company has no investments in FY 2023-24.

(d) Liquidity risk:

Liquidity risk is the risk that The Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due. Also, the Company has unutilized credit limits with banks.

The Company's corporate treasury department is responsible for liquidity, funding as well as settlement management. In addition, processes and policies related to such risks are overseen by senior management.

The working capital position of the Company is given below:

(₹.in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
Cash & cash equivalents	51.06	5.35
Investments in mutual funds (quoted)	-	-
Investments in non convertible bonds/debentures (quoted)	-	-
Interest bearing deposits with corporates	-	-
Investment in commercial paper (unquoted)	-	-

15 Capital Management Structure

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. The Company monitors the return on capital as well as the level of dividends on its equity shares. The Company's objective when managing capital is to maintain an optimal structure so as to maximize shareholder value.

The capital structure is as follows:

The Company is predominantly equity financed which is evident from the capital structure table.

(₹.in Lakhs)		
Particulars	As at March 31, 2024	As at March 31, 2023
Total equity attributable to the equity share holders of the group	(827.02)	(79.95)
As percentage of the total capital	100%	100%
current loans & borrowings	2,000.00	-
Non current loans & borrowings	22,054.17	3,432.24
Total loans & borrowings	24,054.17	3,432.24
As percentage of the total capital	-2909%	-4293%
Total capital (loans and borrowings and equity)	23,227.15	3,352.29

16 Trade Payables and Micro, Small and medium Enterprises

(₹.in Lakhs)		
Particulars	31.03.2024	31.03.2023
(i) Principal amount remaining unpaid to any supplier as at the end of the accounting year	668.28	-
(ii) Interest due thereon remaining unpaid to any supplier as at the end of the accounting year	36.13	-
(iii) The amount of interest paid along with the amounts of the payment made to the supplier beyond the appointed day	-	-
(iv) The amount of interest due and payable for the year	36.13	-
(v) The amount of interest accrued and remaining unpaid at the end of the accounting year	-	-
(vi) The amount of further interest due and payable even in the succeeding year, until such date when the interest dues as above actually paid	-	-

17 Related Parties

Name of the related party	Nature of relationship with the Company	Country of Incorporation/Residential Status
Anthem Biosciences Pvt Ltd	Holding company (100% holding)	India

17.1 Transactions with the above related party

(₹.in Lakhs)

Name of the related party	Nature of transaction	Year ended 31.03.2024	Year ended 31.03.2023
Anthem Biosciences Pvt Ltd	Supply of goods and services	79.04	-
	Purchase of goods and services	112.77	-
	Interest paid on loans advances availed	693.79	39.68

18 Balance outstanding with related party

(₹.in Lakhs)

Related Party	Nature of outstanding	As at 31.03.2024	As at 31.03.2023
Anthem Biosciences Pvt Ltd	Loans and advances payable	17,460.32	2,318.97
	Payables for purchase goods and services	0.83	-
	Receivables for supply of goods and services	93.24	-

19 Key Managerial Personnel

Name	Designation
Ajay Bharadwaj	Director
Ravindra K C	Director
Ganesh Sambasivam	Director

20 Key financial ratios

Particulars	Figures for the current reporting period	Figures for the previous reporting period	Reason if the variance is more than 25%
1. Current Ratio (in times)	1.46	2.14	Due to increase in short term borrowings
2. Debt - Equity Ratio (in times)	(7.97)	(13.92)	Due to increase in long term borrowings
3. Debt Service Coverage Ratio (in times)	0.00	(0.01)	
4. Return on Equity Ratio (%)	-165%	-87%	Due to cash loss
5. Inventory turnover ratio (in times)	21.58	-	
6. Trade Receivables turnover ratio (in times)	2.52	-	
7. Trade payables turnover ratio (in times)	9.47	2.39	Increase in payables
8. Net capital turnover ratio (in times)	0.13	-	
9. Net profit ratio (%)	-361%	-520%	Operating expenses exceeding revenue
10. Return on Capital employed (%)	-2%	-10%	Negative networth

21 Other Statutory Disclosures

- (i) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- (ii) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- (iii) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- (iv) No Relationship or Transactions with any struck off companies during the year.
- (v) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (vi) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (vii) The Company has not any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- (viii) The Company has not been declared as Willfull Defaulter by any Bank or Financial Institutions or any other lender.
- (ix) The Company has complied with the number of layers prescribed under clause (87) of Section 2 of the Act r.w Companies (Restriction on number of layers) Rules, 2017.
- (x) The Company uses an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the accounting software. There is no instance of audit trail feature being tampered with was noted in respect of the accounting software.

Accounting Policies (NeoAnthem Financial Statements)

NEOANTHEM LIFESCIENCES PRIVATE LIMITED

CIN: U24239KA2020PTC136337

Notes forming part of the Audited Standalone Financial Statements for the year ended March 31, 2024.

1. Corporate information:

Neoanthem Lifesciences Private Limited, is a wholly owned subsidiary of Anthem Biosciences Private Limited and was incorporated on the July 22, 2020, under the Companies act, 2013 having its registered office at 49, F1&F2, Canara Bank Road, Bommasandra Industrial Area Phase I-560099. Company operates in biotechnology sector and its business activities includes, discover, develop, manufacture, and commercialize biopharmaceutical products that address significant unmet needs and provide biological solutions to improve industrial performance in all areas. The financial statements of the holding company (Anthem Biosciences Private Limited) are being prepared in compliance with Indian Accounting Standards. Consequently, Indian Accounting Standards have been adopted in the preparation of the Company's financial statements.

2. Significant accounting policies:

(A) Basis of preparation and presentation:

a) Statement of compliance:

These financial statements have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016 as applicable.

These standalone financial statements have been prepared for the Company as a going concern on the basis of relevant Ind AS that are effective at the Company's annual reporting date, March 31, 2024. These standalone financial statements were authorized for issuance by the Company's Board of Directors on September 05, 2024.

b) Basis of measurement:

The financial statements have been prepared on a historical cost convention and on an accrual basis.

c) Use of estimates and judgements:

The preparation of financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on a periodic basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the notes.

(B) Accounting Policies

(i) Functional and presentation currency:

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the Company operates (i.e. the "functional currency"). The financial statements are presented in Indian Rupee, the national currency of India, which is the functional currency of the Company.

(ii) Financial instruments:

All financial instruments are recognized initially at fair value. Transaction costs that are attributable to the acquisition of the financial asset (other than financial assets recorded at fair value through profit or loss) are included in the fair value of the financial assets. Purchase or sale of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trade) are recognised on trade date. While, loans and borrowings and payables are recognised net of directly attributable transaction costs.

For the purpose of subsequent measurement, financial instruments of the Company are classified in the following categories: nonderivative financial assets comprising amortised cost, debt instruments at fair value through other comprehensive income (FVTOCI), equity instruments at FVTOCI or fair value through profit and loss account (FVTPL), non-derivative financial liabilities at amortised cost. The classification of financial instruments depends on the objective of the business model for which it is held. Management determines the classification of its financial instruments at initial recognition.

(a) Non-derivative financial liabilities:

(i) Financial liabilities at amortized cost:

Financial liabilities at amortized cost represented by borrowings, trade and other payables are initially recognized at fair value, and subsequently carried at amortized cost using the effective interest rate method.

(C) Provisions:

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset, if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Provisions for onerous contracts are recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable costs of meeting the future obligations under the contract. Provisions for onerous contracts are measured at the present value of lower of the expected net cost of fulfilling the contract and the expected cost of terminating the contract.

(D) Income tax:

Income tax comprises current and deferred tax. Income tax expense is recognized in the statement of profit and loss except to the extent it relates to items directly recognized in equity or in other comprehensive income.

a) Current income tax:

Current income tax for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the taxable income for the period.

The tax rates and tax laws used to compute the current tax amount are those that are enacted or substantively enacted by the reporting date and applicable for the period. The Company offsets current tax assets and current tax liabilities, where it has a legally enforceable right to set off the recognized amounts and where it intends either to settle on a net basis or to realize the asset and liability simultaneously.

b) Deferred income tax:

Deferred income tax is recognized using the balance sheet approach. Deferred income tax assets and liabilities are recognized for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount in financial statements, except when the deferred income tax arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profits or loss at the time of the transaction.

Deferred income tax asset is recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. Deferred income tax liabilities are recognized for all taxable temporary differences.

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

(E) Earnings per share (EPS):

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the period. Diluted EPS is computed by dividing the net profit after tax by the weighted average number of equity shares considered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date. Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for bonus shares, as appropriate.

(F) Inventories:

Inventories consists of Raw materials only . Inventories are carried at lower of cost and net realizable value. The cost of raw materials are determined on a moving average basis and/specific cost wherever applicable.

(G) Previous year's figures have been re-grouped or re-classified to conform to the present year's presentation.



Sustainability and CSR

ESG Report FY 2023-2024


Anthem Biosciences is committed to embedding sustainability, innovation, and inclusivity into its core operations, reflecting its dedication to environmental, social, and governance (ESG) principles. With 90% of its energy dependency on renewable sources like solar and wind, the company has achieved a 0.37% reduction in per kWh cost through long-standing energy conservation initiatives driven by technology and automation. Anthem demonstrates a strong commitment to water sustainability by recycling 97.8% and 87.2% of wastewater at its Bommasandra and Harohalli sites, respectively, while maintaining low air emission levels and proactive odor management measures.

The company has quantified and compared its Scope 1 and Scope 2 GHG emissions year-on-year, ensuring transparency and accountability in its environmental impact. On the social front, 17% of managerial positions are held by women, and 58% of employees are highly skilled postgraduates, fostering diversity and excellence. Anthem also contributes to the community through CSR initiatives, including lake redevelopment projects at Bommasandra, further exemplifying its commitment to creating a sustainable and inclusive future.




Energy Conservation

90% Energy Sourced from Renewable Sources in FY24 as compared to 93% in FY23




Water Discharge and Water Conservation Approach



* % Waste Water Recycled on the waste water treated is including Sewage

Treatment of Waste Disposal



Effluent Treatment and Waste Disposal (FY24)



Treatment of Waste Disposal

Waste Management (Hazardous, Other Waste & Non-Hazardous)

Waste Disposal	Bommasandra			Harohalli		
	Disposed	KSPCB Limit(MT/An num)	as a %age of Allowed Limit	Disposed	KSPCB Limit(MT/An num)	as a %age of Allowed Limit
Hazardous Waste						
Incinerable waste	120.56	242.5	49.7%	252.56	935	27%
Recyclable waste (Used oil & Spent Solvent)	1036.95	2,608.0	39.7%	2139.8	4,138.9	51.7%
Recyclable (Empty barrels)	41.86	77.0	54.4%	84.6	1,250.0	6.8%
Landfill (ETP Sludge)	242.38	2,450.0	9.8%	1088.98	3,750.0	29%
Other Waste (paper/paper product waste/Rubber/Metal waste waste/Glass waste/wood waste)	20.66	63.9	32.4%	69.85	129.4	54%
Non-Hazardous Waste						
Cell Mass				1991.5	5,110.0	39%




Other Initiatives


Anthem Biosciences continues to advance its sustainability efforts with several key initiatives for FY24. The company has undertaken an automation exercise targeting the chilled water secondary pump, process cooling tower pump, and cooling tower fans to enhance energy efficiency. Existing thermodynamic steam traps are being replaced with inverted bucket steam traps, improving operational performance. At Unit-2 in Harohalli, the switch to PNG (Piped Natural Gas) over conventional fuels like furnace oil was successfully initiated at the end of January 2024.

Further steps include evaluating the feasibility of solar panel installation at Unit-2 and procuring an additional biogas boiler to replace conventional fuels such as furnace oil and high-speed diesel, reinforcing Anthem's commitment to reducing its environmental footprint and adopting greener energy solutions.

Air Emissions



GREENHOUSE GAS EMISSIONS: SCOPE 1, 2 & 3




Air Emission Reduction Initiatives

- Efficient gas scrubbing systems
- Use of vent condensers
- Cold Traps introduced at the vent of the vacuum pumps
- Use of HEPA filters to control indoor air quality in powder handling areas


Greenhouse Gas Emissions

Bommasandra

Scope 1 Emissions



Harohalli



■ Usage of PNG at Unit - 2 commenced w.e.f end Jan-2024

Scope 2 Emissions



1426.145

FY-23


2751.85

FY-24


■ Sustained dependency on renewable sources of energy (Solar + Wind) by 89%

Workforce Diversity by Gender, Age and Qualification



Diversity by Gender, FY24



Diversity by Age, FY24



Diversity by Talent, FY24



*Managerial Role (Deputy Manager and above)

Employee Wellbeing, Engagement and Culture

Health & Vaccination

- Annual Medical Examination done for all employees
- Bommasandra (12/04/2023 to 14/04/2023), and Harohalli (17/04/2023 to 21/04/2023)

Social Wellbeing

- Anthem Day Celebration Dec'23
- Ethnic Day-Oct'23 / Photography day
- Kannada Rajyotsava-Nov'23
- Team outing-PCR and WH / Purchase

Mental Wellbeing

- External Training-Planned in 2024
- International Yoga Day
- Fibe- Financial wellness partner


Physical Wellbeing

- TCS Marathon-May 2023 Bidadi
- APL Cricket tournament
- PPL Cricket tournament-Anthem Women's Team won the Championship

Recognition

- Long Term Service Award
- Introduction of Employee Appreciation cards


Employee Training



Training Mandays


10.6

Occupational Health & Safety Training (FY24)



HR Policies

Anthem Biosciences places great emphasis on fostering a supportive, inclusive, and growth-oriented workplace culture. To achieve this, the company has implemented a comprehensive suite of HR policies designed to enhance employee well-being, career development, and workplace fairness.



CSR Impact Report FY 2023-2024



Transforming Lives, Empowering Communities.

The FY 2024 CSR report themed “Transforming Lives, Empowering Communities” includes details of various CSR projects undertaken by the company and reinforces Anthem’s accountability towards CSR and measures the progress of CSR goals achieved during FY 2024.

The Board has delegated oversight of CSR activities to the Corporate Social Responsibility Committee, presided by the Chairperson.

The key pillars of the CSR policy include:

- **Commitment to the common good of the society by practicing good governance and responsible business activities**
- **Support the agenda of the State and the Country as a whole to ensure sustainability**
- **Undertake projects and social welfare programs which enhances the quality of life**
- **Work towards economic well-being of regional communities in rural, semi-urban and tribal regions**

Anthem has developed a comprehensive policy that shall apply to all CSR activities undertaken and also aims to establish boundaries for acceptable behaviour and guidelines for best practices in CSR related initiatives.



Social Impact Goals

Anthem supports the UN Sustainable Development Goals (SDGs), also referred to as the Global Goals which are a set of 17 integrated goals and 169 targets to end poverty, protect the planet and ensure that humanity enjoys peace and prosperity by 2030, and complies with the CSR Regulations, in particular, Schedule VII, as stipulated in the Companies Act 2013 and applicable statutory requirements notified by the Ministry of Corporate Affairs.



Enhancing Socio-Economic Conditions for Communities

Rather than engaging with local communities to deliver short-term, piecemeal gains, Anthem focuses on CSR projects in the nature of humanitarian assistance that have the potential to realize multiplier benefits in the immediate and long-term horizon. This philosophy stands reflected in Anthem's CSR thrust areas that include multiple infrastructure related projects such as the construction of schools, learning centers, anganwadis, community kitchens, clean drinking water projects and the likes.

Message From Leadership

We, at Anthem Biosciences, believe that building a sustainable and inclusive society is a universal goal and a collective responsibility. We continue to channelize our resources, expertise and network to improve the standard of living of underprivileged communities and expand access to quality healthcare, education, clean water & sanitation and environmental conservation. In FY 2024, our key focus area was building education infrastructure. Aligned to our long-term CSR vision and strategy, we remain ever dedicated and steadfast in our commitment to furthering social welfare projects and expand the scope of coverage in critical areas, viz:

1	Education, Skill -building for the Differently abled, livelihood opportunities <ul style="list-style-type: none"> Promote Education Livelihood Enhancement Projects
2	Health, Eradicating Hunger, Poverty and Malnutrition, Safe Drinking Water and Sanitation <ul style="list-style-type: none"> Health Care Poverty, Eradicating Hunger, Malnutrition Safe Drinking Water Sanitation
3	Gender Equality, Women Empowerment, Old Age Homes, Reducing Inequalities <ul style="list-style-type: none"> Eliminating Socio -Economic Inequalities Ensuring Women Empowerment Setting Up Homes and Hostels For Women
4	Environment, Animal Welfare, Conservation Of Resources <ul style="list-style-type: none"> Conservation Of Natural Resources Environmental Sustainability Agro Forestry Animal Welfare
5	Technology Incubation, Encouraging Sports and Others <ul style="list-style-type: none"> Contributions to PM's National Relief Fund Administrative Overheads Technology Incubation Encouraging Sports



Last year, we utilized ₹ 8.66 Cr (₹ 5.99 Cr in FY2023) on CSR initiatives and impacted communities across rural, semi-urban and tribal areas in Karnataka especially in Harohalli, Kanakapura, Chikkaballapur and Deshipura & Madduru Colony in Chamarajanagara District. I would like to extend my sincere appreciation to all who made this possible, my colleagues at Anthem especially our CSR team, our NGO partner network, government bodies and all stakeholders who extended their whole-hearted support in all our CSR initiatives. Going forward, we reaffirm our commitment to continue to actively pursue CSR goals and enhance the reach and penetration of our social impact and touch many more lives.

With best wishes,

Ajay Bhardwaj,


Managing Director and Chairman, CSR Committee

"Anthem's unwavering commitment towards social welfare stands reflected in our active participation and support for numerous CSR initiatives. CSR has always been integral to our core business ethos of long-term business sustainability, social well-being, and economic growth."





CSR Spends (₹ Cr)



CSR Implementation

Implementation will be done in an inclusive and equitable manner, focused on data-driven, scalable, sustainable practices. A holistic framework of engagement with community and relevant stakeholders shall ensure transparency, consistency & commitment towards the programs.

CSR Monitoring

A systematic, objective review of CSR activities shall be undertaken. The CSR Committee will submit periodic reports to the Board to track progress, alignment with CSR objectives, resource allocation, continued relevance and course correction wherever required.

Anthem has framed a comprehensive CSR Policy that supports social welfare projects for communities. Pursuant to the policy, CSR spend will be at least two percent (2%) of the average net profit of the immediately (3) three preceding financial years in accordance with the provisions of the Companies Act. Net profit shall be calculated in accordance with the Act. Accordingly, the CSR Committee shall recommend the CSR Budget to the Board and seek approval for the CSR spend to be incurred.

The CSR Committee shall be presided by the Chairperson and shall include the Company Secretary and members of the Committee who shall be appointed by the Board.



CSR Committee: Roles and responsibilities:

- Formulate the Company's CSR Policy
- Formulate the Annual Action Plan with timelines and budgetary allocations
- Selection of CSR activities to be undertaken during the financial year ensuring they are of local/state/national context and as stated under Schedule VII of the Act and in convergence with the broader goals of sustainable development.
- Recommendation of CSR Budget to the Board of Directors
- Ensuring transparent implementation of CSR activities
- Monitoring progress of CSR activities
- Ensure compliance with respect to CSR

CSR PROJECTS AT A GLANCE

Building Education Infrastructure

Anthem funded **16 infrastructure projects** to aid underserved communities, which involved school and kitchen hall construction work at Anganwadi and Government Schools.

The educational infrastructure construction was primarily spread across three regions with an aggregated **budget of ₹ 4.9 Cr.** These three areas were:

A) Harohalli (9 schools):

- Government schools at: Devarakaggahalli Bunnikuppe, Kurubarahalli, and government schools alongwith kitchen community halls at Hebbidarmettlu, Byregowdavalase and Jakkasandra area in Harohalli
- Anganawadi schools at Kurubarahalli and Hulisiddegowdanadoddi, and Anganwadi school alongwith kitchen community halls at Jakkasandra

B) Chikkaballapur (4 schools):

Government school at Angharekanahalli, Garehalli, Maralakunte, Devasthanahosahalli.

C) Kanakpura Taluk (3 schools):

Government school and learning center in P. Rampura, Anamanahalli and Adanakuppe localities.

Education is a fundamental right and we stay vigilant that our CSR contributions meet the intended purpose, comply with statutory regulations create a social impact in these underserved communities.



Teacher Enablement Programme

Teacher Enablement Programme

Anthem in association with Meghshala executed its Teacher Enablement Programme in six government schools in collaboration with the Education Department of Karnataka, where digital learning equipments were distributed. This initiative is aimed to train teachers to seamlessly integrate technology and STEM-based education into their daily classroom sessions through distribution of digital tabs / TVs.



Newly adopted schools will be trained in the Meghshala e-learning model & adequate support and guidance will be given by visiting the schools every month and providing

technical and pedagogical training. The Education department will be involved in all steps to ensure more accountability. And engagement with the community in all the regions will be done to support the schools.

Going forward, Anthem and Meghshala will provide continuous training to teachers on using digital platforms, e-lessons, while also offering technical support to assist with any problems they may face.

Project Highlights	
# of Schools impacted	6
# of Tabs distributed	6
# of TVs distributed	6
# of Beneficiaries (Teachers)	17
# of Beneficiaries (Students)	264+
Geographic footprint	Kanakapura, Ramanagara, Karnataka

Tribal Upliftment Programme

Anthem had joined hand with SCEAD Foundation towards tribal upliftment carried out in the belts of Deshipura Colony, Deshipura Village and Madduru Colony, Gundlupet Taluk, Chamarajanagara District, Mysore Division, Karnataka. These areas are adjacent to the Bandipur forest area and the forest border. Under this, the basic necessities and education kits were distributed to the tribals.

Fight Against Hunger

Mid-Day Meals

Malnutrition has disastrous consequences during the formative years of children, a highly vulnerable group. Anthem has supported the school mid-day meal program (**PM-POSHAN**) run by **Akshaya Patra**, impacting **14 schools and ~1,000 children in FY 2024**.

Akshaya Patra (Mid-Day Meals)		
	Bangalore	Mysore
# of Schools	12	2
# of Children	791	205
# of Feeding Days	233	233

Education, Nutritional Support, Medical and Childcare

Anthem financially supported the education, nutrition, and medical care for **19 preschool-children aged between 1.5 to 6 years of age**, belonging to migrant labour communities, who were enrolled at **Diya Ghar Begur Center**, Bangalore, to help foster a secure, caring and learning environment.

In April 2024, **8 Students graduated** from the Diya Ghar Begur Centre (**93% have achieved distinction and 7% have met expectations**). All 8 students are school ready, the centre is working with the parents and local schools (government and affordable private schools) to enroll them in Class 1. In addition, health checkups were conducted and essential items were distributed such as hygiene kits, school stationary and warm woolens.

Diya Ghar (Begur)	# of beneficiaries
Health Check-ups	54
Hygiene Kits	48
Story Books	18
Sweaters	20
Blankets	20
School Bags	22
Water Bottles	22



Other Social Welfare Programmes

Construction of a Community Kitchen Hall at a Shelter Home (Bannerghatta, Bangalore)

Anthem had financially supported AIR Humanitarian Homes, which runs a shelter home located at Bannerghatta to help people who are destitute or homeless to be rescued, treated medically, transformed and rehabilitated. As part of the initiative, the Community Kitchen hall at the shelter home to enable a better hygiene and health for the shelter home residents was funded by Anthem.

Other Charitable Projects

Anthem continues to make monetary contributions to other well known charitable and cultural organizations which aligns with Anthem's CSR Charter:

- Sri Sringeri Sharada Peetham Charitable Trust
- Mitti Social Initiatives
- Vanavasi Kalyana Ashram
- The Association of People with Disability
- Bal Umang Drishya Sanstha (BUDS) Foundation



CSR Impact Highlights

Corporate Social Responsibility (CSR) Activities for Fiscal FY 2024	
CSR Obligation under the Companies Act, 2013:	
Average Net Profit of the Company as per Section 135(5) of the Companies Act, 2013	₹ 4,699,847,121
CSR Obligation for FY 2024, that is, 2% of average net profit of the Company as per section 135(5) of the Companies Act, 2013	₹ 93,996,942
CSR Expenditure in FY 2024	
Amount spent on projects directly by the Company (including overheads) and through various Implementing Agencies for FY 2024	₹ 9,452,693
Amount transferred to Unspent CSR account for ongoing projects as per section 135(6)	₹ 84,544,249

Transforming Lives, Empowering Communities through impactful CSR is a moral responsibility and an opportunity to serve the underprivileged, economically weaker sections of the society. Accordingly, the impact of all CSR activities are constantly reviewed, progress measured CSR processes updated in the wake of the ever-evolving context.

Anthem aims to learn and grow and create a meaningful impact in lives.





Anthem Biosciences Private Limited

Unit I: No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area Phase 1, Bommasandra, Bangalore, 560 099, India

Unit II: Plot No. 276-P & 277-P, Survey No. 20, Harohalli Industrial Area, Phase II, Near Bannikuppe Village, Kanakapura Taluk, Ramnagar District, Harohalli, Karnataka 562112, India

NeoAnthem Lifesciences Private Limited

Unit III: 313-P, 314-P & 318-P, Bannikuppe Road, Harohalli Industrial Area, Phase II, Harohalli, Kanakapura Taluk, Ramanagara District, Harohalli, Karnataka, 562112, India